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| Preface
It is my great pleasure to introduce this new EMCDDA publication Health and social 
responses to drug problems: a European guide. One of the major goals in the EMCDDA 
Strategy 2025 is to contribute to a healthier Europe, and I see this new report as an 
important component of the agency’s activities in this area. By providing an overview of the 
current state of the art in this field and access to more detailed information and practical 
tools, the report, and accompanying web resources, offers support to both policymakers 
and practitioners working to reduce the health and social consequences of drug use. 
In identifying the topics for inclusion in this guide, we have focused on what we see as 
particularly important issues in Europe. One example is the challenge of responding to 
new psychoactive substances. There are also more persistent problems, such as opioid-
related deaths and the high rates of hepatitis C infection among people who inject drugs. 
In addition, with an eye to the future, we have highlighted some emerging issues, including 
the potential vulnerability of migrants and asylum seekers to drug problems, alongside 
opportunities for development, for example, exploiting e-health approaches within 
prevention, treatment and harm reduction interventions. This wide range of topics means 
that the guide will be of interest to diverse audiences with differing needs. For this reason, 
we have adopted an innovative format for this guide, designed to facilitate its use as a 
reference document and a gateway to additional materials online. 
The guide brings together two important areas of the agency’s work in relation to public 
health: reviews of evidence and best practice, in combination with information on the 
European picture from our monitoring systems. It also highlights what we see as the main 
implications for policy and practice that emerge from these. As is the case in all our work, 
we are indebted to a wide range of partners, individuals and organisations at both national 
and European levels, and from other regions, who have contributed to the development 
of this guide. I hope that these partnerships will continue to build, as we carry forward 
the work in this area and seek to further develop the evidence of what works and how to 
implement effective responses that will improve the health of European citizens affected by 
drug problems.
Alexis Goosdeel
Director, EMCDDA
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Definition: health and social responses to drug problems
Responses to drug problems are any actions or interventions that are undertaken to address the negative consequences 
associated with the illicit drugs phenomenon.
In considering health and social responses to drug problems, the focus is on those actions or interventions that address 
drug use and associated health and social harms, such as deaths, infectious diseases, dependency, mental health 
problems and social exclusion. Not included in the definition are actions taken to enforce drug laws or reduce the supply 
of drugs; these are covered in the European Drug Markets Report.
This guide and the associated package of online materials provides a reference point for 
those planning or delivering health and social responses to drug problems in Europe. The 
most appropriate responses will depend on the specific drug problems, the contexts in 
which these occur and the types of intervention that are possible and socially acceptable. 
By providing key information on some of the most important drug issues for Europe and the 
responses available, this guide aims to assist those involved in tackling these challenges to 
develop new programmes and improve existing ones.
This publication will be revised every three years. It complements the annual European 
Drug Report and the triennial European Drug Markets Report. Together these three reports 
aim to provide a comprehensive European picture in order to assist policymakers and 
practitioners to develop and implement policies and interventions that will contribute to a 
healthier and more secure Europe.
The EU Drug Strategy 2013–20 has the objectives of reducing drug demand, dependence, 
drug-related health and social harms, and the supply of drugs. The role of the EMCDDA is 
to support the strategy by providing ‘factual, objective, reliable and comparable information 
at European level concerning drugs and drug addiction and their consequences’; collecting 
information on emerging trends; and providing information on best practice in the EU 
Member States and facilitating exchange of such practice between them. To achieve this, 
the EMCDDA gathers information from a wide range of partners, in particular the Reitox 
network, which is made up of national focal points in the EU Member States, Norway and 
Turkey. This guide fulfils the EMCDDA’s mandate with respect to the objectives of reducing 
drug demand and the health and social consequences of drug use. It does not cover drug 
markets and supply reduction, which are covered in the European Drug Markets Report.
Drug use, and its associated problems, is a complex and multifaceted phenomenon 
which changes over time. Therefore, the responses required to prevent and ameliorate the 
associated harms to individuals and societies are, of necessity, many and varied. Moreover, 
they will need to be adapted to changing patterns of both drug use and problems and to 
different national contexts. As a result, providing a comprehensive review of health and social 
responses to drug problems in Europe is not feasible, so instead this publication has been 
designed to provide an introduction to the topic, with more detailed coverage of some of the 
most salient drug issues from a European perspective. Importantly, it provides a gateway to 
online resources that offer more in-depth information and which will be regularly updated.
Introduction
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Health and social responses to drug problems
Health and social responses to drug use and related problems occur at various levels and 
can be approached from many angles. These include different:
  structural levels – European, national, regional, local, service level;
  perspectives – policy, planner, practitioner; and
  target groups – whole populations, sub groups, individuals.
At one end of the spectrum national policymakers and planners may be trying to find broad 
public health responses to a range of interlinked drug problems. Equally important, frontline 
practitioners may be concerned with identifying the most appropriate way to respond to 
the needs of individual clients. In reality, the needs of planners and those of practitioners 
may not be so different from each other, although the breadth and scale of the challenges 
they face may differ. Both will be required to undertake some form of assessment of the 
current situation, make decisions based on the range of possible interventions available and 
information on what works or is effective, and develop a plan for implementation and follow-
up. While this guide is primarily geared towards those approaching drug problems from a 
public health planning perspective, both local and national, the mapping of approaches, links 
to evidence and tools will also be useful for frontline workers and responders.
Introduction
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How to use this guide
This guide has been designed as a reference document and is not intended to be read from beginning to end. Between 
the introductory and closing chapters, the building blocks of the guide are the individual sections within the three central 
chapters. There, to make the report easier to read and navigate, each section starts with a summary, and boxes are used 
to highlight key elements, such as definitions, the evidence base, topic overviews and policy implications. Each section 
includes a list of relevant resources. Each box type has a different icon to help readers quickly identify key information 
(see below).
Definitions, explanations, descriptions
Evidence, guidelines or good practice
Spotlight on … important cross-cutting issues or themes
Implications for policy and practice
Further resources
Chapter 1 describes the framework used in the report for thinking about the response process and the factors to take 
account of at each stage. This will be of particular interest to those planning health and social policy or interventions to 
address drug problems, but can equally apply to intervening at the individual level.
Chapters 2 to 4 view health and social responses to a range of drug problems in Europe from three different 
perspectives. There are, inevitably, overlaps between these different perspectives and the most important are 
highlighted within the relevant sections.
Chapter 2 provides examples of responses to problems associated with particular patterns of use, including cannabis 
problems, opioid dependence, drug-related deaths, infectious disease transmission and stimulant use. Emerging 
patterns of drug use, including the use of new psychoactive substances and the misuse of medicines, are also 
addressed, as is polydrug use.
Chapter 3 considers how to respond to the needs of particular target groups, such as the ageing cohort of opioid 
users that exists in many countries; women who use drugs; the new migrants and asylum seekers arriving in Europe; 
vulnerable young people; and families affected by drug use.
Chapter 4 considers examples of responses to drug problems in different settings: prisons, nightlife, festivals and other 
recreational settings, workplaces, educational establishments and local communities.
Chapter 5 focuses on improving implementation. It covers a range of topics, including the use of evidence (and working 
in areas where evidence is scarce); the role of quality standards; and the benefits of taking a systems approach that 
joins up services in order to enhance their effectiveness.
Links to further resources, including the electronic version of the guide, short policy and practice briefings and 
background papers can be found at http://www.emcdda.europa.eu/responses-guide. These will be regularly updated 
with new material.
1
Problem 
definition
Response 
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CHAPTER 1
A framework for 
developing health 
and social responses 
to drug problems
SUMMARY
  Health and social responses to drug problems in Europe 
take place within the context of EU, national and local 
policies and legal frameworks, and these influence the 
selection and implementation of responses.
  Responses must adhere to a set of key principles, for 
example, respect for human rights, including the right to 
the highest attainable standard of physical and mental 
health.
  Developing and implementing responses to drug 
problems, whether at EU, national, local or individual level, 
involves three basic steps:
  identifying the nature of the drug problems to be 
addressed;
  selecting potentially effective interventions to tackle 
these problems; and
  implementing, monitoring and evaluating the impact of 
these interventions.
  Many different factors need to be considered at each 
stage; some of the most important are highlighted in this 
chapter.
The harms associated with drug use depend on the type 
of drugs used and how they are used, who is using them 
and the settings where use takes place. The many different 
ways in which these factors can interact result in a wide 
array of possible drug use scenarios, which are associated 
with health effects of varying severity. The most common 
combinations of forms of drug use, users and settings vary 
between countries in Europe and, as a result, so do the 
nature and extent of their drug problems.
As well as varying between countries, drug use and the 
associated problems may change over time. This means 
that there can be no single blueprint for tackling drug 
problems, and that those tasked with responding to drug 
problems need to regularly review provision and adapt 
existing interventions or develop new ones to meet 
changing needs. It also indicates the need for a systematic 
approach, in which the evaluation of effectiveness is 
integrated into the development and implementation of 
responses to drug problems.
This chapter provides an introduction to the main issues 
to be considered in the development and implementation 
of health and social responses to drug problems. It 
also outlines the framework around which this guide is 
structured. The framework is designed to be useful to those 
involved in developing and implementing health and social 
interventions and to serve as a conceptual checklist when 
reviewing current policy or practice or developing new 
activities.
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A framework for developing health and social responses to drug problems 
1.1  Overarching context 
and key principles
The overall EU approach to drugs is set out in the EU Drug 
Strategy 2013–20 and accompanying action plans. As 
stated in the EU Common Position on UNGASS 2016, 
presented at the United Nations General Assembly 
special session on the world’s drugs problem, this is 
based on the understanding that ‘…drug policies should 
be built upon a sound public health approach, based on 
scientific evidence and supported by reliable and objective 
monitoring systems and evaluation, in compliance with 
human rights recognised as such by international legal 
instruments.’ In line with the EU Strategy, it also highlights 
the need for ‘… an integrated, balanced and evidence-
based approach …’ which addresses both demand 
reduction and supply reduction.
This guide focuses on health and social responses to drug 
problems, which mainly fit under the demand reduction 
element of drug policy. With respect to demand reduction, 
the EU Common Position further states that ‘…effective, 
targeted, multidisciplinary and evidence-based drug 
demand reduction policies should include prevention, 
early detection and intervention, risk and harm reduction, 
treatment, rehabilitation, social reintegration and recovery, 
and build upon continuity of service delivery.’ It emphasises 
that in line with the objective of the drug control treaties to 
protect public health, those who are dependent on drugs 
should be seen as people in need of attention, care and 
treatment in order to improve their health, facilitate social 
reintegration and reduce stigma and marginalisation.
However, both the legal framework and law enforcement 
activities can have a large impact on health and social 
responses, acting as either a barrier to or a facilitator of 
these responses. For example, enforcement activity focused 
on people who use drugs may inhibit help-seeking. Thus, 
drug control activities may exacerbate harms associated 
with use and pose a barrier to efficient and effective 
operation of health and social services. On the other hand, 
employment legislation preventing discrimination against 
people with a history of drug problems may promote social 
reintegration and improve the effectiveness of treatment 
and rehabilitation. The legislative and policy approaches of 
EU Member States, which vary considerably, can have a 
big impact on the health and social responses adopted and 
resourced as well as on their effectiveness.
The common position on UNGASS, the EU drug strategy 
and other EU documents, such as the minimum quality 
standards for demand reduction, also highlight a number 
of key principles for health and social responses to drug 
problems. For the purpose of this guide, we have identified 
those which are central to responses in this area (see box). 
These principles should be fundamental to all health and 
social responses and will be discussed in different contexts 
within this guide.
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1.1 | Overarching context and key principles
Key principles for health and social responses to drug problems in Europe
Health and social responses should:
 be respectful of human rights, including:
 the right to the enjoyment of the highest attainable standard of physical and mental health;
 the right of the drug user to give informed consent to treatment;
  respect ethical principles, including informed consent, confidentiality and equity of access;
  promote service user and peer involvement in service design and delivery;
  take a public health approach;
  be based on an assessment of needs and tailored to the specific needs of the target population;
  respond to cultural and social characteristics, including gender issues and health inequalities; and
  be properly designed and based on evidence, duly monitored and evaluated.
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A framework for developing health and social responses to drug problems 
The process of responding to drug problems can be divided 
into three broad stages (Figure 1.1): the identification of the 
particular drug problems to be addressed; the selection of 
the response or interventions that are to be put in place; 
and the implementation of the interventions, in which 
monitoring and impact evaluation should be an integral part. 
This approach can be applied when developing responses 
any level — national, local or system level. Equally, these 
same basic processes apply whether one is developing 
a response to a particular problem for the first time or 
reviewing current provision. While not the primary focus 
here, the same broad steps — problem identification or 
needs assessment, response or intervention selection, 
and implementation and review — are also pertinent when 
working with individuals with drug problems.
In all cases, the starting point should be obtaining an 
understanding of the extent and nature of the problems to 
be tackled, which may then be translated into objectives for 
change. This may come from reviewing the available data on 
the problem, ranging from national statistics to local research 
and needs assessments, and consulting with stakeholders. 
The selection of priorities and intervention objectives will 
stem from the problem definition and be informed by public 
and political attitudes and local and national priorities.
In the second phase, decisions are made as to what 
actions should be taken and plans made to implement 
them. Factors to be considered at this stage are the types 
of intervention likely to be effective, the target groups and 
the settings in which the measures will be implemented. 
Depending on the circumstances, this might involve 
selecting from a range of intervention options with evidence 
of effectiveness, or adopting and adapting interventions 
that have been shown to work elsewhere. If no suitable 
options exist, it may involve developing a new intervention. 
Where a programme or strategy is already in place, it may 
be necessary to review provision in light of the needs of 
particular groups or to fill gaps in coverage. These decisions 
will be influenced by considerations such as the scale and 
severity of the problem, the resources and competencies 
available, the outcomes expected and the values and 
preferences of the community.
Once responses have been chosen, the next phase is 
implementation. Whether an evidence-based intervention 
works in a particular case will depend on how it is 
implemented and the local context. Therefore an essential 
component in this phase is monitoring and evaluation of the 
implementation, including the costs and outcomes, to feed 
back into an ongoing review and planning process.
The remaining sections in this chapter describe the 
response planning framework and the factors that need to 
be taken into account in each phase in more detail.
FIGURE 1.1
The three broad stages of developing responses to drug problems
Problem 
definition
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framework
Problem definition and needs assessment
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Problem definition or needs assessment may be undertaken 
at different levels and by a variety of actors, including public 
authorities, planners, consultants or practitioners. Various 
approaches are possible and numerous tools are available 
to assist in the process, for example, the Prevention 
and Evaluation Resources Kit (PERK) and the routine 
epidemiological indicators maintained by the EMCDDA. 
At the individual level, health practitioners may use well 
established assessment tools such as the European 
Addiction Severity Index or the Drug Use Disorders 
Identification Test. The online Evaluation Instruments Bank 
contains a wide selection of such tools that may be useful 
at the individual and population levels.
Key questions that need to be addressed at the initial 
assessment stage are who is affected, what types of 
substances and patterns of use are involved, and where the 
problem is occurring. Responses need to be tailored to the 
particular drug problems being experienced, and these may 
differ between countries and over time. The wide array of 
factors that need to be considered at this stage in the process 
are discussed in this section and illustrated in Figure 1.2.
FIGURE 1.2
Factors to be considered in stage 1: problem definition
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A framework for developing health and social responses to drug problems 
|  Role of drug type and patterns of use  in drug-related harms
Psychoactive drugs act on the brain producing a variety 
of effects on perception, mood, thinking and behaviour. 
Initially these effects may be positive, for example, in 
relieving pain or mental distress, or producing pleasure, 
but may also lead to a range of harms. These may be 
associated with intoxication, since drugs may make users 
euphoric and impair thinking and physical co-ordination. If 
an intoxicated person drives a car, operates machinery or 
engages in physical activities, they may injure themselves 
or others, and on occasion, cause death. Depressed 
individuals who are intoxicated may act impulsively on 
suicidal thoughts. Intoxicated people may engage in violent 
acts in social settings that facilitate such behaviour, such 
as bars crowded with other intoxicated individuals. Chronic 
drug use, especially sustained daily use, can produce a 
dependence syndrome, in which users can find it difficult 
to cut down or stop using the drug and continue to use it 
despite it harming their health and well-being and that of 
family members and friends. If such drug use is sustained 
it can produce or exacerbate the symptoms of mental and 
physical disorders and lead to failures in the performance 
of important social roles, such as attending school, working 
or caring for children. In severe cases, sustained heavy daily 
drug use can undermine self-care and end in homelessness.
Drug problems may vary with type of drug, route of 
administration (e.g. orally, smoked or injected) and the 
frequency or pattern of use. These interact with other 
factors, such as the characteristics of the person using 
the drug (e.g. young people, women or men, socially 
integrated or disadvantaged people) and the social settings 
in which the drugs are used (e.g. the workplace, at home, 
in a nightclub or bar, on the streets), to either increase or 
reduce the problems that users experience. It is accordingly 
important to identify which of these factors are relevant 
when developing interventions to address drug problems.
Identifying the main problem drugs and patterns of use 
will indicate the probable major associated harms. Heroin 
and pharmaceutical opioids have a high dependence risk, 
especially if injected. They can lead to fatal overdoses and 
if users share contaminated injection equipment they can 
contract and spread blood-borne infections such as HIV and 
hepatitis B and C.
Stimulants, such as cocaine, MDMA and amphetamines, 
intoxicate. These are often used recreationally, but may 
be associated with more problematic patterns of use 
and modes of ingestion, such as injection or smoking. 
Intoxicated users may engage in risky sexual and other 
behaviour (e.g. driving a car) that puts their safety and that 
of others at risk. When stimulants are used over weeks or 
months in high doses, they may precipitate psychoses and 
serious cardiovascular events, such as heart attacks and 
strokes.
Cannabis has very low risk of fatal outcomes but its use can 
be associated with acute toxicity presentations at hospital. 
The risks of developing dependence on cannabis are lower 
than those of opioids or stimulants, or legal drugs like 
alcohol and tobacco. Nonetheless a substantial minority of 
cannabis users develop problem use and seek help to stop 
using cannabis.
Few regular drug users use only one substance. Most 
engage in polydrug use — the use of multiple drugs, in 
combination or at different times. For example, injecting 
heroin users often use other opioids, alcohol, tobacco, 
benzodiazepines, cannabis and stimulants. Cocaine users 
tend to use the drug alongside alcohol. Many daily cannabis 
users also smoke tobacco. These drug combinations can 
increase the risk of harm, for example, by increasing the 
likelihood of toxic drug effects, fatal overdoses or becoming 
dependent on multiple drugs, which can be more difficult to 
overcome than dependence on a single drug.
|  Variation in harms across individuals and communities
An important step in defining the problem is identifying 
the most important drivers (or factors that are the main 
causes) of harms and which individuals or communities 
are the most affected. For example, is there a problem 
due to increasing cannabis use among young people? 
And if so, is this concentrated among a particular age 
group, community or geographical area? Is this increase in 
cannabis use associated with school drop-out, rising youth 
unemployment, or increasing mental health problems? 
Answering these types of questions will clarify the issues to 
address, the outcomes to be sought and the criteria against 
which to measure the impact of the intervention.
An array of individual and societal factors can make some 
drug users more vulnerable to harm. This is also true with 
respect to the families and communities affected by drug 
problems. These factors interact in complex ways to reduce 
or increase risks and harms associated with drug use. In 
addition, these factors may interact with drug use in a 
circular fashion to create a vicious cycle. Some of the key 
factors that need to be considered and how they impact 
on harms are summarised in the box on page 19.  
More information is provided throughout the report.
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Examples of factors to take into account when assessing drug problems
  Age
In general, the younger a person is when they first use a drug, the more likely they are to use regularly, develop 
dependence and experience drug-related harm later in life. Older long-term drug users may be particularly vulnerable 
to both acute and chronic health problems.
  Gender
Although drug use is less common among females than males, females who use drugs are more likely to develop 
problems and adverse health effects than their male counterparts. Drug use by women of reproductive age can impair 
fertility and, if drugs are used during pregnancy, affect the developing foetus.
  Physical health
People with some physical health problems (e.g. cardiovascular and respiratory diseases) who also use drugs are at 
increased risk of harm. Drug use may exacerbate these conditions and increase the risk of fatal overdose. Drug use 
may also reduce compliance with medical treatment leading to poorer outcomes.
  Mental health
Many people with a drug problem also have co-existing mental health problems. The relationship between drugs and 
mental health is complex: drugs may increase the risk of developing mental health problems in vulnerable people, may 
exacerbate existing mental health problems, and people with depression, anxiety disorders and schizophrenia are 
more likely to develop drug problems if they use drugs.
  Biological influences
An individual’s neurobiological make-up affects how their bodies respond to drugs and their susceptibility to harm; a 
dose that is tolerated in one person may lead to a fatal outcome for another. Personal traits, such as impulsivity, also 
impact on risks of drug use and harms.
  Socio-economic factors
Socially disadvantaged or excluded people are more likely to use drugs and experience drug-related harm. Drug use 
problems can also exacerbate social disadvantage, for example, by reducing the chances that young people will 
complete their education or obtain well-paid jobs. Homeless drug users may engage in riskier drug use practices, such 
as sharing injecting equipment or using drugs in unsafe settings.
  Family factors
Family factors can increase or decrease vulnerability to drug problems. For example, having family members who use 
substances can increase the likelihood of using drugs, while having strong family support and parental monitoring may 
protect against drug problems and help to overcome them.
  Ethnicity, religion and sexual orientation
People from minority groups defined by ethnicity, religion or sexual orientation can be more likely or less likely to use 
drugs than the social majority. Rates of drug use may be higher if drugs are more readily available in their communities 
or prevention programmes are not appropriate to them. If they develop drug problems, stigma and poor access to 
health services may prevent help-seeking. However, some minority communities have lower rates of drug use because 
of strong social cohesion, close family ties and religious prohibitions on drug use.
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Spotlight on … National drug strategies in Europe
National drug strategies are planning and co-ordination tools used by European countries to set out their responses 
to the various health, social and security challenges linked to drug problems. They usually include some general 
principles, objectives and priorities, while specifying actions and those responsible for implementation. These 
strategies support the balanced approach to drug policy put forward in the EU drug strategy (2013–20) and 
associated action plans, addressing both drug demand reduction and drug supply reduction.
Many of the factors that are linked to or exacerbate drug 
problems and drug dependence are broader social issues 
that are also associated with use of other potentially 
addictive substances or behaviours such as tobacco, 
alcohol, gambling, but also to other problems such as 
crime. These potential overlaps are recognised in what 
appears to be a trend in Europe towards drug strategy 
documents that give consideration to other addictive 
substances or are part of a wider addictions strategy.
As of 2016, 18 countries had a drug strategy focusing 
mainly on illicit drugs. In the other 12 countries, the policy 
focus is broader, giving consideration to other addictive 
substances and behaviours (see figure). These broader 
documents still mainly address illicit drugs, with variation 
in the other substances or behaviours considered; all 
of them address alcohol, nine consider tobacco, eight 
cover medicines, three include doping in sports (e.g. 
performance enhancing drugs) and seven look at addictive behaviours (e.g. gambling). There appears to be a trend 
towards broader drug strategies and the distinction between an illicit drugs focus and a broader strategy is not always 
clear cut. For example, within the United Kingdom, although the overall UK strategy focuses mainly on illicit drugs, the 
devolved administrations of Wales and Northern Ireland have broader strategy documents. In other cases a broader focus 
can be found in supporting documents to some elements of the strategy. This can be seen in Finland, where a specific 
prevention action plan addresses alcohol, tobacco, drugs and gambling.
See also the EMCDDA Paper, National drug strategies in Europe: trends and developments.
| The role of setting
The setting in which drugs are used must be taken into 
account, as it can affect the type and extent of harm that 
drug use can cause. Those who use drugs alone may be at 
higher risk of some harms. They will not have anyone to help 
if they experience a drug overdose. Using opioids alone, for 
example, increases the risk of a fatal overdose.
People who use drugs in public places often do so furtively 
and hurriedly. This can increase the risk of an overdose or 
of acquiring a blood-borne virus infection, if they shared 
injecting equipment. Poor hygiene often associated with such 
settings also increases the risk of a range of infections. This 
a particular issue for homeless people. Drug use in prisons is 
also clandestine and risky (see also sections 2.3, 2.4 and 4.1).
Injecting drugs outdoors in cold weather may leave users 
who overdose vulnerable to hypothermia. Alternatively using 
MDMA in a hot nightclub may put a user who is already 
predisposed to hyperthermia, at greater risk of experiencing 
this rare but serious adverse outcome.
|  Identifying and prioritising the problems to be tackled
Needs assessment is likely to identify a range of potential 
problems to be addressed. In deciding which problems to 
tackle, a public health approach is useful. This approach 
firstly assesses the severity of the problems experienced by 
drug users and others, in terms of the nature of the problems 
and the number of people affected by them. It then looks 
Illicit drugs focus
Broader focus
Focus of national drug strategies 
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for interventions that will reduce the population impact of 
the drug problems that have been identified. This approach 
identifies priority areas for action, based on the evidence but 
influenced to some extent by political and public attitudes.
For example, in many European countries, drug overdose 
deaths are a major cause of mortality among men aged 
between 25 and 55 years and in some areas are increasing. 
Heroin or other opioids are implicated in the majority of 
these deaths. These premature deaths have a huge impact 
on families (who lose parents, children or siblings), on wider 
society, and place large demands on emergency health 
services. Reducing opioid-related deaths is therefore a high 
public health priority for drug policy in many jurisdictions.
Deaths and other adverse events associated with new 
psychoactive substances, although rare, often generate 
considerable media attention and public concern. Tackling 
the harms associated with the use of new psychoactive 
substances, which pose unknown risks to users, is therefore 
also a priority across Europe.
Another example is open drug scenes, where drug use and 
dealing take place in public spaces. These scenes, associated 
with public nuisance and possibly violence, often generate 
public concern, and may be a priority for intervention. 
Responses here need to consider both the needs of local 
communities and those of high-risk drug users.
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| Clarifying the objectives for the interventions
Having defined the drug problems that need to be tackled, 
the next step is to identify responses that are likely to 
be effective in dealing with them. Where possible, a 
combination of interventions should be used, as individual 
measures are rarely sufficient. Choosing the appropriate 
responses requires a clear understanding of the primary 
objectives for the interventions. For example, these 
objectives might be one or more of the following:
  to prevent young people from initiating drug use;
  to delay the age of initiation of drug use;
  to prevent experimental drug users from becoming regular 
users;
  to help people to stop using drugs;
  to reduce drug use and harm among people who are 
already using drugs;
  to reduce the drug-related harms experienced by 
communities; or
  to increase the social integration of people with drug 
problems.
The aims will depend upon an assessment of the nature 
and stage of development of the drug problem to be 
addressed, for example:
  Is a new drug beginning to cause problems although the 
number of users is still relatively small?
  Is an established drug like heroin with many high-risk drug 
users causing new problems?
  Is the concern about the resurgence of an illicit drug like 
MDMA?
In the case of a new psychoactive substance, the aim may 
be to discourage young people from experimentation and 
encourage those who have started to stop using or not to 
use regularly, while avoiding giving the impression that the 
use of such drugs is the norm. Research may be needed to 
identify problematic patterns of use of new drugs. Health 
educators may need to explore effective and targeted 
ways of informing drug users about the harms and riskiest 
patterns of drug use, such as peer based interventions, or 
messaging in selected social media that drug users trust.
In the case of an established drug, the aims may be to 
prevent initiation of drug use and to encourage users 
experiencing problems to engage with drug services.
| Selecting the most appropriate response options
The next stage, based on the needs assessment and 
defined objectives, is to decide on an appropriate response. 
There are potentially three ways of addressing this: 
extending or improving an existing response; importing an 
approach or programme that has been used elsewhere; 
or developing a new intervention. In some cases, it 
may be most appropriate to slightly modify existing 
responses (e.g. extending opening hours of a service or 
adding a component to a training programme). In other 
circumstances, a new intervention will be required and a 
number of factors need to be considered to help select the 
most appropriate and effective response (Figure 1.3).
The first questions are what response options are available 
to address the problem and what evidence exists for 
their effectiveness (see Spotlight on understanding and 
1.4  Developing appropriate health 
and social responses
Best practice portal
More detail on the evidence of what works for 
different drug problems, target groups and different 
settings, as well as guidelines and quality standards 
for delivery of different interventions, can be found 
in the Best practice portal on the EMCDDA website. 
Evidence updates are based on systematic reviews, 
reviews of reviews and synthesis of evidence included 
in guidelines (individual studies are usually not 
considered except in rare cases) and are developed in 
collaboration with members of the Cochrane and the 
Campbell collaborations and peer-reviewed by experts 
in the field. The Best practice portal also contains 
collections of European and international guidelines 
and standards and examples of practices.
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Spotlight on … Understanding and using evidence
The types of evidence that may be used in developing and implementing responses include:
  basic science, knowledge of which is useful when designing new interventions;
  evaluations of interventions, such as randomised controlled trials and other experimental designs or observational 
studies;
  implementation studies, which may investigate factors associated with effective service provision; and
  synthesis of expert opinion, for example, as used in guideline development, where all groups of stakeholders, including 
both providers and recipients of the intervention, are involved.
The various types of evidence differ in their strengths and weaknesses and in the information they can provide. Drug-
related problems are multifaceted and require not only medical, but also socio-economic and educational interventions. 
As a result it is often necessary to integrate evidence from a range of disciplines and types of study.
In reviewing what evidence is available to inform decision-making the first step is to define the research question, which 
in turn determines the most appropriate study design. For example, the effectiveness of treatment on individuals is best 
evaluated through randomised controlled trials. To determine the longer-term impact of an intervention that has already 
proven effective or for considering the impact of broader policies or population-based interventions, observational studies 
are likely to be more appropriate. These include interrupted time series or controlled before-and-after studies. It is also 
important to consider the quality and relevance of the available evidence. Are the findings from appropriate study designs; based 
on well-conducted studies that minimise biases; and reported correctly and related to the target groups of interest?
There are a number of ways of assessing the quality or strength of the available evidence. In general, the best evidence 
comes from systematic reviews that combine the results of multiple studies and assess their quality and the extent to 
which they show consistent findings. However, in emerging fields it can take some time for sufficient primary studies to be 
completed and systematic reviews undertaken, and services will often need to be developed in areas where the evidence 
base is weak or partial. When using evidence, it is also important to recognise that the strength of the evidence is not the 
only consideration; there can be effective interventions for which the evidence is currently weak, as well as strong evidence 
that suggests some interventions are ineffective or even can cause harm. Importantly, evidence statements are not broadly 
applicable, but linked to specific outcomes and, usually, specific populations, settings or both. 
To provide evidence ratings for interventions, this guide uses a system based mainly on systematic reviews but which 
also recognises where other more limited evidence exists. These ratings take account of the quality of the reviews, the 
quality of the primary studies they include and the consistency of the findings. The categories used in this guide are:
High quality evidence —  one or more up-to-date systematic reviews that include high-quality primary 
studies with consistent results. The evidence supports the use of the intervention within the context in 
which it was evaluated.
Moderate quality evidence — one or more up-to-date reviews that include a number of primary studies 
of at least moderate quality with generally consistent results. The evidence suggests these interventions 
are likely to be useful in the context in which they have been evaluated but further evaluations are 
recommended.
Lower quality evidence — where there are some high or moderate quality primary studies but no reviews 
available OR there are reviews giving inconsistent results. The evidence is currently limited, but what there 
is shows promise. This suggests these interventions may be worth considering, particularly in the context 
of extending services to address new or unmet needs, but should be evaluated.
The guide also features some good practice guidelines, which may incorporate areas of emerging practice or 
interventions that have not been subject to trials but are nevertheless accepted as valuable.
See the Background paper, Evidence review summary: drug demand reduction, treatment, and harm reduction.
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using evidence, page 23). Ideally, interventions should be 
supported by the strongest available evidence, if possible 
meta-analyses and systematic reviews of large-scale 
randomised controlled trials and observational studies of 
treatment outcome that combine the results of multiple 
studies of large numbers of individuals. However, this is 
not always available, and at the other end of the spectrum, 
when evidence is very limited or not available, expert 
consensus may be the best option available until better 
evidence is obtained.
If no suitable responses are available then research may 
be required to develop an intervention, investigate its 
feasibility, and evaluate its acceptability to the target group. 
Later, when the programme has been implemented and 
experience gained in using it, research will be needed to 
evaluate it.
The main types of responses available and modes of 
delivery are described briefly in section 1.5. A combination 
of response measures will often be required to tackle the 
multiple aspects of complex problems.
Another factor to be considered at this stage is the specific 
target groups for the intervention. For example, to whom will 
the programme be delivered:
  the whole population of potential users, for example, the 
adult population;
  subsets of the population who are at higher risk of 
initiating drug use or who may have particular needs, 
such as socially disadvantaged youth, homeless people, 
women, ethnic minority groups; or
  people who are already using drugs or have individual 
vulnerability?
A final consideration is the setting in which the programme 
will be delivered, such as schools, nightlife settings, 
workplaces, prisons or treatment facilities. These varied 
settings provide opportunities and impose constraints, 
which must be taken into account.
In addition to those listed above, other factors will need to 
be taken into account when making choices about the mix 
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of interventions to implement. These include the available 
structures and resources for delivering the interventions. 
For example:
  Are there government, not-for-profit, civil society and 
charitable organisations that are already providing these 
types of services?
  Are services available at a sufficient scale or do they have 
the capacity to expand their services?
  What additional resources may be required to enable them 
expand capacity, for example, funds for new buildings, 
additional staff and staff training?
At times of limited resources or if there is a need for a 
rapid response to a crisis, there may need to be a trade-
off between coverage of services (reaching the greatest 
number of people) and the intensity or level of provision 
(service quality) that can be provided.
The level of political priority given to the drug problem is 
an important factor in resource allocation. Is it sufficient 
to generate the resources needed to expand capacity? Or 
will existing service providers be expected to address the 
new problem within existing resources? How will decisions 
be made on prioritising the delivery of services to different 
clients and allocating resources between different services?
Public attitudes towards drug use may be major determinants 
of political priority, the amount of societal resources allocated 
to, and the approach taken in addressing drug problems. 
These attitudes will depend on the prevailing ‘governing 
images’ of drug use, whether drug use is primarily seen as a 
vice, a crime, a personal choice, an illness, or a disability.
A country’s drug laws may impact on which responses are 
provided. In all EU countries, possession of controlled drugs 
is defined by law as an offence and in many, use of these 
drugs is a crime. In principle, those who use illicit drugs can 
be sentenced to prison, but many countries take a public 
health approach to health and social problems arising from 
drug use and divert drug users from the criminal justice 
system into treatment. In some countries this has led to 
increased funding for treatment and assistance to address 
the health and social problems experienced by drug users.
Understanding the social costs of drug problems
The costs to society associated with the illicit drug phenomenon are extensive and varied. They include negative 
consequences for individuals and their families, as well as impacts on neighbourhoods and society at large. These 
result in expenditure on health care services and within the criminal justice system. Further costs include the provision 
of social benefits, funding of prevention interventions, and education and research concerning drug use.
Understanding the cost of drug-related responses is important for planning and setting priorities. However, information 
on drug-related public expenditure in Europe, at both local and national level, remains sparse and heterogeneous. For 
the 23 countries that have produced estimates in the past 10 years, it appears that drug-related public expenditure 
is in the region of between 0.01 % and 0.5 % of gross domestic product (GDP). Demand reduction is estimated to 
make up between 23 % and 83 % of total drug-related public expenditure, with drug treatment and other health costs 
accounting for much of that. A recent report (Drug treatment expenditure: a methodological overview) on methods for 
estimating expenditure on drug treatment has highlighted both the developments in the field of treatment expenditure 
estimation and also the many remaining challenges to the production of robust and comparable estimates. It also 
provides a basis for developing work in this area in the future.
However, public spending on responses to the drug problem is only part of the costs borne by society in relation to 
illicit drugs. There are also the costs borne by individuals and other external costs to society, such as lost productivity 
due to premature deaths and illness linked to drug use as well as the economic impact on neighbourhoods affected 
by drug dealing or open drug scenes. In addition to such potentially measurable costs must be added the human 
harm, pain and suffering and other consequences, which are not readily measurable but still need to be borne in mind. 
Estimates of these wider societal costs of drug use may be useful for estimating the impact and cost-benefit of health 
and social responses and making the case for allocating more resources to these responses. In the European countries 
for which information is available, the social cost of illicit drugs is estimated to be between 0.1 % and 2 % of GDP.
See the topic page on drug-related public expenditure on the EMCDDA website and LEADER project guidance document at Alicerap.eu.
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A wide range of health and social responses are available 
for tackling drug problems. These may be used with 
different populations, at different stages in the drug problem 
and individually or in combination. When considered at the 
national or local level, all these measures may form part of 
a comprehensive drug demand reduction system and they 
need to be co-ordinated and integrated.
| Prevention approaches
Approaches to drug prevention cover a wide spectrum, 
ranging from those that target society as a whole 
(environmental prevention) to interventions focusing on at-
risk individuals (indicated prevention). The main challenges 
are in matching these different strategies to target groups 
and contexts and ensuring that they are evidence-based 
and have sufficient population coverage. Most prevention 
strategies focus on substance use in general, some also 
consider associated problems, such as violence and 
sexual risk behaviour; a limited number focus on specific 
substances, such as alcohol, tobacco or cannabis.
Environmental prevention strategies aim to change the 
cultural, social, physical and economic environments in 
which people make choices about drug use. They include 
measures such as alcohol pricing and bans on tobacco 
advertising and smoking, for which there is good evidence 
of effectiveness. Other strategies aim to provide protective 
school environments, for example, by promoting a positive 
and supportive learning climate and teaching citizenship 
norms and values.
Universal prevention addresses entire populations, usually 
in school and community settings, with the aim of giving 
young people the social competences to avoid or delay 
initiation of substance use.
Selective prevention intervenes with specific groups, 
families or communities who are more likely to develop drug 
use or dependence, often because they have fewer social 
ties and resources.
Indicated prevention targets individuals with behavioural 
or psychological problems that predict a higher risk of 
substance use problems later in life. In most European 
countries, indicated prevention primarily involves 
counselling young substance users.
| Treatment
A range of interventions are used for the treatment of drug 
problems in Europe, including psychosocial interventions, 
opioid substitution and detoxification. The relative 
importance of the different treatment modalities in each 
country is influenced by several factors, including the 
organisation of the national health care system and the 
nature of the drug problems in each country. Drug treatment 
services may be provided in a variety of outpatient and 
inpatient settings: specialist treatment units; primary health 
care and mental health clinics; low-threshold agencies; 
hospital-based residential units and specialist residential 
centres; and units in prison (see Figure 1.4).
Most drug treatment in Europe is provided in outpatient 
settings and the two main modalities of outpatient treatment 
in Europe are opioid substitution treatment and psychosocial 
interventions.
Substitution treatment is the predominant intervention for 
opioid users in Europe. It is generally provided in specialist 
outpatient settings, though in some countries it is also 
available in inpatient settings and prisons. In addition, 
office-based general practitioners play an important role, 
often in shared-care arrangements with specialist addiction 
treatment centres, in about a third of all EU Member States.
Psychosocial interventions include counselling, 
motivational interviewing, cognitive behavioural therapy, 
case management, group and family therapy, and relapse 
prevention. These interventions support users to manage and 
overcome drug problems. They are the main form of treatment 
provided to users of stimulant drugs, such as cocaine and 
amphetamines. They are also provided to opioid users in 
combination with opioid substitution treatment. In many 
countries, responsibility for outpatient psychosocial treatment 
is shared between public institutions and non-governmental 
organisations. Commercial providers generally play a minor 
role in the provision of psychosocial interventions in Europe.
1.5  Main types of responses 
available
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A smaller proportion of drug treatment in Europe is provided 
in inpatient settings. Inpatient or residential treatment, 
whether hospital-based or non hospital-based, requires 
clients to live in the treatment facility for several weeks to 
several months, with a view to enabling clients to abstain 
from drug use. The provision of opioid maintenance 
treatment in inpatient settings is rare, but exists for 
selected client groups with high levels of morbidity. A 
prerequisite for entry may be detoxification, a short-term, 
medically supervised intervention aimed at the reduction 
and cessation of substance use, with support provided 
to alleviate withdrawal symptoms or other negative 
effects. Detoxification is usually provided as an inpatient 
intervention in hospitals, specialised treatment centres or 
residential facilities with medical or psychiatric wards.
In inpatient settings, clients receive individually structured 
psychosocial treatments and take part in activities to 
rehabilitate and reintegrate them into society. A therapeutic 
community approach is often used. Inpatient treatment 
may also be provided in psychiatric hospitals for those with 
comorbid mental health problems. Public institutions, the 
private sector and non-governmental organisations are all 
involved in the provision of inpatient care in Europe, with the 
main providers varying between countries.
Increasingly, a wide range of drug prevention and treatment 
interventions are provided online. Internet-based interventions 
have the potential to extend the reach and geographical 
coverage of treatment programmes to people experiencing 
drug use problems who may not otherwise access specialist 
drug services (see Spotlight on e-health, page 119, and the 
Background paper on e-health and m-health).
| Social reintegration
Social exclusion is experienced by many high-risk drug 
users, especially chronic opioid users. Unemployment 
and low educational attainment are common, and many 
are homeless or living in unstable accommodation. 
Interventions addressing these issues focus on the social 
reintegration of drug users, including improving a person’s 
ability to gain and maintain employment.
Approaches taken include vocational training programmes 
that aim to improve skills and qualities needed to find 
and secure employment. The transition from treatment 
to mainstream employment may be facilitated by social 
enterprises and cooperatives that offer work experience 
and supported employment. Programmes that engage with 
employers to encourage them to employ people who have 
had drug problems and provide in-work support are also 
valuable (see section 4.3 on responses in the workplace).
Addressing housing problems is also often essential for 
social reintegration. Housing support services may provide 
short- or long-term accommodation, as well as access 
to other services such as medical care, drug treatment, 
social activities, education and training. These include 
programmes such as ‘Housing First’, which provide 
accommodation as quickly as possible before tackling an 
individual’s drug problem or providing other support.
| Harm reduction
Harm reduction encompasses interventions, programmes 
and policies that seek to reduce the health, social and 
economic harms of drug use to individuals, communities 
and societies. A core principle of harm reduction is the 
FIGURE 1.4
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development of pragmatic responses to dealing with drug 
use through a hierarchy of intervention goals that place 
primary emphasis on reducing the health-related harms of 
continued drug use. It addresses the immediate health and 
social needs of problem drug users, especially the socially 
excluded, by offering opioid substitution treatment and 
needle and syringe programmes to prevent overdose deaths 
and reduce the spread of infectious diseases. Additional 
approaches include outreach work, health promotion and 
education.
In 2003, the Council of the Ministers of the European Union 
passed a recommendation on the prevention and reduction 
of health-related harm associated with drug dependence, 
in which Member States were urged to adopt a number 
of policies and interventions to tackle health-related harm 
associated with drug dependence. In 2007, the Commission 
of the European Communities confirmed the prevention and 
reduction of drug-related harm as a public health objective 
in all countries. National drug policies increasingly reflect 
the harm-reduction objectives defined in the EU drugs 
strategy, and there is broad agreement within Europe on 
the importance of reducing harms, in particular the spread 
of infectious diseases and overdose-related morbidity and 
mortality.
In the more recent past, new opportunities for improving 
the reach and effectiveness of harm reduction interventions 
have opened up, especially through developments in the 
field of information technology and mobile applications. 
New approaches include, for example, the use of e-health 
applications to deliver brief interventions and recovery 
support more widely, and the use of behavioural insights 
to develop more effective programmes (see also Spotlight 
on e-health interventions, page 119, and Spotlight on 
behavioural insights, page 169).
Implementing, monitoring and evaluating the selected responses
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1.6  Implementing, 
monitoring and evaluating 
the selected responses
Successful implementation of any policy response depends 
on a range of factors that will need to be considered 
when planning or reviewing policies or programmes (see 
Figure 1.5).
| Factors affecting implementation
Firstly, policymaker and public support is essential. 
Policymakers and the public need to agree that there is a 
drug problem that requires a specific response. They may 
also need to be persuaded that a public health approach 
is more appropriate than a largely public order response. 
Advocacy that draws attention to the cost-benefits of action 
and inaction may be needed to ensure the allocation of the 
societal resources required for an effective public policy 
response.
Effective implementation of an intervention depends on 
having sufficient numbers of skilled staff to deliver it. This 
may require training additional staff to allow services 
to expand. It may also involve retraining staff more 
accustomed to dealing with other types of problem drug 
users (e.g. injecting opioid users rather than problem 
stimulant or cannabis users) or who need to work with new 
groups, such as younger drug users.
Interventions also require appropriate facilities and 
locations to house treatment, conduct outreach or other 
programmes. Community engagement may be essential if 
communities are to host treatment or outreach services. 
Concerns that will need to be addressed include fears that 
services will attract drug users and increase drug-related 
problems, or lead to users congregating around services 
and openly engaging in drug dealing and drug use.
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| Management and co-ordination of services
Management systems are needed to co-ordinate the efforts 
of different agencies and services that are attempting 
to address drug problems. Co-ordination may require 
the establishment of advisory committees or reference 
groups with broad representation from key stakeholders. 
These can determine the direction of an overall strategy. 
They also ensure the involvement of all those affected by 
a policy, which facilitates wider acceptance of the policy 
approaches.
In addition, the interaction between drug problems and 
other health and social problems means that it is important 
to ensure proper co-ordination between drug services and 
other health services. For example, drug problems are often 
associated with mental health problems and it is therefore 
essential that drug and mental health services work 
together to ensure both problems are addressed effectively 
(see Spotlight on comorbid substance use and mental 
health problems, page 31). Unfortunately, this often does 
not occur.
Quality standards for service provision are another 
mechanism for assisting effective implementation. These 
are discussed in Chapter 5. The EU has published minimum 
quality standards in drug demand reduction that cover 
prevention, risk and harm reduction and treatment, social 
reintegration and rehabilitation.
Regular consultations with agencies involved in service 
delivery may be needed in order to identify and address 
implementation problems. Service user representatives 
can provide feedback on service performance and make 
suggestions on how to improve service design and delivery. 
It is critical to create an organisational culture in which there 
is collaboration rather than competition between agencies 
and services for resources and clients.
| Monitoring and evaluation of service delivery
Monitoring, evaluation and feedback are essential for 
good service delivery. They enable staff to monitor the 
performance of their programmes, improve delivery, assess 
cost-efficiency and account to funders on the services 
that they deliver. It should also allow the identification of 
unintended negative consequences of interventions or other 
actions, for example, a change in practice leading to higher 
drop-out rates, or where actions taken to prevent diversion 
of prescription medicines reduce access for patients 
who require them, leading to ineffective treatment and 
associated pain and suffering and increased health care 
costs.
Monitoring the implementation and uptake of interventions 
requires sustainable data collection systems. If the data are 
to be useful, forms need to be routinely and well completed. 
Results should be fed back to staff to demonstrate the 
value of data collection. Examples of the types of questions 
that need to be asked in monitoring and evaluating 
interventions are:
  What types of intervention have been delivered (e.g. 
counselling, social support, opioid substitution treatment)?
  How many and what types of clients or target groups have 
they served?
  What are the outcomes in terms of preventing or reducing 
drug use and drug-related harm or improving quality of life 
of clients?
  How do the intervention costs compare to alternative 
programmes or services?
These data are valuable for both internal and external 
purposes, for example: evaluating and refining services and 
responses to clients; reporting to funding bodies; making 
the case for continued or additional funding for current 
services; or arguing for alternative more cost-effective 
interventions. Monitoring and assessment of ongoing 
service delivery are usually undertaken by the services 
themselves, while outcome and impact evaluation is ideally 
undertaken by external evaluators, who can be more 
objective. Monitoring and evaluation is discussed in more 
detail in section 5.3.
As there may be a delay before interventions have any 
detectable effects on drug-related harm, the challenge for 
policymakers may be to ensure that services continue to be 
funded when a perceived drug crisis has passed. Research 
findings on the impact of services, their cost-effectiveness 
and the population-level scale of drug problems can play a 
useful role in this process.
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Spotlight on … Comorbid substance use and mental health problems
Mental health problems are very common in those with a substance use disorder, and these patients have more 
clinically and psychosocially severe problems than patients with substance use disorders without comorbid mental 
health problems.
The most frequent psychiatric comorbidities among individuals with substance use disorders are major depression, 
anxiety (mainly panic and post-traumatic stress disorders) and personality disorders (mainly antisocial and borderline). 
The presence of these comorbid mental health problems increases the difficulty of treating substance use disorders, 
increases the risk of chronicity, and leads to poorer prognoses for both the psychiatric and the substance use disorders.
There is broad agreement in the literature that the two types of disorders should be addressed using a multidisciplinary 
approach in which drug and mental health professionals work together towards common goals. However, there is a lack 
of consensus on the most appropriate treatment setting and the best pharmacological and psychosocial strategies 
to use.
The main barrier in treating comorbid substance use and psychiatric disorders is the separation of mental health and 
drug use treatment networks in most European countries. This often means that each treatment service lacks sufficient 
expertise to treat both types of disorders and this leads to different treatment approaches, regulations and financial 
resources.
Improving responses for people with comorbidity
A systematic approach is needed to detect and treat comorbid mental health problems in people with substance use 
disorders.
Substance use and psychiatric disorders should be assessed using validated instruments. Standard screening 
instruments for substance use disorders and for psychiatric disorders can be used routinely when limited staff time or 
lack of expertise prevents more extended assessments.
The therapeutic approaches to tackle dual diagnosis, whether pharmacological, psychological or both, have to address 
both disorders from the first point of contact to identify the best option for each individual.
There is a need for:
  An in-depth review of service organisation in European countries.
  A multinational study using a standardised methodology to facilitate cross-national comparisons.
  The introduction of specific items about psychiatric comorbidity in substance use disorder patients into reporting 
systems across Europe to allow routine monitoring.
  Treatment outcome studies to improve the evidence base for pharmacological and psychosocial treatments for people 
with comorbid substance use and psychiatric disorders.
  A comprehensive review and research on possible early interventions to identify high-risk cases (e.g. early adolescents) 
in order to develop prevention measures.
See the 2015 EMCDDA Insight, Comorbidity of substance use and mental disorders in Europe.
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Further resources
EMCDDA
  Prevention and Evaluation Resources Kit (PERK).
  Evaluation Instruments Bank.
  Best practice portal.
  Drug-related public expenditure.
  Drug treatment expenditure: a methodological overview, EMCDDA Insights, 2017.
  National drug strategies in Europe: trends and developments, 2017.
  Evidence review summary: drug demand reduction, treatment, and harm reduction, Harry R. Sumnall, Geoff Bates and 
Lisa Jones, Background paper.
Other sources
  EU drug strategy (2013–2020).
  EU action plan on drugs 2017–2020.
  EU Common Position on UNGASS 2016.
  EU Minimum Quality Standards for demand reduction.
  LEADER project guidance. 
  Report ‘On the implementation of the Council Recommendation of 18 June 2003 on the prevention and reduction of 
health-related harm associated with drug dependence’.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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This chapter considers problems from the perspective of 
particular patterns of drug use and the specific substances 
that are of concern in many EU countries. In each case an 
overview of the most important aspects of the problem 
is provided along with a review of the interventions 
that might be appropriate to respond to them. This 
is accompanied by a short summary of the evidence 
available on effectiveness, a review of the responses that 
are currently in use across Europe and consideration of 
some of the related implications for policy and practice. 
Links are also provided to more detailed information on the 
topics covered.
The drug problems covered in this chapter are:
  problems associated with cannabis use;
  opioid dependence;
  opioid-related deaths;
  viral hepatitis, HIV and other infections associated with 
injecting use;
  problems associated with stimulant use;
  new psychoactive substances;
  misuse of medicines;
  polydrug use.
CHAPTER 2
Problems arising from 
particular types or 
patterns of drug use
Problems arising from particular types or patterns of drug use
SUMMARY
Issues
Cannabis use can result in, or exacerbate, 
a range of physical and mental health, 
social and economic problems. Problems 
are more likely to develop if use begins at 
a young age and develops into regular and 
long-term use. The primary objectives for 
health and social responses to address 
cannabis use and associated problems 
should therefore include:
  preventing use, or delaying its onset from 
adolescence until young adulthood;
  preventing the escalation of cannabis 
use from occasional to regular use;
  reducing harmful modes of use; and
  providing interventions, including 
treatment, for people whose cannabis 
use has become problematic.
Response options
  Prevention programmes, such as multicomponent school interventions 
that develop social competences and refusal skills, healthy decision-
making and coping, and correct normative misperceptions about drug 
use; family interventions; and structured computer-based interventions.
  Brief interventions, for example, motivational interviewing delivered in 
emergency departments or primary care settings.
  Treatment: research suggests that cognitive behavioural therapy, 
motivational interviewing and contingency management can reduce 
cannabis use and harm in the short term; multidimensional family 
therapy can help reduce use in high-severity young patients; and some 
web- and computer-based interventions can reduce cannabis use in the 
short term.
  Harm reduction interventions, for example, addressing the harms 
associated with smoking cannabis, especially when used together with 
tobacco.
European picture
  Universal prevention is widespread but not always evidence-based. 
Selective prevention approaches are used in some European countries, 
most commonly with young offenders or with youth in care institutions, 
but little is known about their effectiveness. Indicated prevention 
approaches and brief interventions do not appear to be widely used.
  Many EU countries offer treatment for people with cannabis problems 
within generic drug treatment programmes, and cannabis-specific 
treatment is available in half of the countries. Most treatment is provided 
in community or outpatient settings and increasingly online.
 keywords: cannabis,  
 prevention, e-health,  
 young people,  
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 brief interventions 
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|  Understanding the problem and key objectives for responses
Cannabis is the most widely used illicit drug in Europe and 
globally. An estimated 17.1 million young Europeans (aged 
15–34), or 13.9 % of this age group, used cannabis in the 
last year. This estimate includes 10 million aged 15–24 
(17.7 % of this age group). The age of first use of cannabis 
is lower than for most other illicit drugs and cannabis use is 
highest among young adults.
Cannabis use is often experimental, commonly lasting for 
only a short period of time in early adulthood. However, 
a minority of users do develop more persistent and 
problematic patterns of cannabis use and these problems 
are strongly associated with regular, long-term and high-
dose use. These problems can include:
  poor physical health (e.g. chronic respiratory symptoms);
  mental health problems (e.g. cannabis dependence and 
psychotic symptoms); and
  social and economic problems arising from poor school 
performance, failure to complete school, impaired work 
performance or involvement in the criminal justice system.
These outcomes are more likely if users begin regular use 
in adolescence, when young brains are still developing. The 
risks may increase with the use of higher potency cannabis 
products, especially those with high concentrations of the 
psychoactive component tetrahydrocannabinol (THC) and 
lower concentrations of another component, cannabidiol 
(CBD).
The negative consequences for young people of criminal 
records for use or possession offences have raised 
concerns in some countries that criminal penalties may 
be disproportionate to the harms caused by cannabis use 
itself. This is one of the factors driving experimentation with 
different regulatory models in this area (see Spotlight on the 
impact of new cannabis regulation models on responses, 
page 40).
In Europe, the most common method of using cannabis is 
by smoking it mixed with tobacco. This brings additional 
health risks and the associated nicotine dependence may 
also make treatment more difficult. It also points to the need 
for a more holistic consideration of policies and responses 
relating to cannabis and tobacco.
Concerns have also been growing about problems 
associated with highly potent synthetic cannabinoid 
receptor agonists, commonly referred to as synthetic 
cannabinoids. Despite acting on the same cannabinoid 
receptors in the brain, these substances are very 
different from cannabis and are discussed in this report 
in section 2.6 on new psychoactive substances and 
section 4.1 on prisons.
The primary objectives for health and social responses 
to address cannabis use and associated problems may 
include:
  preventing use, or delaying its onset from adolescence 
until young adulthood;
  preventing the escalation of cannabis use from occasional 
to regular use;
  reducing harmful modes of use; and
  providing treatment for people whose cannabis use has 
become problematic.
Policymakers might also want to consider how to reduce the 
involvement of young cannabis users in the criminal justice 
system.
| Response options
Interventions to prevent, delay onset or escalation 
of cannabis use
Prevention programmes that are effective in relation to 
cannabis use generally take a developmental perspective 
and are not substance-specific. Prevention programmes 
for adolescents often aim to reduce or delay cannabis use 
along with the use of alcohol and cigarettes.
Well-designed school-based prevention programmes have 
been shown to reduce cannabis use. Such programmes are 
manualised (that is their implementation is standardised 
through the use of protocols and manuals for those 
delivering them) and generally have multiple aims: to 
develop social competences and refusal skills; to improve 
decision-making and coping; to raise awareness of social 
influences on drug use; to correct normative misperceptions 
that drug use is common among peers; and to provide 
information about the risks of using drugs. School-based 
programmes that focus solely on increasing students’ 
knowledge of the risks of drug use have been found to be 
ineffective in preventing cannabis and other drug use. For 
examples of positively evaluated programmes see the Best 
practice portal (see also section 4.4).
There is moderate quality evidence that some manualised 
universal family interventions for parents and children 
may prevent cannabis use. Prevention programmes that 
are delivered across multiple settings and domains (e.g. in 
school and to the family, involving mentoring and media 
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campaigns) appear to be the most effective. Evidence on 
the effectiveness of selective prevention targeted at the 
families of young people categorised as ‘at-risk’ is mixed 
and no conclusions can be drawn about the effectiveness 
of this approach.
Standalone mass media campaigns (including TV, radio, 
print and internet) that use social marketing principles 
and disseminate information about the risk of using 
drugs tend to be evaluated as ineffective in respect to 
behavioural change. It is therefore generally recommended 
that they should only be considered as part of a wider 
set of programmes that incorporate a broader range of 
approaches.
Brief interventions generally aim to intervene in the early 
stages of drug use to reduce the intensity of use or 
prevent escalation to problem use. They are most often 
used in responding to drugs that are commonly used 
by young people, such as cannabis. These interventions 
are time-limited and targeting and delivery methods vary 
considerably. Part of the attraction of this approach is 
that it may be used in different settings, for example, by 
general practitioners, counsellors, youth workers or police 
officers. They often incorporate elements of motivational 
interviewing. A recent EMCDDA review found that while 
there was some research supporting their effectiveness, 
this remains limited and this is an area where further 
studies are required. Some innovative work has been done 
in developing online brief interventions, and there is some 
also some limited (lower quality) evidence that structured 
interventions delivered via computers and the internet may 
help prevent cannabis use when delivered in schools, or to 
family groups.
Harm reduction for cannabis use
Harm reduction for cannabis use has received less attention 
than for other substances but is nevertheless important. 
Harm reduction interventions for cannabis users may 
focus on avoiding more problematic consumption patterns, 
limiting consumption, and raising awareness of the need for 
vigilance against possible negative impacts of use on other 
areas of life, for example, school performance or social 
relationships. A recent review of the literature by Fischer 
et al. (2017), undertaken to update Low Risk Cannabis 
Guidelines for Canada, provides relevant evidence-based 
recommendations that are drawn on below.
Addressing the specific harms associated with smoking 
cannabis, especially in combination with tobacco, is 
another important, but neglected topic. Interventions in 
this area would focus on encouraging alternative routes 
of administration, which do not involve smoking or use of 
tobacco, and limiting harm from inhalation.
Alternatives to smoking, such as vaporisers or edibles, are 
available although these methods are not risk-free. Use of 
edibles eliminates respiratory risks but the delayed onset 
of psychoactive effect may result in the use of larger than 
intended doses and acute adverse effects. There is little 
evidence on which to judge the potential relative benefits or 
harms of some of the established and new technologies in 
Overview of the evidence on … interventions to prevent or delay cannabis use
Multicomponent interventions can reduce alcohol and cannabis use when delivered in schools using 
social influence approaches, correcting normative misperceptions and developing social competences 
and refusal skills. Programmes that only provide information about the risks of using drugs have not been 
found to be effective in preventing use.
Universal family interventions, such as Familias Unidas, Focus on Kids, Strengthening Families 10–14, may 
be effective in preventing cannabis use when delivered across multiple settings and domains.
Structured computer-based interventions may be effective in preventing cannabis use when delivered in 
schools or to family groups.
Motivational interviewing interventions targeting cannabis use may be effective when delivered in 
emergency departments or primary care settings.
It is unclear if school-based brief interventions can reduce substance use in young people although some 
information suggests they may possibly have some limited impact on cannabis use.
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this area. Nevertheless it is clear that from a public health 
point of view the co-use of tobacco with cannabis should be 
avoided.
Smoking practices, such as ‘deep inhalation’ and breath-
holding, which are commonly used when smoking cannabis, 
increase the intake of toxic material into the lungs. Users 
should be encouraged to avoid these practices.
Higher THC-content products are associated with higher 
risks for acute and chronic problems. Users should be made 
aware of the value of knowing the nature and composition 
of the cannabis products that they use. There is some 
experimental evidence to suggest that CBD may moderate 
the psychoactive and potential adverse effects of THC, so 
the use of cannabis containing lower THC and higher CBD 
levels would be advisable. However, in an illicit market, 
information on the THC and CBD content is not generally 
available.
Research suggests that driving while intoxicated with 
cannabis increases the risks of having a motor vehicle 
accident, and these risks are likely to greater if alcohol 
or other psychoactive substances are also consumed. It 
would appear prudent that users should refrain from driving 
(or operating dangerous machinery) for at least 6 hours 
after using cannabis. Users also need to be aware of, and 
respect, locally applicable legal limits defining cannabis-
impaired driving.
The use of cannabis should be particularly avoided by 
some population groups that appear to be at higher risk 
of experiencing cannabis-related harm. These include 
individuals with a personal or family history of psychosis or 
a substance use disorder, adolescents, and also pregnant 
women, to avoid adverse effects on the foetus.
Treatment for problematic cannabis use
Treatment for cannabis problems is based mainly on 
psychosocial approaches, family-based interventions 
for adolescents and cognitive behavioural interventions 
for adults. The available evidence provides support 
for a combination of cognitive behavioural therapy, 
motivational interviewing and contingency management. 
In addition, there is some moderate quality evidence that 
multidimensional family therapy may be effective for young 
cannabis users. Internet and digital-based interventions 
are increasingly used to reach cannabis users and show 
promising preliminary results in reducing consumption and 
facilitating face to face treatment (when needed). Better 
quality evidence is needed on the effectiveness of this 
approach.
A number of experimental studies are investigating 
the use of pharmacological interventions for cannabis-
related problems. This includes the potential for using 
THC, and synthetic versions of it, in combination with 
other psychoactive medicines, including antidepressants, 
anxiolytics and mood stabilisers. To date, results have been 
inconsistent, and no effective pharmacological approach to 
treat cannabis dependence has been identified.
|  What is being done in Europe to respond to cannabis use and associated problems
Prevention
Manualised universal prevention programmes aimed at 
developing social competences and refusal skills and 
addressing social influences and correcting normative 
misperceptions about drug use are reported to be a central 
component in national prevention programmes in seven 
EU countries. Evidence-based family programmes have a 
Overview of the evidence on … treating problematic cannabis use
Behavioural interventions (e.g. cognitive behavioural therapy, motivational interviewing and contingency 
management) can reduce use and improve psychosocial functioning in adults and adolescents in the 
short term.
Multidimensional family therapy helps reduce use and keep patients in treatment, especially in high-
severity young patients.
Web- and computer-based interventions may be effective in reducing cannabis use, at least in the short 
term, and are a cost-effective way of reaching a large number of cannabis users.
40 |
Problems arising from particular types or patterns of drug use
Spotlight on … The impact of new cannabis regulation models on responses
Cannabis regulation in the European Union
A number of EU jurisdictions have reduced penalties for using or possessing small amounts of cannabis and, in some cases, 
for cultivation of a few plants for personal use. Most EU countries now use fines, cautions, and probation as penalties for 
possession of small quantities of cannabis. Most of these changes have been the result of changes in formal or informal 
enforcement policies towards possession rather than national legal changes.
The Netherlands has tolerated small retail sales of cannabis for about 40 years. More recently, Spain’s cannabis social clubs 
have produced cannabis for non-profit supply to members. These clubs have proliferated and are appearing in other parts 
of Europe. Medicinal products derived from cannabis have been approved for use in many EU countries and, at the time of 
publication, cannabis use for medical purposes is allowed or tolerated in several Member States.
Cannabis legalisation in the Americas
In contrast to the European Union, a policy of legalising recreational cannabis use by adults has been introduced in some 
parts of the Americas:
  Citizens in eight US states voted to allow the commercial production and sale of cannabis to adults for recreational 
use (Colorado and Washington, 2012; Oregon and Alaska in 2014; and California, Massachusetts, Maine and Nevada 
in 2016). In addition, voters in Washington DC approved a measure to legalise home grows, possession, and gifting of 
cannabis, but not retail stores.
  In 2013, Uruguay was the first country to legalise cannabis for adult use.
  In 2017 the Canadian federal government introduced legislation to legalise commercial production and sale of cannabis 
for recreational use by adults.
Pros and cons of legalisation
Advocates of legalisation have argued that it will: limit adolescents’ access to cannabis; improve the regulation of cannabis 
products; reduce cannabis users’ exposure to more harmful drugs; eliminate criminal penalties for cannabis use; and generate 
tax revenue that can be used to prevent and treat cannabis use disorders.
Opponents of legalisation argue that the associated normalisation of cannabis use and eventual reduction in price will 
increase the number of cannabis users and heavy use among existing users, and thereby increase overall cannabis-related 
harm in the community. They also note that we know very little about the health consequences of the high-potency products 
typically sold in states that have legalised.
What are the possible impacts of cannabis legalisation?
It is too early to draw strong conclusions about the impact of cannabis legalisation, but the following potential positive and 
negative impacts should be monitored:
  Changes in the level or patterns of cannabis use.
  Presentations to emergency departments for accidental poisonings of children; cannabis intoxication in adults; and 
severe vomiting syndromes in heavy users.
  Treatment seeking for cannabis use among adults and adolescents, and referral sources.
  Motor vehicle accidents, in total and those involving cannabis and alcohol.
  Linked changes in the use and harms associated with other controlled and regulated psychoactive substances 
(including alcohol, tobacco, medicines and illicit drugs, such as opioids) to assess the overall public health impact.
  Costs associated with different approaches (including criminal justice costs, the impact on offending, and costs 
associated with regulating the marketplace).
See the 2017 EMCDDA report on cannabis legislation in Europe and the Background paper, New developments in cannabis regulation.
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slightly wider availability. Other countries have prioritised 
other prevention approaches, for example, environmental 
prevention measures (see section 4.2 for more information 
about these) or community approaches (see section 4.5).
Selective prevention responses for vulnerable groups are 
common in the Nordic countries, Ireland, and parts of Spain 
and Italy. These address both individual behaviours and 
social contexts and, at the local level, often involve multiple 
services and stakeholders (e.g. social services, family, 
youth and police). The most common target groups are 
young offenders, pupils with academic and social problems 
and youth in care institutions. Little is known about the 
contents of these prevention strategies and evaluations 
of their effectiveness are limited. Expert opinion suggests 
that the most commonly used techniques are based on 
information provision. Provision of indicated prevention 
for at-risk individuals is limited in Europe, with only four 
countries reporting that these programmes are available to 
the majority of those in need of them (see also section 3.4 
on responses for vulnerable young people).
Brief interventions
The relatively low cost of brief interventions and the fact 
that they can potentially be delivered in multiple settings 
by a variety of professionals after only brief training makes 
them intuitively appealing but also very varied in nature. 
Examples that have been implemented in several European 
countries include eSBIRT, which provides brief interventions 
in emergency departments; Preventure, a programme for 
schoolchildren assessed as having risky personality traits; 
and Fred, which targets young people at an early stage 
of criminal prosecution. However, it appears that brief 
interventions have not been widely implemented in Europe. 
Only three countries report full and extensive provision of 
these interventions in schools, and two report this level of 
provision in low-threshold services.
In France special centres have been established for young 
people who use cannabis or other psychoactive substances, 
and also for their relatives, who may be reluctant to access 
traditional treatment services. These Consultations Jeunes 
Consommateurs (CJC) are subordinate to specialist 
addiction treatment centres (CSAPA). Their mission is to 
intervene early, between prevention and care.
Treatment for cannabis problems
The number of first-time treatment entrants for cannabis 
problems in the European Union increased from 43 000 
in 2006 to 76 000 in 2015 (Figure 2.1). Since 2009, 
cannabis has been the most frequently reported primary 
drug among new treatment clients. This rise may be due to 
a number of factors including changes in cannabis use in 
the general population, especially intensive use; changing 
risk perceptions; increasing availability of more potent 
cannabis products; and changes in treatment provision 
and referral. The criminal justice system has become an 
important source of referral for cannabis treatment; in 
2015 over a quarter of cannabis users entering treatment 
for the first time in Europe were referred from the criminal 
justice system, and in some countries this proportion 
is considerably higher. The data are also influenced by 
FIGURE 2.1
Cannabis users entering treatment in Europe: trends over time and source of referral in 2015
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Trends in first-time entrants are based on 23 countries. Due to changes in the flow of data at national level, data since 2014 for Italy is not comparable with 
earlier years.
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differing national definitions and practices with respect to 
what constitutes treatment for cannabis-related disorders, 
which can range from a brief intervention session delivered 
online to admission to residential care.
In Europe, most cannabis treatment is provided in 
community or outpatient settings, but it is also worth noting 
that around one in five people entering inpatient drug 
treatment report primary cannabis-related problems. While 
many European countries offer treatment for people with 
cannabis problems within generic substance use treatment 
programmes, around half have cannabis-specific treatment 
options. The development of specific cannabis treatment 
programmes may be linked to specific local or national 
needs (e.g. existing services may be very opioid-focused 
and not attractive to some groups of cannabis users).
Availability and coverage of treatment options to cannabis 
users differ between countries and may not necessarily be 
related to the availability of specific programmes. In those 
countries that have developed cannabis-specific treatment, 
coverage of the affected population is rated as ‘good’, and 
experts report that the majority of individuals in need of 
treatment for cannabis use disorders have access to treatment. 
A few countries, however, have only limited coverage, 
sometimes despite high overall levels of need. Less is known 
about the accessibility of treatment for cannabis use disorders 
in countries that do not offer cannabis-specific interventions. 
Responding to cannabis use and problems: implications for policy and practice
Basics
  Core responses in this area include general prevention approaches aimed at discouraging use or delaying onset, brief 
interventions for those with minor problems and formal treatment for those with more serious problems.
Opportunities
  More attention should be paid to harm reduction approaches to cannabis use, particularly with respect to the patterns 
of use and co-use with tobacco.
  Greater use of e-health approaches.
  The new regulatory models for cannabis that are emerging globally can provide valuable information on the pros and 
cons of different options for regulation and their likely impact on responses to cannabis problems.
Gaps
  There is still a need to develop a better understanding of the nature of cannabis-related disorders and what constitutes 
the most effective and appropriate treatment options for different clients.
  A better understanding is needed of the types of treatment being received by the increasing numbers of people entering 
treatment for cannabis use in Europe, in order to ensure that provision is appropriate and efficient.
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Further resources
EMCDDA
  Best practice portal.
  Statistical bulletin.
  Cannabis legislation in Europe, 2017.
  European drug report: trends and developments 2017.
  Treatment of cannabis-related disorders in Europe, Insights, 2015.
  New developments in cannabis regulation, Beau Kilmer, Background paper.
  Implementation of drug-, alcohol- and tobacco-related brief interventions in the European Union Member States, 
Norway and Turkey, Technical report, 2017.
Other sources
  Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J. and Room, R. (2017), ‘Lower-risk 
cannabis use guidelines: a comprehensive update of evidence and recommendations’, American Journal of Public 
Health: published online before print June 23, 2017. DOI: 10.2105/AJPH.2017.303818
  Montanari, L., Guarita, B., Mounteney, J., Zipfel, N. and Simon, S. (2017), ‘Cannabis use among people entering drug 
treatment in Europe: A growing phenomenon?’, European Addiction Research 23, pp. 113–121.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
Although the prevalence of opioid 
dependence among European adults is low 
and varies considerably between countries, 
it is associated with a disproportionate 
amount of drug-related harm that includes 
infectious diseases and other health 
problems, mortality, unemployment, crime, 
homelessness and social exclusion. Heroin 
use remains a major concern but in many 
European countries the use of synthetic 
opioids has also been growing and in a few 
countries now predominates.
Response options
  Pharmacological interventions, such as opioid substitution treatment (OST), usually 
with methadone of buprenorphine. Heroin-assisted treatment may be useful for 
people who have not responded to other forms of OST.
  Behavioural and psychosocial interventions to address psychological and social 
aspects of drug use include brief interventions, structured psychological therapies, 
motivational interventions, contingency management, and behavioural couples 
therapy. They are often used in conjunction with pharmacological interventions.
  Residential rehabilitation involves living in a treatment facility and following a 
structured, care-planned programme of medical, therapeutic and other activities.  
This approach is suitable for clients with medium or high levels of need.
  Self-help and mutual aid groups teach cognitive, behavioural and techniques of  
self-management without formal professional guidance.
  Recovery/reintegration support services, for example, employment and housing 
support.
Effective long-term treatment of opioid dependence often requires multiple treatment 
episodes and combinations of responses. Harm reduction interventions, mental health 
and other services, addressing co-occurring mental and physical health problems, will 
also be important.
European picture
  Opioid users are the largest group in specialised drug treatment in Europe. However, 
differences exist between countries. These differences reflect variations in prevalence 
but also in the orientation of the drug treatment systems.
  The most common treatment approach is opioid substitution treatment, usually 
provided in outpatient settings. Methadone (63 %) and buprenorphine (35 %) are 
the medicines most commonly used for OST in Europe. It is estimated that overall, 
around 50 % of people with opioid dependence receive some form of substitution 
treatment but coverage varies greatly between countries.
  All European countries provide some residential treatment but the level of provision 
varies greatly.
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|  Understanding the problem and key objectives for responses
Injecting use of opioids, particularly heroin, has been the 
major drug problem in many European countries for the last 
40 years. Heroin is the most commonly used illicit opioid 
in Europe and may be smoked, snorted or injected. The 
misuse of opioids other than heroin, such as methadone, 
buprenorphine and fentanyl, may be increasing. In three 
countries these were the most common opioids used by 
people entering treatment in 2015: fentanyl in Estonia and 
buprenorphine in the Czech Republic and Finland.
The prevalence of high-risk opioid use among adults (15–
64) in Europe is estimated at 0.4 % of the EU population 
or about 1.3 million people. However, there is considerable 
variability in prevalence between countries, with estimates 
ranging from less than 1 to more than 8 cases per 1 000 
population aged 15–64. It should also be noted that 
producing these estimates is methodologically challenging 
and they need to be interpreted with caution.
Although the prevalence of illicit opioid use is much 
lower than that of other drugs, the opioids account for a 
disproportionate amount of drug-related harm including:
  high rates of dependence, often associated with 
unemployment, criminal acts to obtain money to buy 
drugs, homelessness and social exclusion;
  large numbers of opioid-related deaths, particularly from 
overdoses;
  ‘open drug scenes’ and drug-related crime that blight 
some neighbourhoods; and
  the spread of HIV, viral hepatitis and other infections 
through sharing injecting equipment.
Primary opioid users make up a large proportion of people 
in drug treatment. Problematic opioid use is also associated 
with social exclusion and disadvantage, and overcoming 
addiction and reintegrating into communities often requires 
long-term treatment and multiple treatment episodes.
Overall the available data suggest that new recruitment 
into heroin use, and especially injecting use, is lower now 
than in the past. However, many long-term opioid users in 
Europe are polydrug users who are now in their 40s and 
50s. Long histories of injecting drug use, poor health, bad 
living conditions and concurrent tobacco and alcohol use 
make these users susceptible to chronic health problems, 
such as cardiovascular, liver and respiratory diseases. The 
challenges in responding to the complex needs of this 
group are discussed in section 3.1.
Responses tackling opioid dependence aim to engage 
dependent users in treatment and provide other support 
to address their manifold psychosocial and chronic 
health problems and to reduce their social exclusion. The 
achievement of overcoming their dependence on opioids 
is usually a long-term rather than an immediate objective 
of treatment. Harm reduction services, such as needle 
and syringe programmes, also play an important role in 
engaging people with opioid dependence with services and 
treating opioid-related harms, such as overdose. They are 
discussed in more detail in sections 2.3 and 2.4.
| Response options
A range of approaches are available for treating people with 
opioid dependence and supporting their reintegration into 
the community:
  Pharmacological interventions, such as long-term 
opioid substitution treatment (OST), the most common 
medications used being methadone or buprenorphine. 
These are generally combined with psychosocial 
interventions.
  Behavioural and psychosocial interventions to address 
psychological and social aspects of drug use include 
brief interventions, structured psychological therapies, 
motivational interventions, contingency management, and 
behavioural couples therapy.
  Residential rehabilitation involves living in treatment 
facilities and following a structured, care-planned 
programme of medical, therapeutic and other activities. 
This option is suitable for clients with medium or high 
levels of drug-related needs. Stays can be short or long 
depending on individual needs.
  Self-help and mutual aid groups teach cognitive, 
behavioural and techniques of self-management without 
formal professional guidance.
  Recovery/reintegration support services, for example, 
employment and housing support.
Evidence from controlled trials and observational studies 
indicates that drug treatment is effective in reducing 
the harms of opioid use and dependence. In addition to 
reducing reported injecting risk behaviours, treatment 
also reduces overdose risk, criminality and societal 
harms, including the adverse impacts on families and 
neighbourhoods (see the overview of the evidence box 
for a summary of the evidence for different treatment 
types). Opioid detoxification under heavy sedation is not 
recommended and can be harmful.
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Compared to other areas, the evidence base for 
treating opioid problems is relatively robust. It is not 
complete, however, and important questions require 
further investigation. It is unclear, for example, whether 
detoxification under minimal sedation helps opioid users 
to complete treatment and avoid relapse, or if opioid-
dependent adolescents respond better to detoxification 
or OST.
Effective long-term treatment for opioid dependence often 
requires multiple treatment episodes and combinations 
of responses. For example, opioid substitution treatment 
generally involves long-term pharmacological maintenance, 
typically in combination with psychosocial interventions and 
regular medical contacts to produce improvements across 
a range of health and social outcomes. Quality of treatment 
delivery is important: adequate doses of opioid substitution 
medicines are essential to prevent people taking heroin 
or other opioids on top of their prescription. Continuity 
of treatment is also vital, as the period immediately after 
leaving treatment, whether because of drop-out, discharge 
or transfer between services (e.g. on release from prison) 
is one of high risk of overdose (see sections 2.3 and 3.1). 
Similarly, to sustain good outcomes over the longer term, 
those in OST may benefit from a range of additional 
measures, such as relapse prevention and support for 
social reintegration, including training and employment and 
housing support.
Some sub-groups may have particular support needs: see 
section 3.1 on older problem drug users and section 3.2 on 
responding to the needs of women who use drugs.
Overview of the evidence on … treating opioid dependence
Opioid substitution treatment keeps patients in treatment, reduces illicit opioid use, related risk behaviour 
and mortality, and improves mental health. Its impact may be enhanced by psychosocial support together.
Methadone and buprenorphine are both recommended as medications for long-term pharmacological 
maintenance treatments. 
Methadone retains more people in the early weeks of treatment than buprenorphine.
Heroin-assisted treatment has been found to be effective for chronic opioid users who have not 
responded to methadone treatment.
Methadone or buprenorphine are effective treatment options for people who are dependent on 
pharmaceutical opioids.
Opioid substitution treatment is strongly recommended over detoxification for opioid-dependent pregnant 
women. Psychosocial interventions alone do not improve opioid-related or obstetrical outcomes. 
When detoxification is indicated, tapered doses of methadone or buprenorphine should be used in 
combination with psychosocial interventions. 
Detoxification with alpha2-adrenergic agonists (e.g. clonidine) is also effective but methadone has fewer 
adverse effects.
Use of naltrexone for relapse prevention is generally not recommended, except in cases in which relapse 
would have serious and immediate consequences.
Providing drug users with an incentive-based treatment approach (contingency management) and 
employment helps improve their social conditions.
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|  What is being done in Europe to respond to opioid dependence
Overall picture
Opioid users are the largest group in specialised drug 
treatment, although this varies between countries. For 
example, while the vast majority of treatment entrants in 
Estonia were opioid users they make up less than 5 % in 
Hungary. In 2015, 191 000 clients entered specialised 
addiction treatment in Europe with opioids as their primary 
drug; 37 000 of these were first-time entrants, most of 
whom (79 %) were primary heroin users.
Most treatment for people with opioid dependence in 
Europe is provided on an outpatient basis, most commonly 
in specialist drug services. Low-threshold services, 
generic health care and mental health care, and general 
practitioners all play an important role in some countries. 
Inpatient care is less common but still remains important 
in terms of the numbers of those treated with psychiatric 
hospitals, therapeutic communities and specialised 
residential treatment centres all utilised for this purpose.
A wide range of services are provided to drug users in 
European treatment settings and these may vary by setting. 
This complexity, coupled with the generally long-term nature 
of treatment for opioid dependence, means that case 
management plays an important role in ensuring services 
meet the needs of each individual and they remain engaged 
in treatment. Linkage to other services, such as mental 
health and sexual health services, is also important but is 
often problematic — see Spotlight on comorbid substance 
use and mental disorders, page 31, and Spotlight on 
addressing sexual health issues associated with drug use, 
page 72.
Opioid substitution treatment in Europe
It is estimated that around 50 % of opioid-dependent 
persons in Europe receive some form of substitution 
treatment. National estimates vary from 10 % to 80 %, 
highlighting both the heterogeneous situation found in 
Europe in respect to treatment coverage and the fact that 
treatment provision remains insufficient in many parts of 
Europe (Figure 2.2).
FIGURE 2.2
Opioid substitution treatment in Europe: coverage and principal drug prescribed
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48 |
Problems arising from particular types or patterns of drug use
Research conducted in 12 European countries (ATOME, the 
Access To Opioid Medication in Europe research project) 
explored factors that may limit the adequate availability of 
opioid medicines, including those used for the treatment of 
opioid dependence. Legal and regulatory barriers, restrictive 
policies, limited knowledge and negative attitudes, narrow 
inclusion criteria and costs; were all found to represent 
potential obstacles to achieving adequate levels of 
treatment provision. Important barriers to improving access 
to care in some countries were restrictions that limited 
the number of medical practitioners who could prescribe 
OST medications, or the number pharmacies that were 
permitted to dispense these products.
In 2015 an estimated 630 000 opioid users received OST 
in the European Union, this figure has declined slightly 
overall (5 %) since 2010. Some countries have reported 
more significant reductions during this period, with OST 
treatment numbers falling by more than a quarter, in 
Hungary, the Netherlands, Portugal and Spain, for example. 
Spotlight on … From harm reduction to recovery: the variety of treatment goals
What are the main goals of treatment?
Abstinence from drug use has been the traditional long-term goal of most forms of addiction treatment. The term 
‘recovery’ in addiction has historically been used within the ‘Twelve-step’ movement. More recently, recovery has 
been conceived as a process of achieving voluntary control of substances and working towards positive outcomes in 
broad areas of life. The concept of recovery overlaps with that of social reintegration and requires many of the same 
interventions, such as training and employment support programmes and housing provision.
The advent of HIV/AIDS in the 1980s brought a service focus on harm reduction. Services often adopted a ‘hierarchy of 
goals’ in which stopping or reducing injecting and the use of heroin was the first step towards achieving the longer-term 
goals of abstinence and recovery. More recently there has been a renewed debate about the relative roles of abstinence 
and recovery goals alongside harm reduction.
Are these treatment goals mutually exclusive?
Opioid users are among the groups for whom achieving treatment goals can be most challenging, especially those in 
long-term OST, where high levels of morbidity and poor social integration are common. Recovery, if viewed in terms 
of full-time employment, good health and so on, may not be a realistic goal for this prematurely aged and ageing 
population (see section 3.1). Many have never been employed and are therefore very difficult to integrate into the labour 
market. Many have long-term health conditions, which need to be taken into account by services working to achieve 
the best quality of life for this marginalised and stigmatised group of drug users. Achieving improved outcomes for this 
group may need a re-examination of drug treatment goals and viewing them as complementary rather than competing. 
A harm reduction orientation may be most appropriate in the initial stages of OST treatment to reduce risk and promote 
engagement. After stabilisation in OST, the longer-term focus may shift to reintegration and recovery in order to enable 
users to achieve a better quality of life and a wider range of goals.
Those entering treatment have different backgrounds, problems and resources to draw on that are likely to change 
over time. Treatment goals and the support services provided therefore need to be individually-tailored and regularly 
reviewed.
Implications for service provision
An enhanced focus on recovery and reintegration implies a greater partnership with service users to redesign services 
to improve quality of life and meet their wider needs. These new treatment models also need to harness local services 
and community assets and address stigma and discrimination that can act as barriers to drug users integrating into 
their communities. Greater peer involvement may increase service users’ social connectedness and well-being, inspire 
hope and enable users to work as volunteers in non-clinical posts to enhance service cost-effectiveness.
See the Background paper, Recovery, reintegration, abstinence, harm reduction: the role of different goals within drug treatment in the European context.
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At the same time, 14 countries have expanded treatment 
coverage. Over the same period many countries have 
observed an overall increase in the age of those receiving 
OST (see section 3.1).
Methadone and buprenorphine-based medicines are 
the most commonly prescribed OST drugs in Europe, 
accounting for about 63 % and 35 % of all OST treatments 
respectively. There is also limited use of other substances, 
such as slow-release morphine or diacetylmorphine (in 
heroin-assisted treatment), which are estimated to be 
prescribed to around 2 % of OST clients.
Heroin-assisted treatment is available in Denmark, Germany, 
the Netherlands and the United Kingdom. Luxembourg is 
in the process of introducing this form of treatment and it 
is also available to some users under compassionate use 
principles following a clinical trial in parts of Spain.
Residential treatment approaches
In most European countries, residential treatment 
programmes are an important element of treatment and 
rehabilitation for opioid drug users.
The term ‘residential treatment’ encompasses a range 
of treatment models where those with drug problems 
live together as a therapeutic unit, usually either in the 
community or in a hospital setting. Historically these 
approaches have tended to be abstinence-oriented, 
although there is now also a growing interest in integrating 
OST into this setting. Evidence-based clinical guidelines 
and service standards for quality assurance in residential 
treatment exist in most countries where this approach 
is commonly used. The therapeutic approaches used in 
residential treatment settings commonly include the use 
of 12-step or Minnesota models and cognitive behavioural 
interventions.
Treatment for opioid dependence: implications for policy and practice
Basics
  The core intervention is OST in combination with psychosocial treatment. This is an effective way to reduce illicit 
opioid use, transmission of infectious disease, drug overdose and crime.
  Different medicines are available for substitution treatment. Therapeutic choices need to be based on individual 
needs, involve a dialogue with patients and be regularly reviewed.
  Abstinence-oriented psychosocial treatment in residential settings can benefit some opioid-dependent people if they 
remain in treatment. However, this form of treatment is relatively costly and the relapse-rate is often high, with an 
increased risk of fatal overdose. Appropriate client selection and management are important as is support in the event 
of relapse.
Opportunities
  Optimise service delivery: The quality of treatment delivery is important, in particular, adequate doses of opioid 
substitution medicines are essential and continuity of treatment is vital. Increasing access to OST should remain a 
public health priority in those countries where it falls below recommended levels.
  Where good coverage has been achieved and many of those in OST treatment have now been in care for many years 
there may be a need to increase the attention given to social reintegration, including employment, and to review 
what constitutes appropriate individual therapeutic goals for different individuals and to promote recovery where 
appropriate.
Gaps
  Treatment services should be alert for the use of opioids other than heroin among treatment entrants and also 
polysubstance use, including alcohol and tobacco.
  Better information on unmet need for treatment is required in order to ensure appropriate levels of service availability.
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The level of residential treatment provision differs between 
countries. More than two-thirds of the 2 500 facilities in 
Europe are found in just six countries, with Italy accounting 
for the highest number of these (708). The treatment 
approaches used in residential settings also vary across 
Europe. In 15 countries the therapeutic community 
approach is used by most residential programmes.
Typically, people entering inpatient treatment are men in 
their early 30s. They are more socially disadvantaged than 
people entering outpatient treatment (lower education, 
unstable living conditions and unemployed). Just under half 
enter treatment for primary opioid problems (mainly heroin).
Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  Pregnancy and opioid use: strategies for treatment, EMCDDA Papers, 2014.
  Residential treatment for drug use in Europe, EMCDDA Papers, 2014.
  Therapeutic communities for treating addictions in Europe: evidence, current practices and future challenges, Insights, 
2014.
  Trends in heroin use in Europe: what do treatment demand data tell us? Perspectives on drugs, 2013.
  Social reintegration and employment: evidence and interventions for drug users in treatment, Insights, 2012.
  New heroin-assisted treatment, Insights, 2012.
  Recovery, reintegration, abstinence, harm reduction: the role of different goals within the drug treatment  
in the European context, Background paper, Annette Dale-Perera.
Other sources
  WHO Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence, 2009.
  WHO Guidelines for identification and management of substance use and substance use disorders in pregnancy, 2014.
  ATOME project. Final report and recommendations to ministries of health, 2014.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
Mortality directly or indirectly related 
to use of opioids is a major cause of 
avoidable premature deaths among 
European adults. Overall drug-related 
mortality rates are 1–2 % per year among 
high-risk opioid users in Europe and drug 
overdoses account for over 7 000 deaths 
per annum. Other important causes of 
death among high-risk opioid users are 
infections, accidents, violence and suicide.
Key periods of increased risk follow 
periods of abstinence when tolerance 
is lost, particularly on leaving prison or 
abstinence-based treatment.
Responses options
These mainly focus on preventing the occurrence of overdoses and on improving 
the survival of those who overdose.
  Enrolling and retaining problem opioid users in OST and ensuring continuity 
between treatment in prisons and the community and at other transition points.
  Promoting overdose awareness, particularly around key risk periods and other 
risk factors, such as concurrent alcohol or benzodiazepine use.
  Ensuring opioid antagonist (naloxone) availability and promoting appropriate 
use by professionals responding to or intervening in drug overdoses.
  Education and training of drug users, peers and family members to identify 
overdoses and intervene with take-home naloxone while waiting for the 
ambulance to arrive.
  Provision of drug consumption rooms to support safer injecting.
European picture
  Around half of opioid-dependent people in Europe are enrolled in OST, but 
coverage varies widely between countries.
  Overdose risk information provision is now available in 28 EMCDDA reporting 
countries.
  In 2016, there were 78 drug consumption rooms operating in 6 EU countries 
and Norway. There were also 12 operating in Switzerland.
  Take-home naloxone programmes existed in ten European countries in 2016.
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|  Understanding the problem and key objectives for responses
Mortality directly or indirectly related to use of opioids 
is a major cause of avoidable premature deaths among 
European adults. There were over 7 500 overdose deaths 
in the European Union in 2015, with opioids implicated in 
approximately 80 % of cases. The overall mortality rate for 
overdose deaths in the European Union is approximately 
20 deaths per million population, though national rates 
and trends vary considerably. This variation is due to a 
range of factors including differences in the numbers at 
risk of overdose deaths, and in the reporting and coding of 
overdose cases in national mortality databases.
All-cause mortality rates among cohorts of high-risk opioid 
users are in the range of 1–2 % per year, which is 5 to 10 
times that found among peers of the same age and gender. 
The primary cause of this increased mortality is drug 
overdose, but important contributions are made by causes 
indirectly related to drug use, such as infections, accidents, 
violence and suicide. Poor physical health is common 
Spotlight on … Fentanils
What are fentanils?
Fentanils are a family of highly potent opioids. A small number are used in human and veterinary medicine, in 
anaesthesia and for pain management. Recently an increasing number of uncontrolled fentanils have been reported to 
Europe’s early warning system for new psychoactive substances. Fentanils have appeared on online markets and on 
the illicit market, sometimes sold as, or mixed with, heroin, other illicit drugs, and even counterfeit medicines. Due to 
their potential to cause serious harm, 15 fentanils have so far been controlled under the 1961 United Nations Single 
Convention on Narcotic Drugs. However, new fentanils, not controlled under the UN conventions, can be manufactured 
and traded relatively freely and openly by chemical and pharmaceutical companies, mainly based in China. These 
developments are part of a phenomenon that has seen the appearance of a wide range of new psychoactive substances 
on Europe’s drug market over the past decade (see section 2.6).
Why are fentanils of concern?
The illicit use of fentanils is a growing concern in Europe because of their high risk of fatal overdose caused by severe 
respiratory depression. Long-term opioid users risk overdose due to lack of familiarity with the effects and appropriate 
dosage of these new substances. In users without tolerance to opioids even very small doses may be fatal. Estonia has 
experienced injecting use of these drugs for over a decade and reported high numbers of overdose deaths. Other EU 
countries have also reported fentanil-related deaths. Fentanils present risks, not only to those who use them (sometimes 
unknowingly), but also to people, such as postal workers, police and customs officers, families and friends of users, who 
may be accidentally exposed to them.
These substances are easy to conceal and transport because very small amounts produce many thousands of doses. 
This makes them both a very attractive commodity for organised crime and a challenge for drug control agencies. A new 
area of concern is the appearance of novel dosage forms, such as nasal sprays and e-liquids for vaping in electronic 
cigarettes, which make fentanils easier to use and possibly more socially acceptable.
How is Europe responding?
Early warning systems, including the EU Early Warning System based at the EMCDDA, play an important role in the 
identification and response to harms caused by new fentanils, by facilitating a rapid reaction to threats to public health 
related to these drugs (see EMCDDA website for risk assessments of fentanils, and box EU Early Warning System, page 78).
Responses to acute poisoning caused by fentanils should follow the guidelines for opioid poisoning generally, including 
the administration of naloxone for respiratory depression. However, recent experience suggests that larger and repeated 
doses of naloxone may be required to reverse poisoning in some cases. Training and guidance relating to the treatment 
of opioid poisoning, and associated with naloxone programmes, therefore needs to explicitly recognise appropriate 
responses to fentanil poisoning. This should include guidance with respect to the adequacy of stocks of naloxone to meet 
the needs associated with potential outbreaks of fentanil poisoning.
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among high-risk opioid users and is reflected in high rates 
of chronic pulmonary and cardiovascular conditions (often 
tobacco-related) and liver problems from HCV infections 
and heavy alcohol use. These conditions account for an 
increased share of hospitalisations and deaths with age. 
There is now an increasingly ageing opioid-using population 
in many European countries, which may have an impact 
on both direct and indirect mortality rates. Since 2007, 
the number of reported overdose deaths has increased 
among older age groups and decreased among younger 
age groups (see section 3.1 on older people with drug 
problems).
The type of substance used, the route of administration 
and the health of the user all have an impact on the risk 
of overdose. Heroin and its metabolites are found in the 
majority of fatal overdoses in Europe, often in combination 
with other substances. There has been a recent increase 
in heroin-related deaths in Europe but other opioids 
(methadone, buprenorphine and to a lesser extent other 
prescription opioids and fentanils) are found in a substantial 
proportion of overdose deaths and predominate in a few 
countries. The role of illicitly produced synthetic opioids 
is probably under-reported because their presence 
is not routinely tested in many countries. Typically, 
multiple substances are implicated in overdose deaths; 
benzodiazepines and alcohol, often present alongside 
opioids.
A number of situational factors can increase the risk 
of drug overdose death including, in the case of opioid 
users, disruption of treatment provision or discontinuity 
of treatment and care. In certain situations, for example, 
following detoxification or discharge from drug-free 
treatment, the tolerance of drug users to opioids is greatly 
reduced and as a result they are at particularly high risk of 
overdosing if they resume use. For these same reasons, 
failure to ensure continuity of care through inadequate 
referral and follow-up on release from prison has also been 
identified as an important risk factor.
| Response options
The main responses aimed at reducing opioid deaths are 
of two broad types: the first involves a set of interventions 
geared towards preventing overdoses occurring, while the 
second focuses on preventing death when overdoses do 
occur (Figure 2.3). In addition, broader harm reduction 
interventions can reduce vulnerability to overdose while 
wider public health interventions that reduce drug use 
and empower drug users to protect themselves may also 
provide an environment in which overdoses are less likely. 
This third group of broader interventions are not discussed 
here but are covered elsewhere in this guide.
Retention in treatment reduces overdose risk
The risk of overdose is reduced while opioid users remain 
in OST. A meta-analysis of observational studies shows 
that OST, using methadone and buprenorphine, reduces 
overdose and all causes of death in opioid-dependent 
people. The mortality rate of clients in methadone treatment 
FIGURE 2.3
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is less than a third of that among opioid users not in 
treatment. Analyses of overdose deaths at different stages 
in OST suggest that preventive interventions need to be 
focused on the first 4 weeks of treatment (particularly for 
methadone) and in the first four weeks after treatment 
exit. These are two periods when the risk of overdose 
is especially elevated. People who frequently enter and 
leave treatment are particularly vulnerable to overdosing; 
so are drug users immediately after leaving prison (see 
section 4.1). To prevent prison post-release deaths, 
proactive and prepared referral to community OST or other 
appropriate treatment options (‘throughcare’ or ‘continuity 
of care’) is important. Treatment services also need to 
ensure that clients are aware of the risks of overdose when 
leaving treatment and how to reduce these.
Overdose awareness training and  
public health alerts
Effective communication with users can act as a catalyst 
for reducing harm, as many drug users underestimate, 
or are unaware of their overdose risks. Ideally, overdose 
prevention, education and counselling interventions should 
be routinely provided by trained professionals in health and 
primary care settings, including harm reduction services, 
such as needle and syringe programmes. Screening opioid 
users for overdose risk may reduce overall mortality, while 
overdose risk assessments can provide early identification 
of high-risk individuals.
The United States and Canada have seen a dramatic rise 
in opioid-related deaths in recent years, in part driven 
by the misuse of medicinal products and in part by the 
appearance of synthetic opioids (including fentanils) on 
the illicit drug market. Europe has not experienced these 
problems at the level seen in North America. Nevertheless, 
synthetic opioids, both diverted from legitimate uses and 
produced for sale on the illicit drug market, are a significant 
problem in some countries. The increasing number of new 
uncontrolled opioids being reported to the EU Early Warning 
System adds to concerns in this area (see section 2.6 and 
Spotlight on fentanils, page 52). Given the potential of these 
drugs to cause harm, it is important that Europe continues 
to be vigilant and is prepared to respond quickly and 
effectively to any increase in the threats observed in this 
area. This requires investment in surveillance capabilities, 
including better toxicological information on drug-related 
deaths. It also signals the need to identify the sources of 
the opioids involved in these deaths in order to identify 
appropriate responses (see also section 2.7). It also requires 
countries to have appropriate prevention, treatment and 
harm reduction capacities in place and be prepared if 
necessary to strengthen their responses to reduce opioid-
related mortality.
Drug consumption rooms
Ideally, drug consumption rooms are professionally 
supervised health care facilities in which drug users can use 
drugs in safer and hygienic conditions under the supervision 
of trained staff. They aim to reduce the risks of unhygienic 
injecting (including serious infectious complications such as 
septicaemia and endocarditis), prevent overdoses and link 
drug users with treatment, health and social services (see 
Spotlight on drug consumption rooms, page 156).
Drug consumption rooms were originally developed as a 
public health response to the rapid spread of HIV/AIDS 
among injecting drug users in the 1980s and to problems 
posed by public drug use. These facilities are designed to 
attract hard-to-reach drug users, especially marginalised 
ones who inject drugs on the streets, under risky and 
unhygienic conditions. There are a number of ways in which 
they can reduce overdose deaths: by directly intervening in 
overdoses that occur on site; providing overdose prevention 
awareness raising and training, including training in the 
Overview of the evidence on … reducing opioid-related deaths
Overdose deaths are reduced among opioid users while they are in opioid substitution treatment.
There is growing evidence that education and training interventions with take-home naloxone prevents 
deaths from opioid overdose. 
Intranasal administration of naloxone is effective in treatment of opioid overdose.
Drug consumption rooms increase safer injecting, reduce blood-borne infections and overdoses and 
encourage people who inject drugs to engage with care services. These services are furthermore 
associated with positive effects on public order.
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use of naloxone to service users. They can also promote 
engagement in OST treatment.
There is consistent evidence from observational studies 
that drug consumption rooms increase safer injecting 
among those who use them and reduce overdoses near the 
services. They also encourage people who inject drugs to 
engage with health care services. The extent to which drug 
consumption rooms reduce overdose mortality will depend 
on what proportion of the population of people who inject 
opioids is able to access them and what other overdose-
related interventions are undertaken.
Naloxone to reverse overdose
Heroin and other opioids bind to receptors in the nervous 
system including areas of the brain implicated in the 
control of breathing. Their use can suppress breathing, 
leading to a loss of consciousness, organ failure and death. 
However, many overdose deaths could be prevented by 
the interventions of others, who witness them. Naloxone is 
an opioid antagonist that can reverse opioid overdoses. In 
2014, the World Health Organization (WHO) recommended 
that naloxone should be made available to anyone likely 
to witness an opioid overdose. Ensuring it is available and 
used by first responders, such as the police, ambulance 
staff and in emergency rooms, is therefore essential. In 
addition, training of drug users and others who are likely 
to witness overdoses, such as family members and hostel 
workers, on how to recognise and respond to overdoses, 
combined with naloxone distribution can reduce opioid 
overdose deaths. People who receive overdose prevention 
training and learn how to administer naloxone safely 
and effectively to others can save the lives of those who 
overdose in their presence. Emerging evidence on the 
effectiveness of naloxone for intranasal administration is 
promising and may facilitate use by a wider range of people 
in the future.
FIGURE 2.4
Interventions in place in European countries that can reduce opioid-related deaths
Take-home naloxone programmes Drug consumption rooms
Heroin-assisted treatment Opioid substitution treatment
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech 
Republic 
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Turkey
United 
Kingdom
NB: Year of data, 2016.
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Recently released prisoners may particularly benefit from 
access to naloxone. An evaluation of a programme to 
distribute naloxone to prisoners on release in Scotland 
found that it was associated with significantly fewer opioid-
related deaths within a month of prison release.
|  What is being done in Europe to prevent  opioid-related deaths
As described in section 2.2, it is estimated that about half 
of those who are dependent on opioids in the European 
Union receive some form of opioid substitution treatment, 
although coverage varies widely.
Twenty-eight EMCDDA reporting countries report that they 
distribute overdose risk information. This is sometimes 
available in different languages for foreign-born drug users. 
There is increasing use of the internet and new channels of 
communication, such as e-health overdose risk assessment 
tools and overdose awareness videos that can be shown in 
the waiting rooms of drug treatment facilities.
Drug consumption rooms have been operating in Europe 
for 30 years: the first was established in Berne, Switzerland 
in 1986. In 2016, there were 78 facilities operating in 6 EU 
countries and Norway (Figure 2.4). This includes the first 
two drug consumption rooms to open in France as part 
of a 6-year trial, and the establishment of new facilities 
in Denmark and Norway. There were also 12 facilities 
operating in Switzerland, and a number of other countries 
are considering legislation to permit the establishment of 
drug consumption rooms. This indicates growing interest in 
this kind of provision.
In recent years in Europe, there has been increased 
distribution of ‘take-home’ naloxone to opioid users, 
partners, peers and families, along with training in 
recognising and responding to overdoses. Take-home 
naloxone programmes have also been made available to 
staff of services that regularly come into contact with drug 
users.
There are take-home naloxone programmes in ten European 
countries. After being scaled up in community settings 
Reducing opioid-related deaths: implications for policy and practice
Basics
Core interventions in this area include:
  Sufficient provision of opioid substitution treatment, with adequate dosage, case management and additional support.
  Naloxone made available to and used by first responders, such as ambulance staff, paramedics and others who attend 
overdose incidents.
  Overdose awareness training to promote less risky use among people who use opioids (such as avoiding injection, 
mixing drugs and alcohol, not using alone, and fractioning the dose).
Opportunities
  Establish take-home naloxone programmes to make naloxone widely available to people at high risk of opioid overdose 
and to their peers, partners and family to enable them to intervene while waiting for the ambulance services to arrive.
  Improve throughcare between prison and community to prevent drug-related deaths in the first two weeks after prison 
release, when overdose risk is extraordinarily high.
Gaps
  Identify and review barriers to the establishment of drug consumption rooms in areas with high numbers of people 
injecting drugs in public places.
  Provide enhanced support to those who leave abstinence-based treatment, because their lost opioid tolerance 
increases the risk of fatal overdose.
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since 2013, take-home naloxone provision in Estonia was 
extended to prisons in 2015. Similar prison release-based 
naloxone distribution programmes are also reported in 
several other countries.
Until 2017, take-home naloxone kits generally included 
syringes pre-filled with the medication, for injectable use. A 
formulation for intranasal use and a specific applicator tool 
has been developed and is becoming available in Europe to 
facilitate use of the drug by laypersons.
Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  Preventing overdose deaths in Europe, Perspectives on drugs, 2017.
  Drug consumption rooms: an overview of provision and evidence, Perspectives on drugs, 2017.
  Preventing opioid overdose deaths with take-home naloxone, Insights, 2016.
  Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone, EMCDDA Papers, 2015.
Other sources
  UNODC. Opioid overdose: preventing and reducing opioid overdose mortality, 2014.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
The sharing of injecting equipment increases the 
risk of the transmission and acquisition of blood-
borne infections, such as HIV and hepatitis B and C 
viruses. Historically interventions targeting people 
who inject drugs — primarily OST, needle and syringe 
programmes and harm reduction measures to reduce 
risk behaviour — were mainly focused on reducing 
HIV transmission. The success of these measures 
can be seen in the low share of HIV transmission 
attributed to drug injecting (about 5 % of diagnoses 
for which the route of transmission is known), which 
has been stable for the past decade. Nevertheless, 
injecting drug use remains an important mode of HIV 
transmission in some countries and injecting-related 
HIV outbreaks still occur in Europe, especially where 
service coverage is low.
Hepatitis C is the most prevalent blood-borne 
virus infection among people who inject drugs. 
The development of highly effective treatments 
for hepatitis C has led to a shift in focus towards 
addressing the high rates of hepatitis C virus (HCV) 
infection found among people who inject drugs. 
Chronic HCV infection can result in deaths from 
severe liver disease, such as cirrhosis and liver cancer.
Response options
  Providing opioid substitution treatment and other effective drug 
dependence treatment to people who inject drugs.
  Needle and syringe programmes providing sterile injection 
equipment to injectors.
  Vaccination against hepatitis A and B, tetanus and influenza, and 
also pneumococcal vaccine for HIV-positive individuals.
  Routine testing for HIV, HCV (HBV for unvaccinated) and other 
infections including tuberculosis.
  This needs to be linked to referral and treatment provision for 
those found to be infected, including the new direct-acting antiviral 
treatments for HCV that are now available.
  Health promotion focused on safer injecting behaviour; sexual 
health, including condom use; and disease prevention, testing and 
treatment.
  Developing proactive, multi-component approaches that are adapted 
user needs and local conditions.
European picture
  Of the 30 countries monitored by EMCDDA, all except Turkey provide 
clean injecting equipment free of charge via specialised outlets. 
However, there are considerable differences in coverage, indicating 
a need to increase service provision in some countries.
  All EU countries provide OST but coverage in some remains low, 
including countries which report risk factors for HIV or hepatitis C 
infection among injecting drug users.
  An increasing number of European countries have adopted, or are 
preparing, hepatitis C strategies and alongside this new direct-acting 
antiviral treatments for HCV are being introduced in some countries 
with the aim of eliminating the infection.
 keywords: infectious  
 diseases, health harms of  
 drug use, drug consumption  
 room, hepatitis, needle and  
 syringe programmes 
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|  Understanding the problem and key objectives for responses
In the 1980s and 1990s transmission attributed to 
injecting drug use was the main route of HIV infection 
in Europe. Since then, increased availability of harm 
reduction and treatment interventions, such as syringe 
provision, OST and combination antiretroviral therapy, 
and a decline in the prevalence of injecting drug use, 
have been accompanied by a dramatic fall in notified 
HIV infections attributed to drug injecting. Nevertheless, 
injecting drug use remains an important mode of HIV 
transmission in some EU countries, and sporadic 
outbreaks continue to occur in other countries. In addition, 
despite decreases over recent years, more than 1 in 10 
new AIDS cases in the European Union are still attributed 
to injecting drug use. This may signal late diagnosis or bad 
case management, both of which are avoidable causes 
of harm to patients. Many of these cases were reported 
in Greece, Latvia and Romania, where HIV testing and 
treatment responses may require strengthening.
Infection with the hepatitis C virus (HCV) is highly prevalent 
among injecting drug users in Europe. Infection is often 
asymptomatic, and many of those infected are unaware 
of their infection status. The virus can cause both acute 
and chronic hepatitis, with an estimated 75–80 % of 
those infected going on to develop chronic infection. 
Chronic hepatitis C can lead to severe liver disease, such 
as cirrhosis and cancer, which may result in death. The 
prevalence of HCV antibodies (a marker of having been 
infected by the virus) among national samples of people 
who inject drugs is very variable, but in 2014/15, rates in 
most national samples were above 40 %.
Infection with the hepatitis B virus (HBV) is less common, 
as an effective vaccine is widely used in national 
immunisation programmes. However, people who use 
drugs may be missed by regular campaigns. Good data are 
lacking but of the seven countries with national estimates, 
between 2.2 % and 11 % of people who inject drugs were 
infected with hepatitis B. HBV may be transmitted through 
sharing injection equipment, sexual contact, or from mother 
to child (in pregnancy, and during and after birth).
Drug injection also carries a risk for other infectious 
diseases, such as wound botulism and anthrax. 
Marginalised groups, including people with serious drug 
problems, whether or not they inject, may also be at 
increased risk of contracting infectious diseases such as 
tuberculosis. Drug injecting may cause damage to veins and 
associated circulatory problems. For example, injecting of 
drugs that come in tablet form, such as buprenorphine, may 
a number of potentially serious health problems.
Although opioids are the predominant drugs injected in 
Europe, other drugs, such as amphetamines, mephedrone 
and anabolic steroids, are injected by sizeable numbers 
of people. The same risks of infection and other harms 
associated with injecting apply to them. Regardless of 
which drugs are injected, the major public health goal is 
the same — the reduction of transmission of infectious 
diseases acquired through sharing contaminated syringes, 
needles and other injecting equipment.
This may be achieved through a combination of two broad 
approaches. Firstly, seeking to reduce the number of unsafe 
injecting occasions that occur by providing effective drug 
treatment, and sufficient, readily accessible supplies of 
clean injection equipment, to eliminate the need for sharing 
used equipment. The second approach aims to reduce the 
number of people who are infected, by treating those who 
have the condition and by vaccinating uninfected people at 
risk of infection.
| Response options
The concerns about the spread of HIV and AIDS in the 
1980s and 1990s prompted the development of needle and 
syringe programmes and other harm reduction approaches. 
The main interventions available to prevent and control 
the spread of infections among people who inject drugs 
are highlighted in the box on good practice (page 60). 
Treatment for opioid dependence also plays an important 
role in preventing the spread of HIV and viral hepatitis 
and is discussed in section 2.2. People in OST inject less 
frequently and engage in less risky injecting behaviour. This 
section considers other interventions to prevent blood-
borne and other infections.
Needle and syringe programmes
There is moderate quality epidemiological evidence 
that needle and syringe programmes may reduce HIV 
transmission among people who inject drugs. There is 
similar evidence, but not quite as strong, that needle and 
syringe programmes may also reduce HCV transmission. 
However, to have an impact on population rates of HIV and 
HCV transmission it is necessary for needle and syringe 
programmes to be provided at a sufficiently large scale and 
in combination with other responses, such as treatment. 
In addition to needle and syringe provision, there is also 
evidence that providing other types of equipment, for 
example, sterile cookers or filters, reduces injecting risk 
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behaviours. The provision of filters may be particularly 
important in countries where people inject substances that 
come in the form of tablets, such as buprenorphine, and 
can result in a range of health complications that can be 
difficult and expensive to treat.
Testing and treatment provision for HIV and  
viral hepatitis
Treatment of HIV and HCV infection is effective in people 
who inject drugs (moderate quality evidence). Stigma and 
marginalisation remain important barriers to testing and 
treatment for blood-borne virus infection among people 
who inject drugs and may delay diagnosis and treatment. 
For example, in 2015, 58 % of newly notified HIV infections 
related to injecting were diagnosed late, compared with 
47 % for all routes of transmission. Early diagnosis and 
initiation of anti-retroviral therapy reduces morbidity and 
mortality, offering infected people a greater chance of 
a normal life expectancy and potentially reducing HIV 
transmission to others. The policy of ‘test-and-treat’ for 
HIV, when anti-retroviral therapy is started directly after 
a HIV diagnosis, is therefore important for addressing HIV 
infection among people who inject drugs.
In many countries, community-based, low-threshold drug 
services offer testing for infectious diseases. EU minimum 
quality standards for drug treatment promote voluntary 
testing for blood-borne diseases at community agencies 
and counselling about risk behaviours and assistance in 
managing illnesses. These services can increase rates of 
vaccination against hepatitis A and B.
Early detection of HCV infection and treatment with the new 
highly effective direct-acting antiviral drugs has considerable 
potential to prevent liver disease and deaths (Figure 2.5). 
A systematic review of the evidence suggests that many 
infections go undiagnosed and untreated among people who 
inject drugs. There also remains a need for more empirical 
data and evaluations of the impact of scaling up hepatitis 
C treatment among people who inject drugs in order to 
demonstrate how to maximise health gains in this area.
Good practice for controlling infectious diseases among people who inject drugs
Key intervention components are:
  Injection equipment: Provision of, and legal access to, sterile needles, syringes and other equipment free of charge, as 
part of a multi-component approach that includes harm-reduction, counselling and treatment programmes.
  Vaccination: Immunisation against hepatitis A and B, tetanus and influenza as well as pneumococcal vaccination for 
HIV-positive individuals.
  Drug dependence treatment: Opioid substitution treatment and other effective forms of drug dependence treatment.
  Testing: Routine voluntary and confidential testing with informed consent for HIV, HCV (HBV for unvaccinated) and other 
infections including tuberculosis, linked to treatment referral.
  Infectious disease treatment: Antiviral treatment for those who are infected with HIV, HBV or HCV. Anti-tuberculosis 
treatment of active tuberculosis cases, prophylaxis for latent cases and treatment for other infectious diseases when 
clinically indicated.
  Health promotion: Health promotion focused on safer injecting behaviour; sexual health, including condom use; and 
disease prevention, testing and treatment.
  Targeted delivery of services: Services should be combined and delivered according to user needs and local conditions 
through outreach and fixed sites offering drug treatment, harm reduction, counselling and testing, and referrals to 
general primary health and specialist medical services.
The combination of these interventions enhances their effectiveness.
Adapted from: European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction. Prevention and 
control of infectious diseases among people who inject drugs. Stockholm: ECDC; 2011.
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The enhancement of treatment uptake is important for people 
who inject drugs, and effective treatment options need to be 
available and easily accessible for this population group. The 
co-location of hepatitis C treatment and opioid substitution 
treatment is likely to facilitate user access. Improving 
treatment adherence among people who inject drugs can 
also be improved. Case management, support services and 
the provision of education and training to improve health- and 
HCV-literacy among people who inject drugs and service 
providers are likely to be of benefit here.
Scaling up hepatitis C treatment is essential in order to 
reduce the prevalence and transmission of HCV infection 
among people who inject drugs. European clinical guidelines 
recommend that all patients with chronic liver disease from 
HCV infection should be considered for therapy, regardless 
of disease stage. They also recommend that treatment be 
provided without delay to individuals at risk of transmitting 
the virus, such as people who inject drugs. Ideally, this 
should be tailored to individual needs and provided in a 
multidisciplinary setting.
New all-oral combinations of direct-acting antiviral drugs can 
eliminate HCV infection in more than 90 % of cases in 8–12 
weeks. These are becoming the first-line treatment for HCV 
infection because they are safe and effective. Hepatitis C 
can now be safely treated in people who inject drugs, and 
access and referral pathways need to be extended, including 
through offering the treatment in specialised drug services in 
community settings to increase uptake and availability.
Treatment for hepatitis B virus (HBV) infection, unlike 
hepatitis C treatment, is long-term and does not eliminate 
the virus. Universal vaccination of children for hepatitis B and 
vaccination campaigns targeting high-risk groups mean that 
hepatitis B should become increasingly rare in the future. 
However, as vaccine coverage of populations of injecting 
drug users can be poor, they need to be viewed as a group 
appropriate for additional screening and vaccination using 
the WHO-recommended Accelerated Schedule. Vaccination 
should be offered to those who inject drugs at all service 
contacts, whether at low-threshold harm reduction facilities, 
treatment services or in prisons (see section 4.1).
It is important that services are provided within a co-
ordinated multi-component programme in order to 
maximise effectiveness. The programmes also need to be 
tailored to the needs of different groups of people, who may 
have different patterns of injecting drug use.
FIGURE 2.5
Hepatitis C treatment before and after the advent of direct-acting antiviral agents
10–50% 90 to >95% 
Several pills per day 
plus weekly interferon injections
6 to 12 months
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Side effects of interferon are common High efficacy and optimal tolerability
Liver biopsy was often a necessary 
requirement for initiating treatment
Non-invasive methods to determine the 
level of fibrosis of the liver
12 to 24 weeks, but can be as short as 8 weeks
1–3 pills per day
Medication and frequency
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Cure rates
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Adverse side effects
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Establishing links between drug and sexual health service 
providers may be particularly important for responding 
effectively to the spread of infections related to the injection 
of stimulants and other drugs by men who have sex with 
men. Prevention interventions for this group include testing 
and treatment of infections, health education and the 
distribution of prevention materials, including condoms and 
sterile injecting equipment. To prevent sexually acquired HIV 
infection, pre-exposure prophylaxis is an additional option 
for populations at highest risk.
Drug consumption rooms can also play a role in preventing the 
spread of infectious diseases associated with injecting drug 
use (see Spotlight on drug consumption rooms, page 156).
|  What is being done in Europe to prevent the spread of infectious diseases associated with injecting drug use
The provision of interventions to prevent the spread of 
infectious diseases associated with injecting drug use 
needs to be considered in the context of the prevalence 
of risk factors for transmission, such as injecting use and 
disease prevalence rates and trends. Figure 2.6 provides 
a summary of available information on some key risk factors 
and intervention coverage in the European Union, Norway and 
Turkey.
Opioid substitution treatment
Information on OST provision in the European Union 
is discussed in more detail in section 2.2 but is also 
summarised in Figure 2.6. This indicates that there are a 
number of EU countries with low coverage of OST, needle 
and syringe programmes, or both; some of which have 
a number of other potential risk factors for HIV or HCV 
infection among people who inject drugs.
Needle and syringe programmes
Of the 30 countries monitored by the EMCDDA, all except 
Turkey provide clean injecting equipment free of charge 
via specialised outlets. There are, however, considerable 
differences between countries in the geographical distribution 
of syringe outlets and in the proportion of injectors covered by 
needle and syringe programmes. In the 17 countries for which 
estimates of the number of injecting drug users are available, 
about half (9 countries) are rated as providing a low number 
of syringes, through specialised and publicly subsidised 
programmes, relative to the number of injecting drug users.
Spotlight on … Scaling up hepatitis C treatment to eliminate HCV infection
Cost is a major barrier to a widespread scale-up of new hepatitis C treatments. In 2015, for example, the price of the 
medication Sofosbuvir in 20 European countries varied between EUR 25 000 and EUR 91 000 for a 12-week course. 
This means that the cost of treating all adults infected with HCV in these countries would vary between EUR 0.91 million 
and EUR 31.7 million. These costs could be offset by large future savings from the decreased need for treatment for liver 
cirrhosis and liver cancers.
The availability of these improved treatments has prompted many European countries to adopt new viral hepatitis 
strategies, update treatment guidelines and improve HCV testing and treatment. The challenges that remain are low 
levels of HCV testing and unclear referral and treatment pathways.
Modelling suggests that the provision of hepatitis C treatment alongside high coverage of syringe provision and OST 
could reduce HCV transmission to negligible levels. To achieve this would require better case-finding and improved 
access to testing, as well as improved uptake and adherence to treatment. The ideal sites may be ‘HCV treatment-in-the-
community’ services that are integrated with other services for people who inject drugs, including harm reduction and 
treatment programmes. Rapid testing techniques now make this feasible in a variety of contexts, including low-threshold 
services and outreach. Where possible, treatment delivery should take place at the same sites in order to improve 
uptake. These services should collect data on injecting, HCV transmission and HCV prevalence. Hepatitis C case-finding 
and treatment in prison is also a cost-effective way to reduce infection.
The needs and perspectives of those who inject drugs need to be taken into consideration in the scaling up of HCV 
treatment services. This will include research among these groups about how to facilitate their engagement, initiation 
and access to hepatitis C treatment. These studies and evaluation of the impact of scaled-up hepatitis C treatment on 
rates of reinfection are necessary to assist decision-making on the further roll-out of these treatments.
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FIGURE 2.6
Summary indicators for potential elevated risk for HIV and HCV infections among injecting drug users
HIV cases
HIV prevalence 
trend
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or increasing
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increasing
Low HIV notification rate (< 5 cases per million population) and no evidence of an increase.
No significant trend or statistically significant decrease of HIV prevalence. 
National or subnational prevalence levels < 50 % or no significant trend or statistically significant decrease.
Prevalence of injecting drug use low (< 3 ‰).
High coverage (> 50 % of estimated population in opioid substitution treatment).
High coverage (> 200 syringes per estimated injector).
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National or subnational prevalence levels > 60 % or statistically significant increase in HCV prevalence (95 % confidence level).
Prevalence of injecting drug use high (> 6 ‰).
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Low coverage (< 100 syringes per estimated injector).  
NB: Free provision of sterile injecting equipment through needle and syringe programmes is not available in Turkey. OST for the United Kingdom coverage 
refers to England only.
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 Reducing infections associated with injecting drug use: implications for policy 
and practice
Basics
  Core interventions in this area include needle exchange, OST provision, testing and treatment for infectious diseases, 
and health promotion activities.
  Many people who use drugs are unaware of their HCV infection. Testing should be offered as part of the baseline 
package at any contact with drug services.
  Vaccinating people who inject drugs against hepatitis A and B can substantially reduce these infections and their 
serious health effects.
Opportunities
  Implementation of an integrated strategy to provide prevention, outreach, screening and the new highly effective oral 
hepatitis C treatments in co-ordination with harm reduction (including needle and syringe programmes) and drug 
treatment programmes (including OST) in the community and prisons could reduce liver disease and cancers and 
potentially eliminate hepatitis C as a public health threat among people who inject drugs.
  Access to and uptake of testing and treatment of infectious diseases and sexually transmitted infections can be 
increased by developing on-site screening at services for drug users such as drug treatment centres, drug consumption 
rooms or needle and syringe programmes.
Gaps
  Currently, access to needle and syringe programmes and OST is below recommended levels in many EU countries and 
needs to be improved. Better data on HCV treatment uptake are also needed to allow assessment of the adequacy of 
service provision.
  HIV infection in people who inject drugs is often diagnosed late and there are still AIDS cases reported among this 
group. Enhanced HIV testing, immediate initiation of HIV treatment after diagnosis and improved retention in care are 
necessary.
Data from such programmes in 25 countries show that 
over 52 million syringes were distributed in 2014/15. 
However, this number is a considerable underestimate 
because data from Germany, Italy and the United Kingdom 
are not included. Using local data from these countries, 
it is estimated that more than 100 million syringes are 
distributed by national schemes annually in the European 
Union. This figure does not include injecting equipment 
purchased by people who inject drugs directly from 
pharmacies.
Testing and treatment
An increasing number of countries have adopted or are 
preparing specific hepatitis C strategies. Initiatives to tackle 
hepatitis C directed at testing, counselling and treating 
people who inject drugs have increased but still appear to 
be insufficient because HCV prevalence among this group 
is reported to be at medium or high levels or increasing in 
18 of the 23 countries providing information. This is despite 
the evidence of the effectiveness of hepatitis C antiviral 
treatment for people who inject drugs. In part this may 
be explained by the high costs of the new medications, 
although barriers to detection and treatment for hepatitis 
C are also likely to play a part. Some of these barriers are 
being addressed. A new diagnostic tool (the Fibroscan) has 
been introduced, which should facilitate detection of liver 
disease, and new medications have reduced both treatment 
duration and negative side-effects, and therefore should 
facilitate compliance.
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Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  Hepatitis C treatment for injecting drug users, Perspectives on drugs, 2015.
  Hepatitis C among drug users in Europe: epidemiology, treatment and prevention, Insights, 2016.
  Drug-related infectious diseases in Europe: update from the EMCDDA expert network, Rapid communication, 2017.
  Estimating trends in injecting drug use in Europe using national data on drug treatment admissions, Technical paper, 
2015.
  Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users, Manual, 2010.
ECDC and EMCDDA
  Prevention and control of infectious diseases among people who inject drugs, Joint publication, 2011.
Other sources
  UNODC, UNAIDS, WHO. Guidance relating to infectious diseases and injecting drug use (webpage).
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
Overall cocaine is the most commonly used 
stimulant in Europe, though in some countries 
MDMA, amphetamine or methamphetamine 
may be the dominant stimulant.
Many of the harms from using stimulants are 
associated with intensive, high-dose or long-
term consumption. Route of administration 
is an important mediating factor, with both 
stimulant injecting and the smoking of crack 
cocaine or methamphetamine particularly 
associated with more problematic patterns of 
use. However, acute problems can affect even 
experimental or occasional stimulant users.
Stimulants may be used functionally, for 
example, to stay awake when driving, working 
long hours, or when socialising in nightlife 
settings. This means that some of the 
responses appropriate to stimulant use are 
setting specific, or overlap with more generic 
public health measures. The settings in which 
they are used and the fact that stimulants 
are sometimes used in a sexual context 
also mean that drug-related responses may 
overlap with responses to sexual health 
issues, particularly in some groups.
Response options
  Brief interventions, referral to treatment programmes or harm 
reduction services can be offered when users seek help at 
emergency departments for problems related to intoxication or high-
dose use.
  Stimulant injectors need regular access to needle and syringe 
programmes because they may inject more often than opioid users 
during the course of a binge.
  Outreach programmes may be necessary to deliver harm reduction 
interventions to stimulant users who would not otherwise access 
services.
  Treatment using psychosocial interventions can be effective for 
problematic stimulant use. There are no pharmacological treatments 
with good evidence of effectiveness in treating problematic stimulant 
users, but some drugs used to treat depression have been shown to 
help retain amphetamine users in treatment.
European picture
  Cocaine is the main stimulant drug for which people seek treatment 
in Europe (63 000 people in 2015), with the majority of these 
cases in Spain, Italy and the United Kingdom. The number of new 
treatment entrants is stable. A further 7 400 entered treatment for 
primary crack cocaine problems, mostly in the United Kingdom.
  About 34 000 people entered treatment for problems with use of 
amphetamine in 2015, and 9 000 for methamphetamine, mostly in 
Czech Republic and Slovakia. There has been an increase in first-
time treatment entrants for amphetamines since 2009.
  Very few people enter specialised drug treatment for MDMA use; 
harm reduction responses in festival and nightlife settings are more 
relevant to this group.
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|  Understanding the problem and key objectives for responses
Cocaine is the most commonly used illicit stimulant in 
Europe. Among regular cocaine consumers, a broad 
distinction can be made between more socially integrated 
users, who snort powder cocaine (cocaine hydrochloride), 
and marginalised users, who are more likely to inject 
cocaine or smoke crack cocaine (cocaine base) and 
sometimes use opioids.
In many countries, use of the stimulant MDMA (often 
marketed as ‘ecstasy’) declined from a peak in the early to 
mid-2000s. In recent years, some monitoring sources have 
shown that both use and the average content of MDMA in 
tablets has increased. The high amounts of MDMA in some 
tablets have been linked with harms and deaths.
Amphetamine and methamphetamine, two closely 
related stimulants, are both consumed in Europe, 
although amphetamine is more commonly used than 
methamphetamine. Methamphetamine use has historically 
been restricted to the Czech Republic and, more recently, 
Slovakia, although increased use has also been noted 
in some other countries. In some data sources, it is not 
possible to distinguish these two substances, so the 
generic term amphetamines is used to cover both. Both 
drugs can be taken orally or nasally; injection is a common 
route of administration among high-risk users in some 
countries. Methamphetamine can be smoked but this is rare 
in Europe.
European countries vary in respect of the stimulants most 
often used. For example, in the United Kingdom cocaine is 
the illicit stimulant most often used in the past year in the 
general population, closely followed by MDMA. In Finland, 
by contrast, similar proportions report using amphetamine 
and MDMA in the past year and cocaine use is uncommon.
Many of the harms related to the use of stimulants 
are associated with intensive, high-dose or long-term 
consumption. Route of administration is also an important 
mediating factor with both stimulant injecting and the 
smoking of crack cocaine or methamphetamine particularly 
associated with more problematic patterns of use. Acute 
problems can affect even experimental stimulant users, 
but are likely to be less common when stimulant use is 
infrequent and low-dose. Although uncommon, some 
stimulant users engage in high-dose use over extended 
time periods, sometimes lasting several days. Stimulant 
‘binges’ can result in a range of acute harms including 
psychosis, aggression and paranoia, and may also be 
associated with the development of dependence and other 
longer-term health and social problems. High-dose and 
long-term stimulant use may cause serious cardiovascular 
problems, such as strokes, cardiomyopathy and myocardial 
infarctions.
Problematic stimulant use can be associated with risks to 
sexual health. Some men who have sex with men engage 
in ‘chemsex’, which involves injecting methamphetamine 
and other substances to enhance sexual desire. Chemsex 
parties, while apparently uncommon, have been reported 
in a number of major European cities. They have become 
a concern in several European countries because of the 
potential spread of HIV and other sexually transmitted 
infections. Some studies have also reported high rates of 
sex for money or sex for drugs exchanges among women 
with crack cocaine problems. This illustrates a potentially 
more general issue relating to stimulant and other 
substance use among women and men engaged in sex 
work and the need to develop responses that can address 
both substance use and sexual health risk behaviours. In 
addition, the role of drugs in sexual exploitation, including 
drug-facilitated sexual assault, is an area of concern. 
Information on the extent and nature of these problems, 
however, is limited.
Stimulants may be used in combination with alcohol and 
other illicit drugs. Some of these combinations, for example, 
cocaine and alcohol, can result in increased health risks. 
Stimulant users may also use other drugs to manage 
negative after-effects of use and to help induce sleep. 
These drugs include alcohol, cannabis and benzodiazepines. 
For some more problematic users, opioids may be used for 
this purpose. This polysubstance use can expose stimulant 
users to additional risks. For this reason responses in this 
area will often need to consider interactions between the 
use of stimulants and other drugs (see section 2.8 on 
polydrug use).
| Response options
Stimulant use often occurs in recreational settings such 
as nightlife venues or music festivals. Prevention and 
harm reduction programmes for users of MDMA and other 
stimulants in these settings are discussed in section 4.2.
People experiencing acute problems as a result of stimulant 
use may seek help from emergency medical services. The 
interventions offered will be dependent on the symptoms 
reported but often a brief medical or psychological 
intervention may be sufficient. It is important, however, that 
emergency services are aware that it may be necessary to 
provide referral to appropriate treatment, harm reduction or 
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sexual health services. The potential of stimulants to cause 
or aggravate cardiovascular problems also means that 
those responding to cardiovascular emergencies may need 
to consider the role drug use may have played in the event.
Harm reduction for problems arising from  
stimulant use
People who inject stimulants are likely to need greater 
access to needle and syringe programmes because they 
may inject more frequently than opioid users (see also 
section 2.4 on reducing the spread of infections associated 
with injecting drug use).
Responses for this group often include some form of 
outreach and the provision of sterile injection equipment, 
condoms, information on safer injecting, basic hygiene, vein 
and wound care, and antibacterial creams and ointments. 
These would appear to be appropriate responses but there 
is not yet a strong evidence base in this area. Whereas 
there is some limited evidence that outreach programmes 
can help stimulant injectors to reduce medical problems 
associated with injection, such as skin infections, there 
is a lack of robust data to show a measurable reduction 
in injecting or sexual risk behaviours resulting from these 
approaches. Given that stimulant-related problems appear 
to be growing this is an area for further research and 
service development.
There is limited evidence that multisession psychosocial 
and behavioural interventions may reduce sexual risk 
behaviours among people who use drugs. For people 
who use stimulants by smoking, the provision of clean 
crack kits to prevent sharing, information, education and 
communication material and outreach activities may 
be beneficial, but more research is needed into their 
effectiveness. An innovative intervention by low-threshold 
services for methamphetamine users in the Czech 
Republic has been to distribute empty gelatine capsules 
to encourage users to consume the drug orally and reduce 
injection-related risks of HIV and HCV infection. This 
intervention needs to be evaluated in order to explore its 
practicality and impact on behaviour.
Although uncommon in Europe, crystal methamphetamine 
smoking is a form of stimulant use that is particularly 
associated with problems, including respiratory damage and 
dental corrosion. Stimulant problems have the potential to 
evolve and develop rapidly. For example, methamphetamine 
smoking has been reported in Athens among opioid 
drug users since 2011. More recently methamphetamine 
injecting has begun to emerge, mainly in other urban areas 
outside the capital. The use of crystal methamphetamine 
is associated with a range of problems including 
aggressiveness, insomnia, skin inflammations and rashes, 
weight loss and deaths. In Greece, the capacity of low-
threshold drug and mental health care services to respond 
to the needs of these users has been restricted by limited 
service availability in the urban areas outside Athens.
Given the link between stimulant use and risky sexual 
behaviour, sexual health services need to be alert to 
drug use among their clients. Drug services also need to 
assess the sexual health of their clients. These issues are 
discussed in more detail in the Spotlight on addressing 
sexual health issues associated with drug use (page 72).
Treatment for stimulant use problems
People who seek treatment for stimulant use problems 
primarily use either cocaine or amphetamine. Ecstasy 
users rarely seek treatment. People entering treatment for 
problems related to cocaine can be, in very simple terms, 
divided into three groups:
  powder cocaine users, who use cocaine intranasally 
(insufflation or snorting) on its own or in combination with 
cannabis and/or alcohol;
  crack cocaine users, who use crack cocaine often in 
combination with other drugs including heroin;
  polydrug users, who often use cocaine and heroin or other 
drugs and may inject.
To some extent these groups require different approaches. 
Primary powder cocaine users are usually more socially 
integrated than those smoking crack cocaine or using 
opioids. They are more likely to have stable housing and 
a regular income. People seeking treatment for problems 
associated with use of amphetamines are similarly 
heterogeneous in their social conditions and modes of use.
There are no pharmacological treatments with good 
evidence for their effectiveness in treating problematic 
stimulant users. Treatment approaches or interventions that 
have been shown to be useful are described in the evidence 
overview box below. Systematic reviews of clinical trials 
of medications for treating cocaine users have produced 
a mixed picture. Antipsychotic medications are the most 
successful in assisting users to cease use and overcoming 
cravings. Disulfiram, a drug used for alcohol addiction, is 
acceptable to users. None of these medications, however, 
has been found to be as effective in treating cocaine 
problems as OST is in treating opioid dependence. 
Trials of pharmacotherapies (e.g. buproprion, modafinil) 
for methamphetamine have found them to be no more 
effective than placebo.
| 69
2.5 | Responding to problems related to stimulant use
Psychosocial interventions can be effective for cocaine 
users. Contingency management may be effective when 
combined with medication. One systematic review showed 
that cognitive behavioural therapy interventions reduced 
treatment drop-out and use of cocaine. The effect was 
stronger when they were combined with contingency 
management. A recent Belgian study reported that after 
six months of contingency management and community 
reinforcement, abstinence rates among cocaine users were 
three times higher than in those who received standard 
treatment.
|  What is being done in Europe to respond to problems related to stimulant use
In Europe, cocaine treatment usually takes place in 
outpatient settings that primarily treat opioid users. 
Some people seeking treatment for stimulant use may be 
reluctant to use these services because they may not see 
them as meeting their needs and do not identify with the 
opioid clients who may predominate at some services. 
Modifying service delivery models to be more in line with 
client needs may make them more attractive. An Irish pilot 
project on cocaine treatment, for example, found that 
providing evening sessions in outpatient facilities increased 
attendance by people who use cocaine. Outreach work 
can also be conducted immediately before and after the 
weekend, when cocaine use generally is higher.
Spain, Italy and the United Kingdom accounted for three 
quarters (74 %) of all reported treatment entries related to 
cocaine in Europe in 2015. Overall, cocaine was the primary 
drug for around 63 000 clients entering specialised drug 
treatment, of whom around 28 000 were first-time clients. 
After a period of decline, the overall number of cocaine 
first-time treatment entrants has been stable since 2012 
(Figure 2.7). In 2015, 7 400 clients entering treatment in 
Europe reported primary crack cocaine use. The United 
Kingdom accounted for almost two-thirds (4 800) and 
Spain, France and the Netherlands together (1 900) for 
most of the remainder.
Approximately 34 000 clients entering specialised drug 
treatment in Europe in 2015 reported amphetamines as 
their primary drug. Around 14 000 were first-time clients 
(Figure 2.8). Primary amphetamine users accounted 
for more than 15 % of first time treatment entrants in 
Bulgaria, Germany, Finland, Latvia and Poland. Treatment 
entrants with primary methamphetamine problems 
were concentrated in the Czech Republic and Slovakia, 
which together accounted for 90 % of the 9 000 
methamphetamine clients entering specialised treatment 
in Europe. Overall, the number of first-time treatment 
entrants reporting amphetamine or methamphetamine as 
their primary drug increased between 2006 and 2015 in 
most countries. Trends in the proportion reporting injecting 
amphetamines need to be monitored because the decrease 
in injecting seen among users of other substances is not 
evident among amphetamine users.
Although use of methamphetamine among the general 
population is low, use of the drug by some groups within the 
population raise particular challenges and prompt different 
responses from service providers. Services currently 
involved in responding to these problems include mental 
Overview of the evidence on … treatment for problematic stimulant use
Psychosocial interventions can reduce cocaine use by influencing mental processes and the behaviours 
related to the addiction.
Disulfiram for alcohol addiction and antiparkinsonian medications may help cocaine users to reduce their 
use.
Psychosocial treatments (including contingency management) show positive short-term efficacy for crack 
abuse/dependence.
Some drugs used to treat depression (fluoxetine and imipramine) have been found to retain amphetamine 
users in treatment in the short and medium term.
For pregnant women, medications to assist detoxification from stimulants can be used but are only 
recommended for those experiencing withdrawal symptoms.
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FIGURE 2.7
Cocaine users entering treatment in Europe: trends over time and source of referral in 2015
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health, low-threshold, drug treatment, youth and sexual 
health services. For example, in the Czech Republic, where 
injection is the most common route of administration of 
methamphetamine, mental health care and residential 
treatment programmes using a therapeutic community 
model have been at the centre of the response. Services 
are also available that offer information and harm reduction 
advice to methamphetamine users.
In several northern European countries where 
methamphetamine use has emerged among existing 
stimulant users, the same type of treatment is offered to 
users of amphetamine and methamphetamine, generally 
psychosocial interventions. Methamphetamine is also 
reportedly used by recreational drug users, including 
clubbers, in several countries. Youth services have sometimes 
been involved in delivering responses to these users.
In addition, in response to use associated with ‘chemsex’, 
initiatives have been developed specifically for 
methamphetamine users. These include multidisciplinary 
services providing drug and sexual health services or 
improvements in links between services (see Spotlight on 
addressing sexual health issues associated with drug use, 
page 72).
Interventions that have been implemented in Europe 
to reduce the risks associated with methamphetamine 
injection include the provision of smoking equipment or 
safer-smoking kits through needle and syringe programmes. 
Health promotion initiatives tend to focus on general safety 
issues and self-care, including mental health, physical and 
sexual health.
MDMA use is rarely cited as a reason for seeking 
specialised drug treatment. In 2015, it was reported by less 
than 1 % (around 900 cases) of first-time treatment entrants 
in Europe.
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FIGURE 2.8
Users of amphetamines entering treatment in Europe: trends over time and source of referral in 2015
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Responses for stimulant users: implications for policy and practice
Basics
  Problems associated with stimulant use vary depending on patterns of use, the groups who are using and the 
setting in which they are used. Responses therefore need to be tailored to the local patterns of use and problems 
experienced.
  Core responses for stimulant problems currently include psychosocial treatment or brief interventions and harm 
reduction for people who inject drugs.
Opportunities
  Improving links between sexual health and drug treatment services could improve efficiency and effectiveness of both.
Gaps
  Harm reduction interventions for stimulant users need development and evaluation.
  Research into effective pharmacological treatments for stimulant dependence should be prioritised at EU level.
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Spotlight on … Addressing sexual health issues associated with drug use
What is the nature of the problem?
There is a substantial prevalence of drug use, particularly stimulant use, among the clientele of sexual health services 
and sexual health problems are common among persons treated for drug problems. Links between sexual health and 
drug problems can arise in a number of ways:
  Drug use can intoxicate and disinhibit and lead to unintended sexual activities — consensual or not — that result in 
negative consequences, such as regret, mental distress, sexually transmitted infections or unwanted pregnancy.
  Some people with drug problems may engage in sex work to fund drug use, increasing their risks of sexually transmitted 
infections and assault.
  Drugs may be used before or during sex to enhance sexual performance and pleasure (‘chemsex’) increasing risks of 
sexually transmitted infections, sexual assault and the development of drug dependence. Reports of this pattern of 
behaviour among some groups of men who have sex with men have raised concerns in some countries.
  Drugs may be used to cope with the emotional distress arising from a sexual health problem, such as an HIV diagnosis.
In Europe, treatment services for drug and sexual health problems are usually funded separately, have different eligibility 
criteria and are rarely co-located. This makes it challenging to provide ‘joined up’ care for people with both types of 
problems. Each type of service focuses on providing only one type of care, missing an opportunity to address both sets 
of problems.
What responses are required?
Research has not yet identified a good model for services, although new ones are emerging. In the absence of an 
evidence base, there is a need to start collecting better data on the extent of the problem in sexual health and drug 
treatment services in order to:
  identify people with problems related to drug use, including dependence, and sexual health;
  understand their risk behaviours and treatment needs;
  understand where linking or integrating sexual health and drug treatment services may be beneficial, for example, in 
services for men who have sex with men that have been developed in some countries.
The two types of services also need to share expertise and develop treatment pathways by:
  training sexual health staff to assess drug use and offer brief interventions where indicated;
  training drug treatment staff to assess sexual health and offer brief interventions for sexual problems related to drug 
use; and
  encouraging services to work together more closely, for example, through joint training events or staff exchanges.
See the Background paper, Joining up sexual health and drug services to better meet clients’ needs.
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Further resources
EMCDDA
  Best practice portal.
  Statistical bulletin.
  European drug report: trends and developments 2017.
  Emergency health consequences of cocaine use in Europe, Perspectives on drugs, 2014.
  Treatment for cocaine dependence: reviewing current evidence, Perspectives on drugs, 2014.
  Emergency health consequences of cocaine use in Europe. A review of the monitoring of drug-related acute 
emergencies in 30 European countries, Technical report, 2014.
  Health and social responses for methamphetamine users in Europe, Perspectives on drugs, 2014.
  Exploring methamphetamine trends in Europe, EMCDDA Papers, 2014.
  Joining up sexual health and drug services to better meet clients’ needs, Owen Bowden-Jones, Background paper.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
New psychoactive 
substances are drugs that 
are not controlled under the 
United Nations drug control 
conventions but which may 
pose similar threats to health. 
These drugs include synthetic 
cannabinoids, opioids, 
stimulants and hallucinogens. 
Usually they are marketed as 
‘legal’ replacements for the 
illicit drug market; while some 
are also used by small groups 
who wish to explore them for 
novel experiences and effects.
The large number of new 
substances, their diversity 
and the speed at which they 
appear is challenging both for 
monitoring and developing 
effective and timely 
responses.
Response options
  Early-warning and risk assessment supported by data on the chemical identification of new 
substances from forensic and toxicology laboratory networks.
  Risk communication with authorities, professionals and users related to particularly harmful new 
substances.
  Inclusion of new substances into effective generic prevention programmes, with specific 
education and harm reduction messages targeted towards those already using drugs, or at risk 
of using new substances.
  Training and awareness-raising activities for professionals in prevention, treatment and harm 
reduction services in order to enhance their competencies in identifying and responding to use 
of new substances.
  Development of clinical guidelines for the management of acute toxicity caused by new substances.
  Multidisciplinary approaches and the linking up of different services are needed to engage 
vulnerable groups who may not come into contact with traditional services.
Many of the health and social responses to new substances are adaptations of programmes for 
‘established’ drugs. Responses have tended to target particular groups where problems have been 
observed. These vary be country but include: recreational stimulant users, psychonauts, men who have 
sex with men, people avoiding drug tests, and high-risk drug users. There has also been a focus in 
many countries on strengthening legal responses and restricting the availability of these substances.
European picture
  EU legislation provides a 3-step approach of early warning, risk assessment and control 
measures that allows Europe to rapidly identify and react to public health threats caused by new 
substances. The EMCDDA plays a central role in this system by operating the EU Early Warning 
System and undertaking risk assessments to support national and EU-level responses.
  Multidisciplinary harm reduction approaches are being developed and trialled in which 
vulnerable groups who may not come into contact with drug services are being engaged, for 
example, in sexual health settings.
  Clinical guidelines for the treatment of acute intoxications associated with new psychoactive 
substances are being developed and published. Specific guidance on responding to the use of 
these substances in prisons and custodial settings is also being developed in some countries.
  Harm reduction information platforms, often coupled with drug checking, are operating in several 
countries and online.
  Specialist treatment for problems caused by new substances is not well developed in most countries.
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|  Understanding the problem and key objectives for responses
New psychoactive substances are a broad range of drugs 
that are not controlled under the United Nations drug 
control conventions but which may pose similar threats 
to health. These drugs include synthetic cannabinoids, 
opioids, stimulants and hallucinogens as well as a range 
of other substances. In the past few years, a number of 
these substances (such as GHB, GBL, and more recently 
mephedrone as well as some fentanils and synthetic 
cannabinoids) have been controlled under the United 
Nations conventions. Such substances are included in 
this section because they present similar challenges in 
developing responses.
Over the last ten years there has been a large increase 
in the availability of new psychoactive substances in 
Europe. Many of these substances are intended to 
circumvent drug laws and are sold as ‘legal’ replacements 
for cannabis, heroin, cocaine, amphetamines, MDMA 
and benzodiazepines. To increase their availability and 
attractiveness, they have been marketed as ‘legal highs’, 
‘research chemicals’ and ‘food supplements’. New 
substances are also sold on illicit drug markets under their 
own street names or passed off as illicit drugs.
As the range of new substances and products has grown, 
so have the user groups. Initially, most users were people 
who explored them for novel experiences and effects 
(often called ‘psychonauts’), and groups such as electronic 
dance music fans and nightclubbers. Users now include 
broader groups of recreational users, people who self-
medicate, people looking to improve how they look or their 
performance at work, vulnerable groups such as prisoners 
and the homeless, and high-risk drug users (such as 
people who inject opioids). These developments are linked 
to the growing interactions between the markets in new 
substances and illicit drugs in the past few years.
New substances have been linked to a range of harms. 
These include a large increase in non-fatal and fatal 
poisoning and the spread of drug-related infectious 
diseases and bacterial infections. In some cases, these 
have manifested in outbreaks which place substantial 
demands on health care systems. Currently, synthetic 
opioids, such as fentanils, and synthetic cannabinoids, pose 
particular challenges to public health.
The appearance of a large number of highly potent new 
opioids — particularly derivatives of fentanyl — poses new 
challenges. These drugs are sometimes sold as heroin 
or other illicit drugs, or counterfeit medicines. The risk of 
severe and fatal poisoning may be increased, both among 
high-risk opioid users and other user groups who have 
not built up a tolerance to opioids. The high potency of 
these substances may also pose a serious risk though the 
accidental exposure to family and friends of users and to 
first responders, forensic personnel, postal services and 
personnel in custodial settings (see Spotlight on fentanils, 
page 52).
Synthetic cannabinoids are often highly potent substances 
that were initially sold as ‘legal alternatives’ to cannabis. 
They are increasingly being used by marginalised groups, 
such as homeless people, or those who wish to avoid drug 
testing. In prisons, the use and distribution of synthetic 
cannabinoids has been associated with debt, bullying and 
intimidation and acute harms causing hospitalisations and 
deaths (see Spotlight on synthetic cannabinoids, page 81, 
and section 4.1).
Concerns have been raised in a number of European 
countries about the use of drugs such as mephedrone, 
GHB/GBL and methamphetamine by men who have sex 
with men to enhance, sustain, disinhibit or facilitate sexual 
pleasure. This practice, sometimes referred to as ‘chemsex’ 
is associated with high-risk drug and sexual behaviour 
(e.g. injecting, unprotected sex, sex with multiple sexual 
partners), potentially resulting in hospitalisation, overdose, 
sexually transmitted infections, and infection with HIV and 
HCV.
Use of synthetic cathinone stimulants has also been noted 
in some groups of heroin injectors. This can increase the 
frequency of injection and may be associated with tissue 
damage and severe bacterial infections.
| Response options
It is essential to know which new psychoactive substances 
are being sold and used in order to respond appropriately. 
Early warning systems and related monitoring systems can 
play a central role in early identification and response to 
emerging harms caused by new substances (see box on the 
EU Early Warning System). These systems need to be based 
on data on the chemical identification of new substances 
from forensic and toxicology laboratory networks related 
to law enforcement seizures and poisonings) and draw 
on information from a wide range of sources including 
law enforcement, poisons centres, hospital emergency 
departments, and medico-legal death investigations. More 
novel data sources, such as wastewater analysis, analysis 
of drug residues from used syringes and drugs collected 
from amnesty bins, may have potential. Drug checking 
76 |
Problems arising from particular types or patterns of drug use
services may also potentially support early warning systems 
and provide a conduit for information, advice and brief 
interventions to users of new psychoactive substances (see 
Spotlight on drug checking, page 139).
However, there are a number of challenges in measuring 
and monitoring the use and harms from new psychoactive 
substances. These include the large number and range of 
different types of substances available, the speed in which 
they appear on the market, a lack of capacity to detect 
and report on acute harms (and link these to a particular 
substance), and limited information on their pharmacology 
and toxicology.
Assessment of the prevalence and consequences of 
the use of new psychoactive substances is complicated 
because users are often misinformed or unaware of what 
substances they have consumed. New psychoactive 
substances may be sold in the form of mixtures, or as 
branded products whose constituent elements change 
over time, or instead of controlled drugs or mixed with 
them. This also poses challenges for responses to these 
substances. Young people, often in recreational settings 
such as parties and festivals, if unaware of what new 
psychoactive substances they are using and of their 
effects or erroneously believing them to be ‘legal’ and 
possibly ‘safer’ than controlled drugs, may be less able 
to use harm reduction measures and cope with negative 
consequences. As a result, our understanding of patterns 
of new psychoactive substance use remains poor and most 
information comes from populations and settings where 
problems have occurred. Nonetheless, this is sufficient to 
identify a range of settings in which interventions targeting 
problems associated with new psychoactive substance use 
may be required (Figure 2.9).
Responses to new substances often involve adapting 
evidence-based responses to reducing harms for 
established drugs. Adjustments may need to take account 
of specific drug effects, socio-cultural characteristics of risk 
groups (e.g. party-goers, men who have sex with men) or 
particular risk behaviours (e.g. increased access to syringes 
FIGURE 2.9
Intervention settings and the potential new psychoactive substance-related harms and risk behaviours that 
may be reported by or observed among at-risk groups
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for high injecting frequency). Alongside early warning 
systems, responses may include innovative regulatory 
controls, specialised treatment, educational responses (e.g. 
dissemination of educational material), harm reduction 
measures (e.g. provision of sterile injecting equipment) 
and medical treatment of overdoses (e.g. symptomatic 
management of acute emergencies and the administration 
of antidotes). As health care professionals may feel 
unskilled when first confronted by problems caused by new 
substances, basic knowledge sharing, competence building 
and highlighting how to transfer existing competencies to 
new substances may also be important.
Prevention interventions which stress skills and coping 
strategies are effective, independently of the substance. 
School-based prevention activities related to new 
substances should only be delivered as part of generic 
prevention programmes for which there is evidence of 
effectiveness. Components incorporating discussion of new 
substances might focus on providing accurate descriptive 
and injunctive norms. For example, based on local data, this 
may include messages such as, ‘very few people use new 
substances’ and ‘young people like you say they don’t want 
to take risks with unknown new psychoactive substances’). 
More specific education and harm reduction related to 
new substances is most appropriate for target groups 
and individuals who are either already using drugs, or at 
increased risk of doing so.
A particular challenge is delivering interventions to hard-to-
reach populations of new psychoactive substance users who 
are experiencing significant harms. This includes high-risk 
drug users (including opioid injectors), men who have sex with 
men, homeless people and prison inmates. Multidisciplinary 
responses and collaborations between health providers in 
different settings (e.g. sexual health clinics, custodial settings 
and drug treatment centres) are needed to reduce these 
harms (see, for example, Spotlight on addressing sexual 
health issues associated with drug use, page 72).
Emerging good practice for responding to new psychoactive substances
  Early warning capacity to identify, assess and communicate on the risks of particularly harmful substances is 
important for responding to the acute harms associated with new psychoactive substances.
  Develop support and training to empower professionals in existing services to recognise how their skills and 
competences can be applied to responding to problems associated with new psychoactive substances.
  Development of practice guidelines for addressing problems related to new substances is generally based on 
responses to other drugs, for example, drug education, professional training, and low-threshold services such as 
needle and syringe programmes. These responses must be adapted to the harms and needs of different groups of 
users of new substances.
  Build cultural competence (an understanding of how cultural issues influence patterns of drug use and associated 
harms) within services to enhance service engagement and uptake.
  Education, including harm reduction, specific to new substances is most appropriate for target groups and individuals 
who are either already using drugs, or at increased risk of doing so.
  School-based prevention activities related to new substances are best delivered as part of generic prevention 
programmes for which there is evidence of effectiveness.
  Multidisciplinary approaches and the linking up of different services are needed to engage vulnerable groups who 
may not come into contact with traditional services (e.g. men who have sex with men who practise ‘chemsex’ and 
homeless people).
  The development of responses to new substances needs to be evaluated in order to identify effective interventions to 
meet the diverse challenges they pose.
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Cultural competence (an understanding of how cultural 
issues influence patterns of drug use and associated 
harms) is required to ensure service engagement and 
uptake. This means that services need to be accessible and 
welcoming to all groups of potential clients. Staff in services 
seeking to attract people experiencing problems with new 
psychoactive substances may also need to undergo training 
to develop the cultural competencies necessary to work 
with diverse groups of users of new substances, many of 
whom may not have presented to drug services primarily 
focused on ‘traditional’ illicit drugs.
|  What is being done in Europe to respond to problems associated with use of new psychoactive substances
In Europe, Council Decision 2005/387/JHA provides a 
3-step legal framework of early warning, risk assessment 
and control measures that allows the European Union to 
rapidly identify and react to public health threats caused 
by new substances. The EMCDDA is responsible for the 
first two steps in this system, namely operating an early 
warning system together with Europol (the EU police 
agency) and conducting risk assessments (see boxes on EU 
Early Warning System and risk assessment). The European 
Commission, European Parliament and Council of the 
European Union are responsible for control measures.
In European countries, initial responses to the emergence 
of new psychoactive substances have been predominantly 
regulatory in nature, using legislative tools to reduce their 
supply. Health and social responses to the challenges 
posed by new drugs have been slow to emerge, but are 
now gathering momentum in Europe. These include a wide 
range of efforts mirroring the full spectrum of responses 
to established illicit substances, such as drug education 
and training activities, user-led consumer protection 
interventions on the internet, and needle and syringe 
programmes in low-threshold services.
EU Early Warning System
The early warning step of the Council Decision 2005/387/JHA is known as the European Union Early Warning System on 
New Psychoactive Substances. The EMCDDA and Europol are responsible for operating the Early Warning System, which 
is comprised of a multidisciplinary network of 30 national early warning systems of EU Member States, Norway and 
Turkey, Europol and its law enforcement networks, the European Medicines Agency (EMA), the European Commission 
and other partners.
The national systems gather information on the chemical identification of new substances from forensic and toxicology 
laboratory networks. These laboratories analyse samples from seizures made by law enforcement agencies and from 
poisoning and death investigations. They can also include drug samples collected from users, for example, in nightclubs 
and music festivals, or test purchased from vendors. These data may be supplemented by information from law 
enforcement agencies, health care systems, medicine agencies, key informants (such as users, owners and staff of clubs, 
and organisers of festivals), and open source information (such as media reports and user discussion forums on the 
internet). This allows the collection, assessment and rapid reporting of event-based information on the appearance of, 
and harms caused by, new substances found at national level to the EMCDDA.
The EMCDDA collates and analyses this data, as well as data from its other monitoring systems, in order to rapidly detect 
the appearance of new substances and associated harms. This is then used to produce an analysis which includes 
technical information and risk communications, including public health alerts. This includes information on chemistry 
and analysis, manufacture, pharmacology, toxicology, epidemiology, trafficking and distribution of new substances. If 
the information collected on a new substance reported requires a formal response, then the EMCDDA and Europol 
undertake a special investigation into the substance leading to the preparation of a report which is presented to the 
European institutions. Known as a Joint Report, the analysis provided in the report is used by EU decision-makers to 
determine if a formal risk assessment is required. This marks the final stage of early warning.
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More attention is now being paid to developing targeted 
education and prevention activities and to training and 
awareness-raising activities for professionals. Services 
working in nightlife and recreational settings have tended 
to integrate their response to new psychoactive substances 
within established approaches. The internet is also 
increasingly used to provide information and counselling, 
including ‘online-outreach’ interventions to reach new target 
groups. Examples include drug user-led initiatives, such 
as forums and blogs, which provide consumer protection 
information and advice. The impact and accuracy of these 
services is not known and there is the potential for them to 
spread misleading information as well as valuable advice. 
In a few cases, these interventions have been linked with 
drug testing and pill-checking services, with results and 
harm reduction messages disseminated online. There is a 
need for research in the area of risk communication and 
evaluation of different models of providing information on 
new psychoactive substances to users.
There is a limited demand in Europe for specialist drug 
treatment for problems caused by the use of new 
substances. This may be related to a number of factors, 
such as poor identification of use, low prevalence of use, 
and low levels of problematic use. Poor identification of 
use may reflect under-reporting of use or misreporting of 
substances — because users do not know what they are 
consuming — lack of suitable screening and monitoring 
instruments and low professional awareness of new 
EU risk assessment on new psychoactive substances
The second step of Council Decision 2005/387/JHA provides for an assessment of the risks associated with new 
substances. The risk assessment component supports decision-making on new psychoactive substances at EU level, 
adding value to national actions in this area.
A risk assessment takes into account all factors which according to the 1961 or 1971 United Nations drug conventions 
would warrant placing a substance under international control. The EMCDDA has published risk-assessment operating 
guidelines to provide a sound methodological and procedural basis for carrying out a risk assessment, including 
providing a conceptual framework for consideration of risk.
The risk assessment process reviews the possible health and social risks of the substance and the implications of 
placing it under control. The concept of risk includes both the element of probability that some harm may occur 
(usually defined as ‘risk’) and the degree of seriousness of such a harm (usually defined as ‘hazard’). An assessment 
of the risk–benefit ratio of a new psychoactive substance is also needed. Various factors, including the question of 
whether the substance has legitimate uses, such as potential therapeutic benefits, industrial use or other economic 
value, may be taken into account.
The assessment uses the data reported by the network and identified by the EMCDDA through its other monitoring 
systems. Risk assessments are based on a broad range of available evidence, including recent unpublished data, 
the quality of which needs to be appraised. At the risk assessment stage, the prevalence of use of a new substance 
will usually be low and the majority of the available information comes from forensic and toxicology laboratories, law 
enforcement agencies and anecdotal reports. Especially important are reports relating to non-fatal and fatal poisonings 
involving the substance under assessment. As data on the effects of new substances is often extremely limited, part of 
the assessment involves an analysis of the possible nature and risks of the substance with reference to similar known 
substances, both controlled drugs and other substances.
At the end of the risk assessment process a report on the substance is drawn up which contains an analysis of the 
information available, which includes chemistry and pharmacology, dependence producing potential and abuse liability, 
the health and social risks as well as the involvement of organised crime, and its production and distribution. Since 
1997, the EMCDDA has conducted 22 risk assessments on new psychoactive substances. Half of these have been 
conducted in the past three years, reflecting the growth in the market in recent years.
For more information see Action on new drugs and Publications on the EMCDDA website.
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substances. Nevertheless, service developments are now 
seen in some countries.
The emergence of new substances has manifested itself 
in different ways in individual countries, and national 
responses reflect these differences. In Hungary and 
Romania, where injecting synthetic cathinones has been 
reported, needle and syringe exchange services play an 
important role. In the United Kingdom, where significant 
use of mephedrone has been reported, specialist ‘club-drug 
clinics’ are engaging with this client group.
Clinical guidelines for responding to acute and chronic 
health harms are being developed in some European 
countries, for example, the Neptune Guidelines in the 
United Kingdom.
Responding to new psychoactive substances: implications for policy and practice
Basics
Core interventions in this area include:
  Early warning systems to monitor new substances on the market and the harms they cause. These need to be 
supported by the chemical identification of new substances by forensic and toxicology laboratory networks.
  The provision of training material on new substances for health professionals and the creation of knowledge exchange 
platforms for clinicians, health care and social workers at local and national level.
  Interventions addressing the use of new substances based upon responses to established drug groups, but adapted 
appropriately to account for the nature and patterns of use of the new substances, the different user groups and 
contexts of use.
Opportunities
  National health authorities should be encouraged to develop new psychoactive substance guidelines, including on 
overdose management, or translate and adapt existing ones, such as the UK-based NEPTUNE guidelines, to national 
needs.
  Analytical and toxicological testing and risk assessment capacities need to be enhanced and results disseminated in a 
timely and usable way to both risk groups and relevant professionals.
  Services need to be developed to address the specific issues of use of new psychoactive substances among some 
particular groups such as homeless people, prisoners and people who inject drugs.
Gaps
  The effectiveness of the adapted interventions now being used for responding to new substances should be evaluated.
  The impact of different ways of communicating the risks associated with new psychoactive substances is not well 
understood. Therefore there is a need to develop and strengthen the evidence base with respect to risk communication.
  To improve the targeting and development of appropriate responses, better epidemiological data on the extent, 
motivations for use and patterns of use and how they change over time is needed as well as fundamental research 
(pharmacology and toxicology).
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Spotlight on … Synthetic cannabinoids
What are they?
Synthetic cannabinoids (or synthetic cannabinoid receptor agonists) is the name given to a diverse range of 
substances that act on the same brain receptors as tetrahydrocannabinol (THC), the main psychoactive ingredient in 
cannabis. Since 2008, more than 170 synthetic cannabinoids have been detected in Europe in hundreds of different 
products, frequently sold as ‘legal’ replacements for cannabis although their effects are often very different.
Typically, synthetic cannabinoids are sold as ‘herbal smoking mixtures’. Synthetic cannabinoids have also been sold as 
powders and tablets, products that look like cannabis resin and e-liquids for use in electronic cigarettes.
Why is their use of concern?
Many of the synthetic cannabinoids sold on the drug market are more potent than THC. This may explain why the 
harmful effects of synthetic cannabinoids, such as severe and fatal poisoning, may be more common than for 
cannabis. The large doses users may be exposed to are likely to be another important factor.
Smoking mixtures are made by spraying synthetic cannabinoids onto plant material. This crude process can result in 
mixtures that contain large amounts of highly potent cannabinoid, as well as ‘hot pockets’ within them in which the 
cannabinoid is highly concentrated. These make it difficult for users to control their dose and they can inadvertently 
administer a toxic dose. Smoking mixtures have caused a number of mass poisonings in the United States. While 
outbreaks have been rare in Europe, during 2015 more than 200 people were hospitalised over a few days in Poland 
after smoking a product called ‘Mocarz’. Because these products rarely state the ingredients, most users will be 
unaware that they are using a synthetic cannabinoid.
The prevalence of use in the general population appears low but may be higher in socially marginalised populations, 
such as homeless people and prisoners. Synthetic cannabinoids are attractive to these groups because they produce 
strong intoxication at a relatively low price and, in the case of prisons, are not detected in most routine urine testing 
(see section 4.1).
Responding to synthetic cannabinoid problems
Early warning systems play an essential role in identifying and responding to harms caused by synthetic cannabinoids. 
The potential for outbreaks of intoxications and other harms posed by these substances highlights the importance of 
maintaining and strengthening the identification and monitoring of deaths associated with their use.
Drug services need to focus on the individual, their symptoms, and the setting of use rather than on identifying the 
specific substance. It is important to recognise that the needs of synthetic cannabinoid users may significantly differ 
from those of cannabis users.
Prisons may require special approaches to synthetic cannabinoids, which pose both threats to health and security. 
Data collection on the extent of the problem and developing guidance and training for staff in their management is 
important. Prison staff need to be prepared to manage the adverse health effects, which in extreme cases may require 
transfer to hospital, but can also be long-lasting and require ongoing management. Education, harm reduction advice 
and treatment for prisoners who have developed dependence on synthetic cannabinoids should also be provided.
See Synthetic cannabinoids in Europe, EMCDDA Perspectives on drugs.
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Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  EMCDDA EWS reports and updates and the Risk assessment reports.
  Health responses to new psychoactive substances, Perspectives on drugs, 2016.
  Health responses to new psychoactive substances, Rapid communication, 2016.
  Injection of synthetic cathinones, Perspectives on drugs, 2015.
  New psychoactive substances in Europe: Innovative legal responses, 2015.
  Drug-checking as a harm reduction tool for recreational drug users: opportunities and challenges, Tibor Brunt, 
Background paper.
  New psychoactive substances in Europe: legislation and prosecution — current challenges and solutions, 2016.
Other sources
  UNODC. Global SMART programme.
  Neptune group. Neptune clinical guidance, 2015.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
Misuse of medicines refers to the use of a psychoactive 
medicine for self-medication, recreational or 
enhancement purposes, with or without a medical 
prescription and outside accepted medical guidelines. 
It may occur in the context of polydrug use.
Concerns have been growing in many European 
countries about increasing misuse of medicines, 
particularly in the light of large increases in deaths 
from prescription opioid analgesics in the United 
States. However, there are considerable differences 
between Europe and the United States with respect to 
prescribing practices.
The groups of medications that have been associated 
with misuse include:
  Sedatives and hypnotics including barbiturates, 
benzodiazepines and benzodiazepine-like drugs such 
as the z-hypnotics.
  Opioids, including pain relief medications and OST 
(opioid substitution treatment) medications.
  Stimulants prescribed to treat attention deficit and 
hyperactivity disorder (ADHD).
These medicines may be obtained by regular 
prescribing, doctor shopping or visits to multiple 
pharmacies, diversion of supplies onto the illicit market 
and internet purchases. One important driver of misuse 
of medicines is poor prescription practice — this can be over-prescription 
or, particularly in the case of OST medication, under-prescription, which 
can result in people seeking to self-medicate. Clinical good practice in 
the prescription of OST medications reduces diversion and the harms 
associated with misuse of these medications.
Response options
  Monitoring to establish the extent and nature of the problem is essential 
in developing appropriate responses. In addition to key epidemiological 
indicators and pharmacovigilance schemes, other potential data sources 
include hospital emergency cases of drug-related toxicity, sales statistics 
and prescription databases, and monitoring on-line forums where these 
drugs are discussed.
  Prevention approaches include practitioner training and the 
establishment of quality standards and protocols to improve prescribing 
practice; controls on availability, such as limiting sales and packaging 
restrictions and disposal schemes for waste or surplus medicines; using 
special forms for certain drugs; and not allowing telephone or internet 
prescribing.
  Drug treatment providers need to be ready to treat people with problems 
associated with misuse of medicines. This includes recognising the 
potential for clients presenting for treatment for illicit substances 
to also be misusing medicines and addressing this as necessary. In 
addition, since people with primary problems associated with misuse of 
medicines may be reluctant to seek help from traditional drug treatment 
services, alternative treatment in primary care may be necessary.
European picture
  Information is limited on current treatment practices in Europe in 
managing misuse of medicines.
  Work to better understand the extent and nature of the problem 
and monitor developments is underway and includes monitoring of 
acute events through sentinel sites (Euro-DEN Plus) and developing 
wastewater analysis.
  There have been several EU-funded projects, such as CODEMISUSED 
looking at Codeine Use, Misuse and Dependence, and Access To 
Opioid Medication in Europe (ATOME) in this field, and there is ongoing 
collaboration between the EMCDDA and European Medicines Agency.
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|  Understanding the problem and key objectives for responses
The EMCDDA defines misuse of medicines as the use of a 
psychoactive medicine with or without a prescription from 
an appropriate practitioner, clearly outside of accepted 
medical practice or guidelines, for either self-medication, 
recreational or enhancement purposes, including in the 
context of polydrug use.
Misuse of prescription medicines is an increasing concern 
in Europe, although it appears to be much less common in 
Europe than it is in the United States. Information from the 
European Drug Emergencies Network (Euro-DEN Plus), which 
monitors drug-related presentations in 15 (sentinel) hospitals 
in 9 European countries, showed that in 2015 almost a quarter 
of presentations (24 %) involved misuse of prescription 
or over the counter medicines (most commonly opioids 
and benzodiazepines). The sampling used for this exercise 
means that this figure needs to be interpreted with caution. 
Nevertheless, it suggests that misused medications may be a 
problem meriting further monitoring in order to understand the 
extent and patterns of misuse of medicines in Europe.
The majority of these medicines are prescribed according to 
standard practice and guidelines, often for a limited period to 
relieve pain, insomnia or deal with surgical or other trauma. 
Problems may arise in the use of these medications, such as 
when people continue to use them after the original problem 
has passed, use too much or increase their doses beyond 
therapeutic doses as tolerance develops. In addition, people 
who have never been prescribed these medicines may also 
use them for a range of purposes. The misuse of medicines 
in combination with other drugs can lead to interactions that 
can increase harms and may result in death.
The following are some common patterns of medicine misuse:
  Some people with anxiety disorders and other psychiatric 
disorders or pain may misuse medicines to self-
medicate these symptoms. Use that is not in line with 
recommendations may occur among a relatively small 
proportion of those prescribed these drugs who have 
developed tolerance or dependence.
  Some people who misuse medicines have no medical 
reasons for using the drugs and use them for recreational 
or enhancement purposes, for example, to obtain a high, 
improve their physique or to facilitate concentration for 
long periods.
  Many users of heroin or central stimulants also use 
prescription opioids. Benzodiazepines or z-drugs may also 
be used to increase the high, postpone opioid withdrawal or 
to end a stimulant binge. This form of polydrug use can also 
be a form of self-medication in heroin and stimulants users.
Commonly prescribed medicines that may be misused
Sedatives and hypnotics induce sleep, relieve anxiety and produce euphoria. They include barbiturates, benzodiazepines 
and non-benzodiazepine hypnotics such as the ‘z-drugs’ (zaleplon, zopiclone, eszopiclone and zolpidem). 
Benzodiazepines and z-drugs are popular among people who inject drugs. They may also be used by stimulant users 
to ‘come down’ from binges and by heroin users to prolong intoxication and prevent withdrawal. They contribute 
significantly to overdose deaths in people who use illicit opioids (see box on common drug combinations, page 93).
Opioids include natural, synthetic and semi-synthetic substances that act on opioid receptors to produce pain relief 
and euphoria. Taken in high doses they can cause respiratory depression and death. They include a range of pain relief 
medications, which may be available on prescription only or without prescription (sometimes called ‘over the counter’). 
Some of these, such as methadone or buprenorphine, are used as opioid substitute medications.
Central stimulants — increased prescribing of these medicines to treat attention deficit and hyperactivity disorder 
(ADHD) has increased their availability and abuse. Central stimulants may be used as ‘cognitive enhancers’ to stay awake 
and work for prolonged periods or in the belief that they may improve school performance.
Other drugs include a large and varied group of medicines that do not fall into the above categories. A group currently 
causing concern with respect to misuse in some European countries are pregabalin and gabapentin, which are 
prescribed for the control of seizures and treatment of neuropathic pain. A range of other medicines, besides stimulants, 
may be misused for image and performance enhancement, such as, anabolic steroids, peptide hormones, slimming pills 
and sildefanil (commonly known by the brand name Viagra).
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People who misuse medicines obtain them in a range of 
different ways, which are becoming increasingly diverse. 
In the past, availability was almost entirely a result of 
the diversion of prescription medicines, defined as the 
unsanctioned supply of regulated pharmaceuticals from 
legal sources either to the illicit drug market or to a user for 
whom the drugs were not intended. Diversion can occur 
at all points in the medicine supply chain: from the original 
manufacturing site, at the wholesale distributor, in the 
physician’s office or the retail pharmacy or from the patient.
Diversion methods include:
  robberies and thefts from manufacturers, distributors, and 
pharmacies and institutional drug supplies;
  the ‘doctor shopping’ phenomenon, whereby individuals 
consult more than one doctor to obtain multiple 
prescriptions, or visit multiple pharmacies to circumvent 
restrictions on purchase quantities;
  theft (including stealing insurance cards to obtain multiple 
prescriptions), forgery or alteration of prescriptions by 
patients; and
  the illegal sale and recycling of prescriptions by physicians 
and pharmacists.
In addition, insecure storage and disposal of medicines 
in homes and institutions may provide opportunities for 
diversion.
In recent years a number of technological advances have 
reduced the opportunities for some forms of diversion. 
For example, the introduction of electronic record keeping 
and centralised prescription databases reduces the 
opportunity for doctor shopping. On the other hand, the 
advent of online pharmacies has provided another point 
of access. In addition, it appears that some medicines are 
being manufactured specifically for sale for non-medical 
use on the illicit market. Overlaps can exist between the 
phenomena of medicines misuse and the use of new 
psychoactive substances as in the case of fentanils (see 
Spotlight on fentanils, page 52).
| Response options
Monitoring
Gaining an understanding of the extent and nature of the 
misuse of medicines, including prevalence, motivations 
for use and sources of supply as well as monitoring 
change over time is essential for developing appropriate 
responses. However, the diversity of medicines, their 
sources of supply and the different groups who use them, 
and variation between countries in prescribing practice and 
legal frameworks make this a challenging task. This variety 
also makes it important to clearly define what constitutes 
misuse, particularly for cross-national comparisons. The 
extent of the problem needs to be assessed using a variety 
of data sources. Case reports and time series can detect 
signals of misuse that require systematic investigations 
of the extent of the problem. Currently the information on 
the sources of medicines that are being misused or being 
seized is very limited.
Population surveys are costly and have decreasing response 
rates but still provide valuable insights into use. Some 
information on misuse of medicines is also captured by the 
EMCDDA’s key epidemiological indicators. For example, 
the numbers of people seeking treatment for dependence 
on medicines and the number of drug overdose deaths in 
which medicines were implicated. The EU Early Warning 
System and drug seizures data can also help identify 
medicines that are appearing on the illicit market.
Signals of misuse of medicines may also come from 
national or international databases on adverse drug 
effects, such as the Eudravigilance database maintained 
by the European Medicines Agency and WHO’s Uppsala 
Monitoring Centre Adverse Effects Database. These compile 
data on substances associated with adverse events 
reported by hospital emergency departments and other 
sources. They include information on problems associated 
with medicines taken for ‘recreational purpose’ alone or 
with other psychoactive substances. Other sources of 
information include services working with substance users 
and data from driving under the influence cases, autopsies 
and prisons.
Pharmacy sales statistics represents a cheap and efficient 
way to follow medicine use and trends. Sales data should 
be monitored by area to obtain information on levels and 
trends in use. Prescription databases are generally a more 
costly option and are less easily interpreted. These data 
arise from health insurance claims and national prescription 
databases or pharmacy records. They can be analysed to 
provide information on the extent of doctor shopping and 
forged prescriptions. Another indicator of potential misuse 
is when a large proportion of the drug is used by a small 
proportion of consumers.
Prescription opioids, benzodiazepines and other medicines 
are often found on the illicit drugs market. They may be 
obtained by deception, diverted by people who have 
them prescribed, and stolen from patients, pharmacies or 
factories. Seizures by the police tap the illegal market and 
provide an indication of its size.
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Monitoring the internet can also help pick up misuse of 
medicines. Data can be collected from websites in information 
requests about specific medicines or online reports of misuse. 
Wastewater (sewage) analysis is a novel approach to drug 
epidemiology that may give information on the total use of 
these drugs within a community. Weekly temporal variations in 
use may indicate how much is used recreationally.
Prevention and treatment of misuse of medicines
Any medicines control system must ensure the availability 
of medicines for people who need them for medical reasons 
while minimising the scope for their abuse. The WHO 
guidelines on access to controlled medicines seek to ensure 
that drug control measures do not restrict access to medicines 
for those who need them. Lack of such access is a problem in 
a number of countries globally, including some in Europe.
The increasing availability of medicines over the internet 
poses challenges to regulation and will require the 
development of new responses. Many of these, as is often 
the case for actions against diversion at the production and 
distribution stages of supply, will involve law enforcement 
rather than health and social responses. Key for success 
here will be a clearer understanding of the sources of the 
medicines appearing on different markets.
One important driver of misuse of medicines is poor 
prescription practice. This includes over-prescription but also, 
particularly in the case of OST medication, under-prescription 
which leads people to self-medicate. Clinical good practice in 
the prescription of OST medications has been shown to reduce 
the diversion and harms associated with misuse of these 
medications. The use of substitution drugs for the treatment of 
opioid dependence represents a key evidence-based response 
to heroin problems in Europe. It is important that good 
coverage and high quality provision is available to people with 
opioid dependence problems. This is not always the case.
The diversion of these medicines from their intended use in 
drug treatment to non-medical use and sale on illicit drug 
markets can be a problem. An overview of available studies 
suggests that the use of diverted substances has been 
associated with three consequences: fatal and non-fatal 
overdose; an increased incidence of opioid dependence 
(particularly in jurisdictions where heroin is scarce); and 
compromising public acceptance of OST.
Nevertheless, although the diversion of OST medications 
has been described as a growing problem in recent years, 
there has been little systematic monitoring or data on 
the extent and nature of the problem. There is therefore 
a lack of empirical data to inform regulatory decisions 
and to develop prevention and risk management plans. 
Nevertheless, a number of interventions have been 
developed and are currently used in Europe to minimise the 
diversion of OST medications (Figure 2.10). These include:
  the use of misuse-deterrent formulations, for example, 
suboxone or the dilution of methadone to discourage 
injection;
  the development of clinical prescribing guidelines on the 
supervision of doses for people who are not stable in 
treatment;
  educating physicians on safe opioid prescribing, including 
comprehensive initial assessment and regular monitoring 
of patients, and providing information to patients on safe 
use, including appropriate storage and disposal;
  electronic medicine dispensers to promote safe opioid 
prescribing and reduce medical errors;
  control measures such as patient toxicology tests, pill 
counts and unannounced monitoring;
  regulation at a system level via registers of pharmacy 
transactions with disciplinary measures to address 
inappropriate prescribing.
Overview of the evidence concerning … treatment for misuse of medicines
Cognitive behavioural therapy helps to reduce benzodiazepines use when added to tapering dosages in the 
short term.
Tailored letters sent by family doctors to patients, a standardised interview with GPs plus tapered 
doses, and relaxation techniques each showed promising results in individual small studies addressing 
benzodiazepine misuse. These approaches merit further investigation.
It is not clear if motivational interviewing can help to reduce benzodiazepine use.
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FIGURE 2.10
Examples of strategies to prevent the diversion of opioid substitution treatment medication
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The treatment of misuse of medicines is similar to that 
for other drug use disorders and needs to be tailored to 
individual needs. People experiencing problems associated 
with misuse of medicines may come from a wide range of 
social groups. Treatment in primary care settings may be 
more appropriate for some groups who would not readily 
access drug services. Primary care treatment providers 
may be less informed about misuse of medicines and many 
people with problems related to prescription medicines 
do not see themselves as having a drug problem or do 
not disclose it to their doctor. Polydrug users may not 
acknowledge their misuse of medicines so drug treatment 
providers need to assess these patients for misuse of 
medicines and provide treatment as needed.
A strong therapeutic relationship between the patient 
and physician can play an important role in preventing 
misuse of medicines. In dealing with drug-seeking patients, 
doctors need to be aware of the reasons patients provide 
for additional prescriptions, such as lost medicines and 
prescriptions and, if frequently repeated, investigate further. 
They should be cautious in prescribing to unknown patients 
while not withholding medication to patients in need. 
Primary health care workers need to be trained to deal with 
these dilemmas.
Primary health care workers need to know the basics of 
minimal interventions. A simple and effective strategy is to 
send a letter of concern to patients. Further support may 
be needed if this fails (‘stepped care’), which could include 
providing pharmacology education, information about the 
underlying disease and alternatives to pharmacological 
treatments, and referral to support groups or group 
therapy.
|  What is being done in Europe to respond to the misuse of medicines
A number of international organisations and agencies 
have responsibilities in the area of medicines control 
including the European Medicines Agency, the World Health 
Organisation, UNODC and the INCB. The EMCDDA collects 
information from national legislation that covers prescribing, 
the substances authorised, prescription regulations, any 
criteria for enrolment in OST medications and any sanctions 
for infractions. Substitution registers in each EU Member 
State help to avoid double prescriptions that can arise when 
several doctors prescribe in parallel. Use of wastewater 
analysis for monitoring purposes is also being explored.
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Other psychoactive medicines, such as tramadol, 
benzodiazepines and unauthorised medicines sold as 
new psychoactive substances or vice versa, are monitored 
through the EU Early Warning System. It also monitors 
established (controlled) drugs adulterated with unusual or 
harmful cutting agents and substances sold as others (‘new 
opioids’ sold as benzodiazepines, for example).
The European Drug Emergencies Network (Euro-DEN Plus) 
monitors drug-related emergency presentations in 29 
sentinel centres across Europe to provide unique insight 
into acute health harms related to drug use and also to 
medicine misuse.
A number of European research projects are relevant to this 
area. The completed EU-funded project ATOME (Access To 
Opioid Medication in Europe) has already been mentioned 
in section 2.2 above. Another example is CODEMISUSED, 
a 4-year EU-funded project looking at Codeine Use, 
Misuse and Dependence, which commenced in 2013. 
The CODEMISUSED collaboration has collected data on 
prescribed and over the counter codeine use, misuse and 
dependence in partner countries. Data were collected 
by the collaboration from a range of stakeholder groups 
(codeine patients, prescribers, pharmacists, addiction 
treatment specialists, drug users, pharmacy customers and 
addiction treatment patients). Its results will be useful to 
inform the design of a wide range of response measures, 
such as patient information, professional training and 
education, risk detection, surveillance and monitoring, and 
treatment provision.
Information is limited on current treatment practices in 
Europe in managing misuse of medicines. Collecting 
this information is complicated by the fact that much of 
the treatment is carried out by family doctors or general 
practitioners rather than drug treatment services and will 
not be reported to drug treatment monitoring systems.
Misuse of medicines: implications for policy and practice
Basics
Core objectives in this area include:
  Ensuring that regulatory regimes for medicines with abuse potential provide sufficient availability for medical use, while 
limiting opportunities for misuse.
  Ensuring that health care professionals are trained in correct prescribing guidelines and practice, identifying and treating 
problematic use, and how to address signs of misuse.
Opportunities
  Develop and provide alternative treatment options to deal with misuse of medicines for patients who are reluctant to 
seek help in traditional drug dependence treatment settings.
  Promote awareness among patients and the general population of the problem of misuse of medicines in order to 
destigmatise it and encourage help-seeking.
Gaps
  Investigate and monitor the extent and nature of misuse of medicines locally and nationally, in order to facilitate the 
development of appropriate interventions, using a wide range of sources: surveys, treatment demand, sales statistics, 
police seizures, internet trends and wastewater analysis. This should include the relative importance of different sources 
of medicines on the illicit market as well as understanding how many and which people misuse medicines and for what 
reasons.
| 89
2.7 | Addressing the misuse of medicines
Spotlight on … Misuse of benzodiazepines
Benzodiazepines are a widely prescribed group of medicines used to treat anxiety and insomnia and to manage 
alcohol withdrawal. Benzodiazepines are often misused by high-risk opioid users in whom use is associated with 
increased morbidity and mortality.
Much benzodiazepine prescribing to high-risk drug users is for legitimate therapeutic purposes. Nevertheless, there are 
concerns about the health consequences of using benzodiazepines for longer than a few weeks, their use by polydrug 
users, and use that is not in accordance with prescribing guidelines. The misuse of benzodiazepines increases the 
risk of heroin overdose and is associated with higher risks of HIV infection, psychopathology (anxiety and depression), 
poorer treatment outcomes and poorer social functioning.
Opioid users may misuse benzodiazepines to self-medicate, for example, to treat anxiety or insomnia, to alleviate 
opioid withdrawal symptoms or the adverse effects of alcohol or cocaine. Benzodiazepines may also be used to 
prolong the intensity and duration of the effect of opioids, especially when injected. Patients in opioid substitution 
treatment (OST) using methadone, for example, may misuse benzodiazepines to increase the effects of their opioid 
medication when under-dosing allows withdrawal symptoms to re-emerge.
Users obtain benzodiazepines from diversion of prescriptions (such as ‘doctor shopping’), the illicit market or the 
internet. A growing number of benzodiazepines that are not approved medicines within the European Union, such as 
flubromazolam or flubromazepam, have been sold at street level and online.
The combined use of opioids and benzodiazepines is a significant issue among high-risk opioid users in prisons and 
among those receiving treatment. In 2014 data from 18 countries, of the 102 000 treatment entrants citing opioids 
as the primary problem drug, 10 000 (11 %) reported benzodiazepines as a secondary problem drug. This may be an 
underestimate because the use of secondary drugs is often under-reported.
Benzodiazepines are commonly identified in post-mortem examinations of drug-related death cases. Current EMCDDA 
drug-induced deaths data show that benzodiazepines were implicated (i.e. they were thought to have played a role in 
the death), often in combination with opioids, in 28 % of the overdose deaths in Scotland, 48 % in France, 30–32.5 % 
in Portugal and 35 % in Ireland.
What is being done to respond to the issue?
Prescribing and clinical practice guidelines have a critical role to play in the management of benzodiazepine use 
among high-risk opioid drug users. The EMCDDA’s Best practice inventory currently contains six sets of guidelines that 
address these issues, as part of general or specific guidelines for managing opioid use.
See The misuse of benzodiazepines among high-risk opioid users in Europe, EMCDDA Perspectives on drugs.
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Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  The misuse of benzodiazepines among high-risk opioid users in Europe, Perspectives on drugs, 2015.
  Strategies to prevent diversion of opioid substitution treatment medications, Perspectives on drugs, 2016.
  EMCDDA activities in the area of hospital emergency data.
  Misuse of medicines in Europe: risks and prevention, Jørgen G. Bramness, Background paper.
Other sources
  WHO. Access to analgesics and to other controlled medications.
  INCB. Availability of Internationally controlled drugs: ensuring adequate access for medical and scientific purposes. 
Indispensable, adequately available and not unduly restricted, 2015.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
The term ‘polydrug use’ is used to describe the 
use of more than one drug or type of drug by an 
individual either at the same time or sequentially. 
It encompasses use of both illicit drugs and legal 
substances, such as alcohol and medicines.
Among polydrug users, a broad distinction can 
be made between socially marginalised users of 
heroin and a range of other substances — such 
as cocaine, benzodiazepines and alcohol — and 
socially integrated people using combinations 
such as cocaine and alcohol or cannabis and 
alcohol problematically.
The use of multiple drugs potentially increases 
risks and worsens dependence. The most severe 
consequences of polydrug use include fatal 
and non-fatal overdoses, hepatotoxicity and 
compromised treatment outcomes.
Response options
Prevention and harm reduction measures for reducing alcohol 
and drug use in festival and nightlife settings and the misuse of 
medicines may be helpful in reducing polydrug use.
Assessment processes that can identify problematic polydrug use 
in treatment clients are important, as it is common among this 
group. Treatment for other forms of drug dependence can also 
reduce polydrug use in severe and long-term problem drug users.
European picture
  Information is limited on current treatment practices in Europe in 
managing polydrug use.
  While it is assumed that polydrug use is hard to treat, large 
outcome studies in Europe show that treatment significantly 
reduces multiple drug use among highly problematic users.
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|  Understanding the problem and key objectives for responses
The term ‘polydrug use’ is used as a catch-all term to 
describe the use of more than one drug or type of drug by 
an individual. This can involve use of multiple substances 
either at the same time or sequentially within a specified 
time period. It encompasses use of both illicit drugs and 
legal substances, such as alcohol, new psychoactive 
substances and medicines. The range of behaviours 
encompassed by this term is so wide that almost all 
consumers of psychoactive substances can be regarded 
as engaging in some form of polydrug use. For this reason, 
in responding to polydrug use problems, it is necessary 
to focus on specific populations, drug interactions or risk 
behaviours.
Interactions between different drugs, consumed close 
together in time, can increase drug toxicity. The effects of 
some psychoactive substances can increase risky use of 
other substances. For example, alcohol intoxication can 
impair judgements about the amount of opioids consumed 
or the risk of reduced tolerance after leaving treatment or 
prison. Similarly, the combined use of cocaine and alcohol 
can increase toxicological risks. The co-use of several 
substances can also increase the risk of accidents or 
injuries. Polydrug intoxications including alcohol represent 
a significant proportion of drug-related hospital emergency 
presentations.
Polydrug use is very common among people with drug 
problems who seek treatment (see Figure 2.11). In Europe 
over half of the people entering drug treatment report 
consuming several substances in a problematic way 
— though this may be an underestimate as secondary 
drugs are not always recorded. Drug interactions that can 
have important consequences for treatment and health 
outcomes are often seen in drug treatment populations and 
may sometimes go unacknowledged. For example, many 
of those being treated for a primary illicit drug problem will 
also have problems with alcohol use. Tobacco smoking is 
also commonplace. Failing to recognise and address these 
problems is a potential missed opportunity for health gain.
Polydrug use can undermine successful treatment 
approaches if it is not addressed. For example, concurrent 
stimulant use can result in a worse outcome for those 
undergoing OST treatment. Much of the information 
available on polydrug use is based on treatment entry data. 
Leaving aside the national differences, overall the most 
common combinations of drugs recorded among treatment 
clients in Europe are opioids, as the primary drug leading to 
treatment, consumed with cannabis and powder cocaine; 
cocaine, as primary drug, consumed with cannabis and 
alcohol; cannabis, as the primary drug, consumed with 
alcohol and powder cocaine; and stimulants, as the primary 
drug, consumed with alcohol and cannabis. Recognising 
these types of polydrug use is important because the 
use of multiple drugs can aggravate an already difficult 
condition and be associated with increased risk-taking. The 
most severe consequences of these forms of polydrug use 
include fatal and non-fatal overdoses, hepatotoxicity — 
especially in combination with hepatitis C infection — and 
compromised treatment outcomes.
| Response options in Europe
Some prevention approaches used to address misuse 
of medicines have been found to reduce polydrug use 
involving the misuse of medicines. In addition, as most 
effective prevention approaches are non-substance 
specific they should help reduce polydrug use. In particular, 
environmental and other prevention approaches, discussed 
in section 4.2 on festivals and nightlife settings, may 
address some of the risks associated with the use of 
alcohol with other drugs in this recreational context.
FIGURE 2.11
Polydrug use among clients entering treatment, by 
primary drug
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NB: Secondary drugs are those drugs used in addition to the primary drug 
(the one causing the most problems to the client), and are substances 
that cause problems for the client or change the nature of the problem 
as assessed by the client and the therapist. Most recent data for 
28 EU countries (2014 or 2015).
| 93
2.8 | Responding to polydrug use
Treatment services often focus on one particular problem 
substance even though large national treatment outcome 
studies in Australia, Italy and the United Kingdom indicate 
that polydrug use is common in treatment clients. These 
studies also show that drug treatment substantially 
reduces the proportion of clients who use multiple 
substances (moderate quality of evidence). Although the 
lack of randomisation of clients to treatment limits the 
attribution of these changes to treatment, the results 
suggest that treatment can reduce polydrug use in severe 
and long-term problem drug users. These findings are 
supported by systematic reviews of a small number of 
randomised controlled studies that have demonstrated 
that pharmacological and psychosocial interventions, such 
as contingency management, can reduce polydrug use 
(moderate quality of evidence).
Harm reduction services for problematic drug users usually 
address the harms and risk behaviours for injecting rather 
than focusing on a specific substance. Harm reduction 
interventions operate within a broader prevention strategy 
that combines other types of services such as outreach 
work and OST, which improves the health of polydrug users.
There is limited information on current treatment practices 
in the EU Member States for polydrug use. Generally, the 
treatment literature focus on the management of problems 
related to opioids or stimulants. There is little information 
on the management of problems arising from multiple 
substance use. While it is generally assumed that polydrug 
use is hard to treat, large treatment outcome studies in 
Europe show that treatment significantly reduces multiple 
drug use among highly problematic users.
Common drug combinations: effects and consequences
The risks of drug combinations are influenced by characteristics of the user, such as their tolerance, health status or 
genetic or phenotypic factors. Impaired liver function may lead to higher drug concentrations in the blood, increasing 
toxic effects. The quantity and purity of the drugs used and the route of administration have an impact on the effects 
of drug combinations. Intravenous drug use will lead to higher concentrations in the blood.
The following are some of the better-documented effects of common drug combinations:
Alcohol: Alcohol is found in most polydrug use combinations. It may lead to misjudgements about the amount of 
other substances used and change the pharmacokinetics of other substances. Long-term, heavy use of alcohol can 
damage the liver and impair the metabolism of other substances, making it dangerous to consume amounts that would 
otherwise be tolerated. In nightlife and other recreational settings, alcohol use with MDMA, other stimulants and new 
psychoactive substances is common.
Cannabis and tobacco: Smoking cannabis and tobacco together is the most common form of polydrug use in Europe. 
Users combine the two to facilitate combustion. Tobacco use in cannabis joints is often ignored when assessing 
cannabis dependence, although its high abuse liability in humans is well documented.
Cocaine and alcohol: Alcohol can increase levels of cocaine in the blood by about 30 % and produces a psychoactive 
cocaine metabolite (cocaethylene) that has a longer duration of action. The combination increases heart rate and blood 
pressure and can cause cardiovascular problems. Cocaine use may increase alcohol consumption by reducing the 
perceived effects of alcohol intoxication. Violent behaviour and suicidal ideation have been associated with the co-use 
of these two substances.
Opioids and cocaine: Opioids depress the central nervous system whereas cocaine stimulates it. The negative 
cardiovascular effects of cocaine are amplified when used with opioids. Cocaine and opioids used together may 
increase risk of overdose and associated respiratory depression. Cocaine can mask the sedative effects of opioids, 
increasing the risk of a later overdose.
Opioids and benzodiazepines, with or without alcohol: Opioids, benzodiazepines and alcohol are all central nervous 
system depressants and so when used together can increase the risk of fatal and non-fatal opioid overdoses. Older 
drug users may also have impaired metabolism of benzodiazepines, increasing the risk of respiratory depression when 
used with methadone.
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European countries provide a wide range of harm-reduction 
services that include safer-use training, needle and syringe 
programmes, infectious diseases testing and counselling, 
hepatitis B vaccination and treatment of viral hepatitis and 
HIV infection. These can apply also to polydrug users. Client 
health care assessments provide appropriate information, 
advice and basic health care.
Responding to polysubstance use: implications for policy and practice
Basics
  Polydrug use increases the risk of a wide range of drug-related harms. Among the most severe consequences, the 
concomitant use of several depressant drugs such as opioids, benzodiazepines and alcohol increases the risk of fatal 
and non-fatal overdose.
  The management of polydrug use remains a complex and challenging task. Treatment is often less successful for 
individuals who use multiple substances.
  Psychosocial interventions can contribute to reducing polydrug use among treatment clients, especially stimulant use 
among clients in opioid substitution treatment
Opportunities
  The reduction of polydrug use should be a priority within harm reduction interventions.
  Given the impact of polydrug use on overdose risk, information on general dangers and specific risky combinations 
needs to be provided for opioid users and included in counselling interventions for this group.
Gaps
  There is a need to develop a clearer picture of the extent and nature of polydrug use among different drug user groups 
to support the development of appropriate responses.
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Further resources
EMCDDA
  Polydrug use: patterns and responses, Selected issue, 2009.
  Treatment demand indicator (TDI) standard protocol 3.0: Guidelines for reporting data on people entering drug 
treatment in European countries, 2012.
  European drug report: trends and developments 2017.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
3
Some sub-groups of the population have particular drug 
problems, needs or vulnerabilities that require specific 
interventions. In this section drug problems and how to respond 
effectively are reviewed through the lenses of particular 
groups of people who are likely to be particularly affected. This 
provides a different perspective on some of the issues raised in 
Chapter 2, where a drug-specific perspective was developed. 
It also better reflects the logic of service development, where a 
range of different drug issues may be relevant to the needs of a 
particular target group.
The following sections consider both the needs profile and how 
it is possible to respond better to the needs of the following 
groups:
  the growing group of older people with problematic opioid use;
  women with drug problems;
  newly arrived migrants, refugees and asylum seekers;
  vulnerable young people; and
  families of people with drug problems.
In each case, a description of the type of drug problems 
faced by these groups is provided, based on the available 
epidemiological and clinical evidence. Examples are given 
of social and health responses that have been developed to 
address these needs in various EU countries.
In the case of many of these subpopulations of drug users, 
there is limited information on the effectiveness of preventive, 
treatment and harm reduction interventions. The information 
provided in these sections is accordingly based on what 
appears to be the consensus of expert opinion about 
current best practice. This often assumes that evidence-
based interventions in the broader drug-using population 
may also be effective in these subpopulations. Important 
caveats here are that whereas this is a reasonable approach 
to take for service development and makes best use of the 
available knowledge base, responses will always need to be 
configured appropriately for the different contexts in which 
they are implemented. Monitoring and evaluation are even 
more important in areas where the evidence base is poor (see 
Chapter 5).
 CHAPTER 3
Responding to the 
needs of particular 
groups
Responding to the needs of particular groups
SUMMARY
Issues
People over the age of 40 make up an increasing 
share of those with an opioid problem in Europe. 
This is reflected in the increasing age of those 
in drug treatment and those dying of opioid 
overdoses.
In this group of older opioid users, the physical 
ageing process may be accelerated by the 
cumulative effects of polydrug use, overdose and 
infections over many years. Older people with 
opioid problems have higher rates of degenerative 
disorders, circulatory and respiratory problems, 
pneumonia, breathlessness, diabetes, hepatitis 
and liver cirrhosis than their peers and younger 
people who use drugs. They may also be more 
susceptible to infection, overdose and suicide.
In addition, their social networks may be reduced 
because of premature death and stigma, which 
can further increase social exclusion and isolation 
from families. The stigma and shame of still using 
drugs may also act as a barrier to help-seeking.
Response needs
  Drug treatment services tailored to the needs of older people need 
to provide multidisciplinary care to address their medical and 
psychological needs as well as their social isolation.
  Improved access to, and uptake of, hepatitis C antiviral therapies.
  Specialised nursing homes for long-term residential care of ageing drug 
users.
  Awareness-raising and training of health and social care staff dealing 
with elderly people about how to respond to the needs of older 
people with drug problems to ensure appropriate care and avoid 
stigmatisation.
  Appropriate physical health care, including dental health services
  Advocacy support to increase self-esteem, acceptance and positive 
feelings about the future, with peer-led approaches likely to be 
particularly appropriate.
Implications for future developments in Europe
  Planning of services to meet the future health and social care needs of 
this growing cohort of older drug users in Europe is needed.
  This may require having age-specialised care services that host social 
activities and events, and provide regular peer and volunteer support.
  An integrated, multidisciplinary approach is needed with interagency 
partnerships and referral between specialised and mainstream health 
and social services to address the needs of older opioid users.
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|  Health and social issues and key objectives for responding to older people with drug problems in Europe
This section considers the needs of older people with a 
drug problem, defined here as people aged 40 or over, 
whose recurrent opioid use is causing or placing them 
at high risk of harm. This group makes up an increasing 
proportion of opioid users in Europe, as illustrated by two 
trends in EMCDDA treatment and drug-related death data 
(Figure 3.1). Between 2006 and 2015, the number of new 
opioid users entering treatment in the European Union 
decreased by 45 %, compared with a 9 % decline for all 
drugs. The mean age of clients entering treatment for 
opioid problems increased from 33 to 38 years, and the 
proportion over 40 increased from 1 in 5 in 2006 to almost 
2 in 5 in 2015. In addition, the average age of drug-related 
deaths (which are mainly related to opioids) increased by 
5 years between 2006 and 2015. Among these deaths, the 
proportion aged above 40 years increased from around 1 in 
3 in 2006 to nearly 1 in 2 in 2015.
Although the focus of the section is on older people 
with problems associated with opioid use, there are also 
groups of older people who use other substances in a 
problematic way, for example, alcohol or medicines. While 
these have not been specifically addressed here, some 
of the responses discussed may also be relevant to these 
groups.
A wide range of health conditions can reduce the quality 
of life of those who have long histories of drug use. A large 
proportion of older people with problematic drug use in 
Europe initiated heroin use during the 1980s and 1990s. 
Many of those with long injecting careers have contracted 
HIV and hepatitis C virus (HCV) infection and their long 
history of problematic drug use may also have accelerated 
their ageing. Typically this group has higher rates of physical 
and mental health problems than their non-drug-using 
peers and younger people who use drugs. An earlier onset 
of degenerative disorders, circulatory and respiratory 
problems, pneumonia, breathlessness, diabetes, hepatitis 
and liver cirrhosis is also possible. They can also be more at 
risk of drug-related infections, overdose and suicide. Dental 
problems may also be a serious concern.
Most of this group of older opioid users have received 
or still receive methadone or buprenorphine treatment. 
Little is known about the interaction and efficacy of opioid 
medication and treatments of physical disorders and 
impaired liver function.
FIGURE 3.1
The ageing cohort of high-risk drug users
33 38
34 39
1 in 5
1 in 3
2 in 5
1 in 2
2006 2015
Mean age of opioid clients entering treatment
Proportion of opioid clients aged above 40 
entering treatment
Mean age of drug-induced deaths
Proportion of deaths among
users aged above 40
NB: Mean age of drug-induced deaths refers to all EU countries, excluding Greece. Proportion of deaths among users aged above 40 refers to all 
EU countries, excluding Greece and Portugal.
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Rates of blood-borne viral infections are generally high 
among older people who have had long opioid injecting 
careers. For example, a 2015 French survey, undertaken 
in low-threshold centres (ENa-CAARUD), found that 
the self-reported prevalence of HIV was 12 times 
higher (7.4 % versus 0.6 %) and of HCV 4 times higher 
(35.6 % versus 8.9 %) among older drug users (40 or over) 
than among younger drug users (30 or under). Older opioid 
users who contracted HCV early in their lives are at a 
greater risk of developing liver disease and cancer if they 
are not treated.
In addition to physical and psychological problems, older 
people with drug problems are more likely to be isolated. 
Stigma and ageism (discrimination on the grounds of age) 
add to the social exclusion and isolation from families 
and friends that are common in this group. They are 
vulnerable to depression and loneliness because their social 
networks shrink as other older drug users die or recover 
from addiction and move on. The stigma and shame they 
experience from continuing to use drugs as they advance 
into older age can prevent help-seeking, engaging with 
recovery communities or seeking health care.
A significant proportion of older people with drug problems 
live alone, are in housing need and are unemployed and 
economically inactive. In a study of older people with 
problems related to opioid use, carried out in eight EU 
countries, 86 % who entered treatment for heroin use were 
unemployed or economically inactive. Lack of employment 
reduces social networks, skills and knowledge and 
entrenches marginalisation and isolation.
Providing adequate pain relief to older people who use 
opioids can be difficult for generic health care providers 
because these patients may have increased tolerance to 
opioid analgesics. In the absence of guidance on effective 
pain management for this group, providers may under-
medicate them. Health care providers also need to be 
aware that a number of drugs that may be prescribed 
to people with problem opioid use, including alongside 
opioid substitution treatment, present an increased risk of 
overdose, due to their depressant effects on the central 
nervous system. These include gabapentinoid drugs, 
prescribed for neuropathic pain, and benzodiazepines.
Scaling up of harm reduction services in many European 
countries has kept problem heroin users alive into their 
later years. Their complex health and social needs require 
specific policy responses.
|  Responses required for older people with opioid problems
Treatment and care for older people with opioid use 
problems is limited in Europe because most services were 
established to meet the needs of a younger cohort of drug 
users. Older drug users are seen as less motivated, despite 
often doing better in treatment than younger drug users.
Multidisciplinary and innovative approaches are needed 
to address the medical (including dental), psychological 
and social needs of older people with drug problems. 
Their social isolation and loneliness needs to be tackled 
by enhancing coping strategies, improving social networks 
and encouraging activities that enhance well-being. A pilot 
study in the United Kingdom showed that older drug users 
could be recruited into a gym-based exercise scheme, 
but multiple social challenges reduced their ability to 
participate. Men’s shed programmes in Australia, Canada, 
Ireland and the United Kingdom have encouraged older 
men to develop a sense of identity, self-esteem and value 
by learning new skills, developing social networks and 
engaging with communities.
There is a need to improve access to, and uptake of, 
hepatitis C antiviral therapies in this population. Their 
elevated risk of overdose deaths makes them an important 
target for take-home naloxone distribution and other 
overdose prevention strategies (see section 2.3).
Specialised nursing homes for older people with drug 
problems who are not able to care for themselves exist in 
Denmark, Germany and the Netherlands. These may serve 
as models for long-term residential programmes that offer 
care and support to chronic, ageing drug users. Alternatively 
work is needed to integrate those with drug problems into 
geriatric inpatient units and community old age settings. 
Currently these are ill-equipped to offer the comprehensive 
assessment, treatment and care that older people with drug 
problems may need.
The Geriatric Addiction Program was developed in the 
United States to meet the needs of older adults with 
substance misuse problems. The majority of clients were 
referred for alcohol problems, but 15 % had comorbid drug 
problems. The community-based programme provides in-
home substance use intervention, assessment and linkage 
to services for older adults.
There is widespread lack of awareness and skills in the 
geriatric care workforce in dealing with older people who 
use drugs. Training is needed to help this workforce deal 
with the increasing numbers of these patients. Drink Wise 
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Age Well is a national education and awareness-raising 
programme in the United Kingdom that provides training for 
professionals in recognising and responding to alcohol use 
in the over-50s. Similar programmes are needed for older 
drug users. Pain clinic staff may require specialist training 
in managing pain in those who are opioid-dependent based 
around clear treatment protocols. Investment in developing 
a skilled workforce will be vital to improve the recognition of, 
and service provision, for older people with opioid problems.
To tackle the ageism and stigma experienced by these older 
drug users, advocacy support could be provided by older 
people within substance use services. Peer support can 
increase self-esteem, increase feelings of being accepted 
and understood, and increase positive feelings about the 
future. Those in a peer/volunteer role are also likely to 
benefit from this kind of engagement.
Safe and suitable housing is a prerequisite for dealing with 
social, health and physical challenges. The accommodation 
needs of older drug users will often require particular 
attention in those moving away from their drug-using 
networks. Those continuing to use drugs may require 
accommodation in which tenure is not threatened by drug 
use. Housing-first models, which provide accommodation 
as quickly as possible before tackling an individual’s drug 
problem or providing other support, may be useful for 
homeless older drug users.
| Future developments in Europe
Careful planning is needed to meet the future needs of 
the ageing cohort of opioid users seen in many countries 
in Europe. This may require having age-specific groups in 
services, hosting social activities and events, and providing 
regular peer and volunteer support to address their social 
isolation. Physically accessing services may be challenging 
for older people with opioid problems, who may require 
assistance with transport. Home visits may be needed 
for those with mobility problems or living in rural areas, 
satellite services operating out of community centres for 
Older people with opioid problems: implications for policy and practice
Basics
  Key issues for service providers are managing comorbidity, chronic health conditions, overdose deaths, early ageing, 
loneliness and isolation. These needs can be met by modifying or restructuring services and developing specialist 
services that address both health and social care needs.
  Clear communication channels and referral pathways need to be in place between drug services and mainstream 
health and social care services.
Opportunities
  Investment in workforce development for staff involved in generic elderly care, in order to improve their understanding 
of the needs of older people with drug problems, could improve the management of physical and mental health 
problems in this group.
  Developing protocols for managing pain in people who are opioid-dependent for use in pain and palliative care clinics 
would assist the provision of high quality care in these settings.
Gaps
  Screening tools and outcome measures need to be developed that are appropriate for older people with long-standing 
substance misuse and associated health and social problems.
  There is a need to identify promising interventions and models of care to address the health and social problems 
experienced by the growing cohort of older people with opioid problems and to evaluate them to identify and share 
best practice.
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older people and expanded outreach work. An integrated, 
multidisciplinary approach is needed to address the needs 
of older people with drug problems within the communities 
in which they live.
Screening tools and treatment outcome measures for 
older people with substance use problems are lacking. The 
Bristol Drugs Project ‘50 Plus Crowd’ in the United Kingdom 
aims to improve health and well-being among older people 
rather than achieve ‘recovery orientated’ outcomes. An 
employment outcome, for example, may not be relevant for 
retirees or those with no history of sustained employment. 
The practical steps in achieving recovery may differ for 
older and younger drug users. Services might consider 
supervised methadone consumption in the homes of older 
opioid users or allow more take-home doses.
The Addiction Worker Training Programme of the Scottish 
Drugs Forum trains individuals with problematic drug 
and alcohol use to work in social care. The majority in 
the programme are older than 35. Similar programmes 
may provide some older drug users with secure paid 
or voluntary work. Employers may require training to 
understand the health and social issues faced by this 
population.
A joined-up treatment approach for older people with drug 
problems, with interagency partnerships and established 
referral pathways between specialised and mainstream 
health and social services, will be particularly important. 
Training for staff in mainstream services will be essential 
for successful implementation of these models of care.
Given that long-term opioid users aged over 40 are likely 
to make up the majority of the drug treatment population 
in Europe in the near future, these measures need to be 
put in place. In addition, the evidence base for effective 
interventions for this group needs to be developed.
Further resources
EMCDDA
  Ageing and addiction: challenges for treatment systems, Poster, 2015.
  Treatment and care for older drug users, Selected issues, 2010.
  Responding to the needs of ageing drug users, Lauren Johnston, Dave Liddell, Katie Browne and Saket Priyadarshi, 
Background paper.
Other sources
  Scottish Drug Forum. Older people with drug problems in Scotland: addressing the needs of an ageing population.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
Women make up approximately a quarter of all 
people with serious drug problems and around 
one-fifth of all entrants to drug treatment in 
Europe. They are particularly likely to:
  experience stigma and economic 
disadvantage, and to have less social 
support;
  come from families with substance use 
problems and have a substance-using 
partner;
  have children who may play a central role 
in their drug use and recovery; and
  have experienced sexual and physical 
assault and abuse and have co-occurring 
mental disorders.
A number of sub-groups of women with drug 
problems have special needs. These sub-
groups, which often overlap, include pregnant 
and parenting women; women involved in 
sex work, who may often experience violence 
and stigma; women from ethnic minorities, 
who may have been trafficked; and women in 
prison.
Response needs
  Specific services for women. These services may be offered in female-only 
or mixed-gender programmes. They need to be welcoming, non-judgmental, 
supportive and physically and emotionally safe, in order to address stigma and 
trauma. They should promote healthy connections to children, family members 
and significant others.
  Collaboration between drug treatment and mental health services in order to 
address co-occurring substance use and mental health needs.
  Services for pregnant and parenting women, which need to deal with drug 
use, obstetric and gynaecological care, infectious diseases, mental health, and 
personal welfare, as well as providing childcare and family support.
  Measures to overcome the barriers to care for women involved in the sex trade, 
such as evening opening, mobile outreach services and open access support.
  Sensitivity towards ethnic and cultural aspects and the possibility of interpreter 
services when working with women from ethnic minorities.
Implications for future developments in Europe
  The need for and the benefit of specific interventions for women who have 
problems with different drugs, including prescription drugs and polydrug use, 
should be investigated.
  Evaluations, including cost-effectiveness studies, of interventions for women in 
diverse settings across Europe are needed.
  Large knowledge gaps about women’s drug use exist for a number of reasons: 
studies do not always include women; those that do may not disaggregate 
by gender, or address gender issues; most research on drug-using women 
of child-bearing age only deals with opioid users; research on cannabis, new 
psychoactive substances, misuse of medicines and polydrug use among 
women is limited.
 keywords: women,  
 pregnancy, children 
 3.2  Women with drug 
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|  Main health and social problems faced by women with drug problems
In the Europe Union an estimated 35 million women and 
54 million men aged 15 to 64 have tried an illicit drug at 
some time in their life. Generally the gender difference in 
overall drug use is smaller among young people and the 
gap appears to be decreasing among younger age groups in 
many countries of Europe. However, for more intensive and 
problematic forms of drug use, the difference between the 
genders is larger.
Women make up approximately a quarter of all people 
with serious illicit drug problems and around 20 % of all 
entrants to specialist drug treatment in Europe. In some 
studies women have been found to be more likely to access 
treatment because of needs arising from pregnancy or 
parenting or the general tendency for women to more 
readily seek care. Other studies have found women less 
likely to seek specialised services than men because of 
stigma. Women may attribute their problems to physical 
or mental health issues and seek care in the physical 
or mental health sectors. The extent and nature of the 
treatment gap within different regions and sub-groups in 
Europe requires further study.
Women differ from men with drug problems in their social 
characteristics, consequences of substance use and in 
the development and progression to dependence. Women 
present unique concerns that are sex and gender-based, 
but many drug services are male-oriented.
These specific problems are:
  Stigma: Women who use drugs experience more stigma 
than men because they are perceived as contravening 
their roles as mothers and caregivers. Stigma can 
exacerbate guilt and shame, while discriminatory and 
unsupportive services may deter help-seeking.
  Socio-economic burdens: These are heavier for women 
who use drugs because they have lower employment and 
income levels. The cost of drug treatment may be a barrier 
when services are not provided by the state and there 
is no insurance coverage. Transport costs may impede 
access to treatment.
  Social support: Women who use drugs may have less 
social support than men because they are more likely to 
come from families with substance use problems and 
have a substance-using partner. For example, among 
English drug treatment-entrants, three-quarters of women 
had drug-using partners as against two-fifths of men.
  Children: Relationships with children are very important 
and may play a central role in women’s drug use and 
recovery. Female treatment entrants are more likely than 
males to live with their children.
  Drug-using partners: Having a partner who uses drugs 
can play a significant role in women’s drug use initiation, 
continuation and relapse. It also affects their exposure to 
blood-borne viral infections and violence. Substance-using 
men may be unsupportive of treatment and women may 
fear loss of the relationship if they become drug-free.
In addition, compared with men, women who use drugs are 
more likely to have experienced sexual and physical assault 
and abuse as children or as adults and to be exposed to 
intimate partner violence.
Post-traumatic stress disorders and other mental health 
problems, such as anxiety and depression, are more 
common among women drug users. As a consequence, the 
exclusion of persons with dual diagnoses from services may 
impact more on women than men.
Women who inject drugs have specific vulnerabilities 
to blood-borne viral infections. They have a higher HIV 
prevalence than men because they are likely to share 
injecting equipment with more people. They are also more 
likely to trade sex for drugs or money and have difficulties 
negotiating condom use with sexual partners.
A number of sub-groups of women have particular needs 
and may need specific responses that address these 
(see box).
| Responses for women with drug problems
A gender-responsive approach is required to meet the 
needs of women who use drugs. This incorporates a 
consideration of women’s needs in all aspects of service 
design and delivery: structure and organisation, location, 
staffing (including access to female practitioners in all 
services), development, approach and content. These 
programmes may be female-only or a mixed-gender 
programme that incorporates specific services for women. 
This section focuses on the specific needs of particular 
groups of women, but it is important to recognise that 
women with drug problems may be in more than one of 
these groups and that their circumstances will change over 
time (Figure 3.2).
Because of the high levels of stigma and trauma 
experienced by drug-using women, services need to be 
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welcoming, non-judgmental and supportive. They need to 
be physically and emotionally safe for women and to take 
a trauma-informed approach. They need to be holistic and 
comprehensive in order to address the multiple issues that 
women face.
Trauma-informed treatment approaches are recommended 
for women who have experienced trauma and intimate 
partner violence. For women at continuing risk of violence, 
a multi-agency, multi-sector approach is essential, with 
collaborations between health and social services and 
the justice sector. An example of this type of approach is 
a women-only, abstinence-based residential rehabilitation 
service in the United Kingdom in which women participate 
in a range of group therapies based on a manualised, 
trauma-informed treatment programme. The women 
are offered individual counselling, eye movement 
desensitisation and reprocessing to reduce the distress 
of trauma, and family support. Residents can also benefit 
from a structured programme comprising education skills, 
training and recreational activities, and peer support 
groups (Narcotics Anonymous and Alcoholics Anonymous). 
After successful treatment women move into their 
own accommodation or into one of the organisation’s 
resettlement houses and receive ongoing support if 
required.
Services for pregnant and parenting women who use 
drugs need to be non-discriminatory and comprehensive. 
Punitive policies, such as compulsory treatment, deter 
women from seeking treatment. Anonymity can encourage 
women to seek care by removing fear of reprisals. 
Interventions for pregnant women also need to deal with 
their drug use; obstetric and gynaecological care; infectious 
diseases; mental health; and personal and social welfare. 
In some countries specialist family centres and health 
visitor services exist to support pregnant drug users and 
parents of young children. Providing services to pregnant 
and parenting women can benefit both mother and child, 
improving parenting skills and having a positive impact 
on child development, as highlighted in the UNODC’s 
International standards on drug use prevention.
Examples of sub-groups of women with particular needs
Pregnant and parenting women: Drug use in pregnancy can adversely affect the unborn child and the new-born. Each 
year in Europe approximately 30 000 pregnant women use opioids and a similar number have other drug problems. 
Pregnancy and motherhood can be both a strong motivator for, and a barrier to, recovery. Guidelines now exist for the 
clinical management and use of substitution medications during pregnancy and the perinatal period for opioid-using 
women. In addition to stigma, shame and guilt, drug-using women may fear having their children taken away. Women 
have a pivotal role in facilitating health or social care for family members but may be fearful of contacting services 
themselves. They may also be unable to obtain the support they need because of family responsibilities and a lack of 
childcare.
Women involved in sex work: Sex work is often intertwined with drug use; for example, it is estimated that in the range 
of 20 % to 50 % of women who inject drugs, in some countries, are involved in sex work. Many women who trade sex 
for drugs have limited power to practice safe sex or safe injecting practices and are likely to experience violence and 
imprisonment. They also experience more stigma.
Women from ethnic minorities: These women may encounter additional barriers in accessing treatment services, 
such as language difficulties or treatments that conflict with religious beliefs. Their immigration status may affect their 
service eligibility and they may experience racism and discrimination. Some ethnic minority women may be migrants 
who have been trafficked and experienced trauma from war and violence in their homelands. Ethnic, cultural and 
religious diversity needs to be taken into account when working with these women.
Women in prison: Many women in prison have a history of drug use (a review found 30 % to 60 %, although mainly in 
US studies). Women offenders with substance use problems experience more severe problems than women seeking 
treatment in the community. There is a lack of services in prisons to meet their psychological, social and health care 
needs. Prisons are high-risk environments for transmission of blood-borne infections, but access to clean syringes is 
often opposed. This may have a greater impact on women than men because in Europe, female prisoners are more 
likely to inject drugs. These women require diverse interventions in prison and after their release.
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FIGURE 3.2
Service needs and responses for some sub-groups of women with drug problems
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Issues concerning 
target group
Opioid-dependent pregnant women need opioid substitution 
treatment and psychosocial assistance. Many pregnant 
women who use opioids want to stop once they discover they 
are pregnant, but withdrawal is not advised during pregnancy 
because it is increases adverse outcomes for the neonate, 
including miscarriage. Methadone and buprenorphine may 
be used. Buprenorphine is associated with superior neonatal 
outcomes, but women already using methadone should not 
switch unless they are not responding well to methadone.
Multidisciplinary care programmes are provided in various 
countries. Some offer interventions to women who 
use drugs and their children from early pregnancy into 
childhood. Women may be provided with psychosocial 
support, interventions to empower them and build skills that 
strengthen the family, and follow-up with case managers. 
Services need to deal with practical concerns and provide 
childcare. Residential services should provide child-friendly 
accommodation, enabling mothers to stay with their 
children.
Given the centrality of relationships to women, services should 
promote healthy connections to children, family members and 
significant others. Family involvement and connections to the 
community can enhance drug treatment effectiveness.
For women with co-occurring substance use and mental 
health problems, it is important that both problems are 
addressed. This requires a multidisciplinary approach, 
involving professionals from the drug treatment and mental 
health sector collaborating and working towards agreed 
upon, common goals. Unfortunately, this does not always 
happen and, since women have higher rates of many mental 
disorders compared with men, women who use drugs 
may be particularly disadvantaged by this (see Spotlight 
on comorbid substance use and mental health problems, 
page 31).
The high rates of drug use, past abuse and mental health 
problems often found among women in prison means 
that gender-responsive, trauma-informed, integrated 
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interventions need to be provided in order to address 
substance use, trauma, mental health, physical and 
reproductive health, and infectious disease risk. Needle and 
syringe programmes should be considered, such as those at 
Hindelbank women’s prison in Switzerland, where syringes 
can be exchanged via slot machines. Drug substitution 
treatment and psychosocial interventions should be 
available for women with opioid dependence.
In order to prepare women for release from prison, 
interventions need to be considered in the following areas: 
housing and financial issues, vocational and life skills, 
social support and family relationships, and referral to 
drug treatment in the community. One example of this 
sort of provision is the Quartier Intermédiaire Sortantes, a 
pre-release unit near Paris for female prisoners with drug-
related problems.
The barriers to care for women involved in sex work can 
be addressed by evening opening hours, mobile outreach 
services, child care and open access support. A non-
judgmental, empathetic approach, peer support and 
women-only provision is recommended. Interventions 
from needle exchange to treatment and support with 
employment and housing should be provided.
Ethnic and cultural aspects need to be considered when 
working with women from ethnic minorities. Outreach 
Guidelines for the treatment of pregnant women who use drugs
Screening and brief interventions
Health care providers should:
  ask all pregnant women about their use of drugs and alcohol (past and present) as early as possible in the pregnancy 
and at every antenatal visit; and
  offer a brief intervention to all pregnant women using drugs or alcohol.
Psychosocial interventions
Health care providers managing pregnant or postpartum women with alcohol or other substance use disorders should 
offer comprehensive assessment, and individualised care.
Detoxification or quitting programmes
Health care providers should, at the earliest opportunity, advise pregnant women dependent on alcohol or drugs 
to cease their alcohol or drug use and offer, or refer to, detoxification services under medical supervision where 
necessary and applicable.
Pregnant women dependent on opioids should be encouraged to use opioid maintenance treatment rather than to 
attempt opioid detoxification.
Pregnant women with benzodiazepine dependence should undergo a gradual dose reduction, using long-acting 
benzodiazepines.
In withdrawal management for pregnant women with stimulant dependence, psychopharmacological medications may 
be useful to assist with symptoms of psychiatric disorders but are not routinely required.
Pharmacological treatment (maintenance and relapse prevention)
Pharmacotherapy is not recommended for routine treatment of dependence on amphetamine-type stimulants, 
cannabis, cocaine, or volatile agents in pregnant patients.
Pregnant patients with opioid dependence should be advised to continue or commence opioid maintenance therapy 
with either methadone or buprenorphine.
Adapted from WHO Guidelines for the identification and management of substance use and substance use disorders in pregnancy.
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workers who can act as cultural mediators may be required 
to encourage these women to attend and engage in 
treatment. Interpreter services or services in the women’s 
native language may be required and cultural aspects 
considered in matching women to treatment.
| Future developments in Europe
Services able to address the different needs of women with 
drug problems are likely to be increasingly required as the 
difference in demand for drug services narrows between men 
and women. More interventions may be needed for women 
who have problems with cannabis, prescription drugs and 
polydrug use. Interventions may also need to cater for older 
women. Internet-based drug treatment may provide an array 
of women-centred activities, alone or as an adjunct to other 
interventions. These may appeal to women not well served 
by specialised drug services. It is important that policies 
and practices are gender-mainstreamed (i.e. they ensure 
that gender perspectives and the goal of gender equality are 
central) and that women who use drugs participate in the 
planning, formation and development of programmes.
Funding is a challenge in many European countries in times 
of budgetary restraint. Programmes for women may be 
neglected because women are a minority of service users. 
Cost-effectiveness studies of interventions for women in 
diverse settings across Europe are needed to secure long-
term funding.
There are still large knowledge gaps about women’s drug 
use. Studies do not always include women and may not 
disaggregate data by gender or address gender issues. 
Most research on drug use among women of child-bearing 
age only deals with opioid users. More research is needed 
on cannabis and polydrug use among women.
The complex, overlapping issues faced by many women 
who use drugs requires co-ordinated and integrated 
services. Across Europe drug use and mental health 
networks are often separated. Collaboration relies on the 
Spotlight on … Services for pregnant and parenting women
Services for pregnant and parenting women who use drugs need to deal with a wide range of issues besides drug use. 
These include obstetric and gynaecological care, infectious diseases, mental health, and personal and social welfare. The 
services also need to address parenting issues, including women’s concerns that their children may be taken away, and 
provide childcare or child-friendly accommodation.
In Hungary the Józan Babák Klub cares for pregnant women or mothers with a child under 2 years using a three-step 
approach. In the first step, women contact the Józan Babák Klub self-help group to get information about the service. 
In the second step, medical, legal, social and psychological services can be used on an anonymous basis. A pregnant 
or parenting woman who engages in eight sessions of counselling receives EUR 11 per session. In the third step, the 
organisation arranges contact with health care, social or legal services and prenatal services for pregnant women. During 
the second and third steps, a member of the Józan Babák Klub self-help group will accompany women to services.
The Kangaroo project is a programme for parents within a residential setting in Belgium. It aims to enhance parents’ links 
with their children. Women are supported in their parenting role. During the day, children attend nursery, kindergarten or 
school, while mothers attend a therapeutic programme. The project provides information to parents, facilitates parent–
child activities and thematic groups, offers individual consultation and accompanies parents to appointments.
In the United Kingdom, the Family Drug and Alcohol Court service provides an alternative to proceedings when parental 
substance misuse plays a major role. It offers intensive support to parents to cease drug use, keep families together and 
improve child and parent outcomes. After assessment, services are provided by a multidisciplinary team which includes 
a nurse, substance misuse worker, social workers, psychiatrists, a family therapist and service manager. Issues dealt with 
include substance use, physical and mental health, parenting, relationships with children and other family members, 
domestic violence and housing.
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goodwill of stakeholders and cooperation at the individual 
level. Collaborations needed to be embedded in policies.
Staff need to be non-judgmental, non-discriminatory and 
supportive; they also must encourage women who use 
drugs to engage with services and intervene effectively 
with them. This requires awareness of the unique needs 
of women and skills in areas other than substance use. 
Service providers in settings that intersect with drug use 
need to embrace the same attitudes and be knowledgeable 
about drug use. Staff competency should be built through 
education, training, skills development and adequate 
supervision. Community agencies (e.g. child welfare system 
and health care providers) also require training to enhance 
awareness, identify women who use drugs and provide 
interventions, or refer, as necessary.
Services for women with drug problems: implications for policy and practice
Basics
  Provide gender-responsive and trauma-informed services to meet the needs of particular groups of women and 
ensure they are accessible to all in need.
  Provide co-ordinated and integrated services to address issues beyond drug use. This may require embedding 
collaboration with other services, such as mental health and children’s services, into policies and strategies.
  Staff in specialised drug and other health and social services, who come into contact with women who use drugs, 
need to have appropriate attitudes, knowledge and skills to allow them to provide high quality care.
Opportunities
  Include gender breakdowns in routine statistics in order to enhance understanding of drug use trends, 
sociodemographic factors and issues faced by women within a given region and develop appropriate responses.
  Increase the participation of women who use drugs in the planning, formation and development of policies and 
programmes.
  Implementation of the guidelines for provision of services for the treatment of pregnant women who use drugs has 
the potential to improve outcomes for both mother and child.
Gaps
  Reduce knowledge gaps by research that addresses gender issues and considers gender in all aspects of service 
design in order to identify the types of intervention that are most appropriate for different groups of women.
  Include the misuse of prescription drugs in policies and responses.
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Further resources
EMCDDA
  Best practice portal.
  Pregnancy and opioid use: strategies for treatment, EMCDDA Papers, 2014.
  Women and gender issues in drug use, EMCDDA topic page.
  Women who use drugs: Issues, needs, responses, challenges and implications for policy and practice, Sharon Arpa, 
Background paper.
Other sources
  WHO. Guidelines for the identification and management of substance use and substance use disorders in pregnancy, 
2014.
  UNODC. Guidelines on drug prevention and treatment for girls and women, 2016.
  UNODC. International standards on drug use prevention, 2015.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
Europe has a long history of migration and the 
diversity of its ethnicities and religions creates 
complex links between ethnicity and drug use. 
More recently, following a high level of conflicts in 
the Middle East and Africa, more than 1.4 million 
people applied for asylum in the European 
Union in the last half of 2015 and the first half 
of 2016. Over half of the asylum seekers to the 
European Union in 2015 (53 %) were young 
adults (18–34 years), the age group most likely to 
use substances in Europe. Some lessons may be 
drawn from past research on migrants to Europe 
but must be viewed with caution because of 
cultural differences and reasons for migration.
Many migrants have lower rates of substance 
use than their host communities, but some may 
be more vulnerable to substance misuse for 
reasons such as trauma, unemployment and 
poverty, loss of family and social support, and 
the move to a normatively lenient setting. Drugs 
may be used to cope with trauma, boredom, 
uncertainty and frustration around immigration 
status. Vulnerability may be aggravated by 
poor knowledge about and access to treatment 
services.
Response needs
  Cultural competency within existing services and assistance to overcome 
language barriers will be important in identifying and meeting needs of 
new migrants. Some studies report lower rates of health care utilisation, 
particularly for mental health problems. The longer the time taken to get 
residency the greater the use of mental health and addiction services, but 
unmet need still remains. Language problems and cultural factors may be 
major reasons for under-utilisation.
  Preventive interventions for minority ethnic populations are not available 
in all EU countries. With respect to asylum seekers, general awareness-
raising concerning the potential vulnerabilities and marginalisation of 
migrant groups is more common. Some interventions have used peer 
educators to provide information on drug use and its risks and drug and 
alcohol services.
  There is a lack of policies to address migrant health, cultural barriers, 
language problems and addiction, and a lack of staff competence to work 
with migrants.
Areas for future development in Europe
  Undertaking needs assessments and establishing monitoring systems will 
be essential for identifying and addressing emerging problems and filling 
the current data gap in this area.
  Sharing of good practice and programmes within and between countries 
may help to extend service provision to meet the needs of these vulnerable 
groups of individuals.
  Future research should investigate the role that cultural continuities 
between the country of origin and the host country play in drug and 
alcohol use after migration. keywords: migrants,  
 refugees, asylum  
 seekers 
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|  Extent and nature of the potential health problems faced by asylum seekers
Europe has a long history of migration and its population 
includes a diversity of ethnicities and religions. This variety 
and the differing experiences of migrants over different 
generations means that links between ethnicity and drug 
use are very complex and diverse and defy a neat summary.
However, following violent conflicts in several Middle-
Eastern countries and parts of Africa, migration into Europe 
is now at exceptionally high levels. More than 1.4 million 
people applied for asylum in the European Union in the 
last half of 2015 and the first half of 2016. The number of 
asylum applications has never been as high as it is now, 
and this raises concerns about the potential impact across 
a range of policy areas, including the field of drug problems. 
Past research on migrants has limited application to current 
asylum seekers because of differences in cultural values 
and practices and reasons for migration. Nevertheless, 
there may be lessons to be drawn from past experience 
that can help those tasked with responding to the needs of 
this group of migrants.
Over half (53 %) of the asylum seekers to the European 
Union in 2015 were young adults and about one-third were 
children. This produces a healthy migrant paradox: most 
asylum seekers are in relatively good physical and mental 
condition in terms of chronic health conditions but suffer 
more infectious diseases, such as tuberculosis, hepatitis A, 
and more injuries than people in the host country. There are 
large variations between migrant groups of different ethnic 
background which make generalisations problematic. There 
is a lack of information on the recent influx of migrants 
because most of the available data on health status and 
health care access was collected before 2014.
Several factors may make new migrants more vulnerable 
to substance use problems, but others may be protective 
(see Table 3.1). Risk factors include traumatic experiences, 
unemployment and poverty, loss of family and social 
support, and living in a normatively lenient setting. Coping 
with trauma, boredom and frustration, and drinking as a 
social experience were important motivations for drinking in 
African migrants to Australia.
Some studies have found high levels of cultural or ethnic 
identity to be associated with heavier drug use. So is having 
spent a longer time in hostile conditions in the host country 
after migrating. Children of parents who were less well 
acculturated or integrated have higher risks of juvenile drug 
use and abuse. The vulnerability of some ethnic minorities 
to developing illicit drug use problems may be aggravated 
by poor knowledge about and access to treatment services. 
The longer the time taken to obtain a residency permit, the 
greater the use of mental health and addiction services, but 
these services are often still under-used.
On the other hand, some studies find that, in general, 
people from ethnic minority groups drink less alcohol 
than the host population, and refugees are less likely to 
develop alcohol and drug problems than other groups in 
the population, including non-refugee immigrants. These 
differences may be related to cultural, religious and ethnic 
identity. Strong feelings of ethnic identity, sustained 
religious values and strongly maintained family ties may 
initially discourage alcohol drinking, but involvement with 
alcohol may increase with social integration.
Forced migrants may be at risk for substance use disorders 
because of traumatic experiences, comorbid mental 
health disorders, acculturation challenges and social and 
economic inequality. Drug and alcohol use patterns in 
the country of origin may be more significant than past 
trauma in explaining alcohol and drug use patterns. These 
practices may not be sustainable in Europe because of 
changing living circumstances, availability of the substance 
and changes in everyday life. The most important factors 
seem to be dullness of daily life and uncertainty about 
refugee status. Boredom and unemployment, together 
Definitions
The term migrant can be understood as ‘any person who lives temporarily or permanently in a country where he or she 
was not born, and has acquired some significant social ties to this country’ (UNESCO).
The focus here is mainly on asylum seekers. Asylum is a legal status given by a state to a person who is unable to live 
safely in his or her home country because of a fear of persecution for reasons of race, religion, nationality, membership of 
a social group, or political opinion. A refugee is an asylum seeker who has received a permit to live in a country.
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TABLE 3.1
Principal risk and protective factors for substance use problems relevant to the current migration situation
Risk factors Protective factors
Being single Some strong religious affiliations, e.g. being a devout Muslim
Coming from a culture in which substance use is 
normalised (e.g. opium, khat)
Living in strong family unit
Boredom, unemployment Integration in new society language, employment or other activities
Traumatic experiences Good physical and mental condition
Poverty
Poor knowledge about treatment services
Living in run-down neighbourhoods and socially 
deprived areas
with undiagnosed depression, make the asylum seeker 
more likely to continue drug use patterns from their home 
countries, possibly more intensively. One example is khat 
use among Somalis who moved to Europe. Problems related 
to khat appear to have increased after migration because 
they were often unemployed or not permitted to work 
and were able to spend long periods using khat. A similar 
intensification of traditional opium use has been reported 
among Iranian migrants who moved to Europe.
|  Responses and interventions to address the needs of new migrants
A recent study by the European Agency for Fundamental 
Rights (FRA) found no data collection on the number of 
individuals with signs of drug dependence among victims 
of torture or severely traumatised individuals in any of the 
14 Member States covered by their research. However, 
they did find reports from some services of increasing 
numbers of migrants or asylum seekers among the people 
with drug problems they were seeing. Screening and needs 
assessment procedures for migrants and asylum seekers 
need to include potential substance use problems, and staff 
in any services, such as housing and drop-in facilities, need 
to be alert for potential problems. In addition to the range 
of standard assessment tools available, UNHCR and WHO 
have developed assessment tools for use with displaced 
populations and in emergency situations.
Data on health care utilisation by migrants in the European 
Union are also limited. Few countries collect data on 
outpatient care, which is important for mental health. Newly 
arriving or ‘undocumented’ asylum seekers are usually only 
entitled to health care in emergencies, but there is variation 
between countries in how this operates. In addition, asylum 
seekers may be unaware of their rights, and fears about the 
potential impact on their asylum claim may be a barrier to 
help-seeking.
After acquiring refugee status, migrants in most EU countries 
are entitled to the same access to health care as residents. 
Nevertheless, studies report lower rates of health care 
utilisation, particularly for mental health problems. Cultural 
beliefs and language issues that hamper communication 
may be important reasons for under-utilisation. Higher levels 
of acculturation and lower levels of cultural traditionalism 
are associated with increased use of mental health care. A 
recent Dutch report concluded that objective and subjective 
health of asylum seekers is poorer than that of the residential 
population and this gap increases with age.
Drug policies in EU countries rarely target migrants’ use of 
substances. Exceptions include the Dutch government’s 
ban on khat in 2013 and a similar ban in the United 
Kingdom in 2014. An evaluation of the Dutch ban in 2015 
concluded that khat use had declined but problematic 
use had increased. The ban produced a tenfold increase 
in price, a decline in quality and more alcohol use. Before 
and after the ban, the most prevalent problems were family 
disruption and sleeping problems. After the ban, heavy khat 
users reported more financial problems.
The EU drugs action plans that accompany the EU drug 
strategy 2013–2020 have highlighted the need for demand 
reduction activities addressing the situations and needs of 
ethnic minorities, migrants and asylum seekers. This has 
resulted in the development of preventive interventions in 
a number of countries. However, data on the availability of 
such selective prevention interventions for minority groups 
are patchy. From what information is available, coverage 
varies between countries and appears particularly limited 
for marginalised ethnic families (Figure 3.3). The main 
rationale for interventions has been to increase 
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awareness of vulnerabilities and reduce social exclusion 
and marginalisation of migrant groups. Interventions have 
used peer educators to provide information on drug use 
and its risks and about drug and alcohol treatment services. 
Most often these programmes aim to prevent substance 
use by young people. However, they tend to encounter a 
number of obstacles: a lack of policies addressing migrant 
health; cultural barriers; language problems and conceptual 
understandings of addiction; and lack of staff competence 
to work with migrants.
Some new initiatives specifically for refugees and asylum 
seekers are beginning to be reported. For example, in 
Belgium a new small psychosocial team (LaMbda) was 
created in 2015 in order to help asylum seekers with an 
addiction problem to access treatment. The idea is to 
facilitate the link between the reception centres for asylum-
seekers and the low-threshold specialised treatment 
sector. In Cyprus, new migrants have been highlighted as 
a high-risk group for treatment services. The UNODC in 
partnership with the University of Manchester is piloting a 
multi-level trauma-informed parenting and caregiver support 
programme for displaced populations aiming to strengthen 
the capacity of parents to protect their children in the 
difficult circumstances they encounter. The support provided 
ranges from information leaflets, through parent seminars 
and a manualised family skills training programme based on 
the Strengthening Families programme to a more specific 
programme for trauma-exposed families. It is currently being 
tested in several countries in the Middle East and in refugee 
camps in Turkey and with refugees transiting Serbia.
| Future developments in Europe
To fill the current gap in knowledge about the extent and 
nature of substance use problems among new migrants in 
Europe, it will be essential to develop appropriate assessment 
tools, undertake needs assessments and establish monitoring 
systems. These actions will need to be coupled with the 
development of appropriate interventions to address any 
emerging problems and, where necessary, the expansion of 
services, such as mental health care, to meet the needs of 
refugees who have been traumatised or negatively affected in 
other ways.
New programmes will need to be evaluated to ensure they are 
effective. The sharing of good practice and programmes within 
and between countries may help to extend service provision to 
meet the needs of these vulnerable groups of individuals.
FIGURE 3.3
Availability of selective prevention interventions for ethnic minority groups in the European Union, 2015/16
Ethnic families in marginalisationYouth from ethnic groups
Availability Not available No informationFull Rare Extensive Limited 
NB: The information provided here is based on the opinion of an expert (or panel of experts) in each country. Key for ratings of availability: Full, ‘exists in 
nearly all relevant locations’; Extensive: ‘exists in a majority of relevant locations (but not in nearly all of them)’; Limited, ‘exists in more than a few relevant 
locations (but not in a majority of them)’; Rare, ‘exists in just a few relevant locations’; Not available, ‘does not exist’.
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Research is also needed to investigate the role that cultural 
continuities between the country of origin and the host 
country play in drug and alcohol use after migration. This 
will allow the development of prevention and support 
programmes that maximise resilience among these 
people, many of whom will have suffered extensive trauma, 
hardship and dislocation and may continue to experience 
social exclusion and disadvantage following migration.
Migrants, refugees and asylum seekers: implications for policy and practice
Basics
  Migrant groups, such as the current wave of asylum seekers, may be at risk of developing drug problems. There is a 
need to increase awareness of vulnerabilities and reduce social exclusion of these people.
  Services need to be alert to potential health issues, including drug problems, among asylum seekers and be prepared 
to address potential cultural barriers and language difficulties.
  Monitoring of the health needs, including substance misuse issues, of new migrants is needed.
Opportunities
  Services to address the needs of migrant groups are being developed in a number of countries and these should be 
identified and promising practice shared.
Gaps
  Where specific needs are identified new services for prevention and treatment of problems need to be developed. 
These need to be evaluated so that the current limited evidence base is expanded.
Further resources
EMCDDA
  Drug prevention interventions targeting minority ethnic populations: issues raised by 33 case studies, Thematic paper, 
2013.
  Responding to the needs of new migrants, refugees, and asylum seekers, Paul Lemmens and Hans Dupont, 
Background paper.
Other sources
  European Union Agency for Fundamental Rights. Current migration situation in the EU: Torture, trauma and its 
possible impact on drug use, 2017.
  UNHCR and WHO. Rapid assessment of alcohol and other substance use in conflict-affected and displaced 
populations: a field guide, 2008.
  UNHCR and WHO. mhGAP Humanitarian Intervention Guide (mhGAP-HIG): Clinical management of mental, 
neurological and substance use conditions in humanitarian emergencies, 2015.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
Many young people experiment with 
drugs but only a minority become 
dependent on drugs in young 
adulthood. Those who are most 
vulnerable to drug dependence are 
socially disadvantaged young people 
and those having family members 
and peers who use drugs. Individual 
factors, such as poor impulse control, 
also increase vulnerability, as does the 
use of substances at an early age.
Vulnerable young people who develop 
drug dependence are more likely 
to report anxiety and depressive 
disorders; psychotic symptoms and 
disorders; suicidal ideation and suicide 
attempts; blood-borne infections; and 
failure to complete their schooling and 
secure employment. It is not always 
clear to what extent these problems 
increase the risk of drug problems, or 
having a drug problem causes these 
problems.
Response options
  Selective and indicated prevention interventions can be used to intervene early 
to prevent vulnerable young people initiating use and progressing to regular and 
problematic drug use.
  Brief screening questionnaires to detect illicit drug use problems in adolescents in 
primary care settings may be useful.
  E-health approaches to screening and brief interventions are promising ways to 
reach vulnerable young people who are familiar with mobile phones and the internet 
and are reluctant to seek help from health services.
  Treatment services for young people who have developed severe drug problems, 
which need to use appropriate treatment approaches, for example, multidimensional 
family therapy.
  Needle and syringe programmes are needed for young people who inject drugs who 
are at high risk of acquiring blood-borne infections in the early years of their injection 
use. Hepatitis B vaccination should be routinely provided to young people who inject 
drugs.
  Prisons, outreach programmes, needle and syringe programmes and health clinics 
may be good settings in which to intervene with young people at risk of injection-
related harms.
European picture
  Austria, Denmark, Germany, Portugal and Spain have implemented selective 
prevention interventions for pupils in vocational schools.
  Ireland has taken a broader approach by working to improve literacy and numeracy 
among disadvantaged students.
  Community-level interventions targeting high-risk groups of young people in Italy and 
northern Europe, combine outreach, youth work, and formal cooperation between 
local authorities and non-governmental organisations.
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|  Main health and social issues and key objectives for responses for vulnerable young people in Europe
Many young people experiment with illicit drugs or use 
them occasionally, but a minority become regular users and 
may become dependent on drugs in adolescence or young 
adulthood. Drug dependence is more likely to develop in 
young people who have used substances at an earlier age, 
whose family members and siblings are substance users, 
who come from socially disadvantaged backgrounds, and 
whose peers engage in drug use and antisocial behaviour. 
Some individual factors are also associated with increased 
risk of the development of more problematic drug use, such 
as behavioural problems (e.g. impulse control problems, 
attention deficit (hyperactivity) disorder, oppositional defiant 
disorder).
In Europe young people who are highly vulnerable to drug 
problems often have multiple risk factors, such as having 
left school early, being in care institutions, having mental 
health problems, or being in contact with the criminal 
justice system.
Vulnerable young people who develop drug dependence are 
more likely to experience other problems, such as:
  anxiety and depressive disorders;
  psychotic symptoms and psychotic disorders;
  suicidal ideation and suicide attempts;
  blood-borne infections from sharing contaminated 
injecting equipment;
  failure to complete their schooling and secure 
employment; and
  fatal and non-fatal drug overdose.
With the exceptions of blood-borne infections and drug 
overdoses, it is not always clear what the relationship 
is between drug problems and these outcomes. It may 
be that having these problems increases the chances of 
developing drug problems. It may be that having a drug 
problem can cause or worsen these problems. And it may 
be both: having these problems may increase the chance 
of developing drug problems, which make these problems 
worse.
The most obvious way to prevent drug-related problems 
in vulnerable young people would appear to be to prevent 
them from ever starting to use drugs. This may be one 
of the aims of family-based interventions early in the life 
course. However, this may be difficult to achieve for older 
highly vulnerable young people who are living in social 
environments that encourage early drug use and have 
access to drugs at an early age. The aim of most preventive 
interventions in these cases is to intervene early to prevent 
young people from progressing to regular and problematic 
drug use. There is also a case for harm reduction 
interventions that aim to reduce drug-related harm in young 
people engaging in high-risk drug use, such as injecting 
drug use.
|  Responses and interventions to address the needs of vulnerable young people
Selective and indicated prevention
Some universal prevention programmes that also 
benefit vulnerable groups are discussed in section 4.4 
on responses in schools and colleges, while many of the 
responses in Chapter 2, particularly those addressing 
cannabis use problems in section 2.1, will be largely used 
by vulnerable young people since they are at highest risk 
of cannabis use problems. Here the focus is mainly on 
selective and indicated prevention programmes.
Family-based prevention programmes typically train 
parents to support their children to achieve age-specific 
developmental outcomes (including impulse control, social 
competence and gratification delay) that are associated 
with reduced risk of substance use and other behavioural 
problems. Family-based selective prevention programmes 
address marginalised and vulnerable families, including 
those affected by parental substance use problems.
Relatively little is known about the contents of many of 
the family-based interventions delivered in Europe. One 
exception is the Strengthening Families Programme, which 
provides training in parenting skills, and has now been 
implemented in 13 European countries. This internationally 
recommended programme also seeks to remove obstacles 
to participation for vulnerable parents, by providing 
transport and childcare.
Indicated interventions for young people who are using 
drugs or who have personal vulnerability factors as 
described above aim to reduce their drug use, risky 
patterns of drug use and harms that may arise from use. 
Brief screening questionnaires can detect illicit drug use 
problems in adolescents in primary care settings, but there 
is insufficient evidence to decide whether brief interventions 
reduce drug use and related harm in young people in these 
settings.
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A Canadian indicated prevention programme (Preventure) 
that targets adolescent sensation-seeking drinkers in schools 
has been positively evaluated, and adapted for use in the 
Czech Republic, the Netherlands and the United Kingdom. 
Evidence-based indicated programmes for younger children 
in schools exist in Spain (Empecemos) and Germany 
(Trampolin) (see EDDRA on the EMCDDA website).
In general, go-approaches (approaching the target group 
at home or on the street) are likely to be more successful 
in engaging with vulnerable young people than come-
approaches (where young people are expected to present 
at services).
E-health approaches to screening and brief interventions, 
using both computers and mobile phone platforms, are 
a promising way to reach vulnerable young people. These 
approaches may be especially attractive to young people, 
who will generally have access to mobile phones and the 
internet and are familiar and very comfortable with using 
these technologies. E-interventions potentially provide a 
way to increase the reach of early interventions in a high-
risk group of young people who may be reluctant to seek 
help from conventional health services (see Spotlight on 
e-health interventions, page 119).
Harm reduction interventions
Young people who inject drugs are at high risk of acquiring 
blood-borne infections in the early years of injecting. 
Needle and syringe programmes reduce injection-related 
risk behaviours and HIV transmission in young adults, but 
there has been limited research on their impact in young 
people. Hepatitis B vaccination is efficacious and safe, and 
should be routinely provided to young people who inject 
drugs. Prisons, outreach programmes, needle and syringe 
programmes and health clinics may be good settings in 
which to identify and intervene with young people at risk of 
injection-related harms. However, in some cases services 
are not permitted to work with under-18s.
Treatment
Family can play an important role in addressing substance 
use problems among young people. Multidimensional family 
therapy — a process that includes the young person, their 
family and their environment — is a holistic approach that 
can deliver promising results during therapy and these 
can last after the treatment ends. A systematic review of 
five main studies carried out in the United States and the 
European Union indicated the potential for positive results, 
but it is important to ensure implementation fidelity and 
family adherence, which can be difficult. Furthermore, the 
relatively high cost of such treatment must be considered 
before recommending its general use.
Treatment for young people is often for cannabis use 
problems, and these services have been discussed 
in section 2.1. However, vulnerable young people with 
problems related to the use of other drugs may have trouble 
accessing treatment or, where there are dedicated services 
for under-18s, may have difficulties in the transition to adult 
Overview of the evidence on … responses for vulnerable young people
A number of personality traits that increase vulnerability can be detected and mitigated early in life, for 
example, by programmes that improve self- and impulse-control.
Screening and brief intervention is a promising approach to indicated prevention that remains to be 
evaluated. The e-delivery of screening and brief interventions using both computer and mobile phone 
approaches also appears potentially valuable, but needs further research to assess its effectiveness.
Evidence-based approaches for vulnerable youth consist of providing support for educational success 
in general (especially for males), personal and social competence training, and training families in better 
managing and monitoring their offspring. Mentoring programmes can be helpful for vulnerable youth.
Evidence-based approaches for young children (‘child protection‘) include home visiting programmes for 
vulnerable and socially excluded families.
Needle and syringe programmes, vaccination against HBV and opioid substitution treatment are effective in 
older people who inject drugs and are likely to be effective for under-18s, but this is yet to be demonstrated.
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Spotlight on … E-health interventions
What are e-health and m-health?
E-health involves the use of digital technologies to improve health in a variety of ways including:
  providing drug-related information with harm reduction advice (e.g. safer use) with or without personalised feedback 
from professionals and linked with specialised drug services if needed;
  treating patients with substance use disorders via e-health interventions;
  educating treatment professionals using e-learning modules on therapeutic techniques; and
  using digital diaries to monitor substance use in persons being treated for substance use disorders.
M-health is a type of e-health involving the delivery of e-health interventions using mobile phones and similar devices. 
Delivering screening and brief interventions via e-health and m-health applications is a promising innovation for 
substance use problems in vulnerable young people in Europe.
How are these applications being developed in Europe?
An EU-funded project established the Click for Support network, which has developed guidelines for the development 
of e-health interventions. The number of applications is growing. Examples include:
  Quit the Shit (QTS) is a German online cannabis withdrawal programme developed for adolescents aged 15–17 years, 
who want to reduce or quit their cannabis use. An interactive diary helps users monitor their drug use and a 
counselling team provides them with tips and personalised feedback to support users in achieving their personal 
goals;
  The Dutch substance misuse treatment centre, Jellinek, has developed a ‘blended’ programme called MijnJellinek 
(MyJellinek) for people who meet the criteria for a substance use disorder diagnosis, which combines an e-health 
intervention with face-to-face contact with a therapist.
  The Overdose Risk Information Tool (ORION) is an e-health decision support tool for individuals who are at high risk 
of experiencing a drug overdose. Through a number of questions this tool calculates an overdose risk estimate of 
0 (lowest) to 100 (highest) and presents this risk estimate in a visually attractive way, with the aim of facilitating the 
discussion on overdose risk management between substance users and their doctors.
Future developments for Europe
Research into the effectiveness of these interventions is needed, especially among hard-to-reach target populations, 
such as high-risk youth.
An important step is to ensure that e-tools remain online after being developed for research projects. Their running 
costs are often a fraction of the research and development costs, so it would be very cost-effective to make these tools 
available after projects are completed.
Advances in technology have also opened up possibilities for continuous, real-time data collection and feedback from 
smartphones, social media, sensors and self-report. Quality management and data security are important issues. 
End users could be harmed if data confidentiality is not protected. European-level policy and good practices on data 
security need to be incorporated into e-health interventions for substance users.
See the Background paper, E-health and m-health: using new technologies to respond to drug problems.
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services. There is a need to identify models of good practice 
and expand the evidence base around treatment provision 
for children and adolescents with drug problems.
|  What is being done in Europe with respect to interventions for vulnerable young people
Austria, Denmark, Germany, Portugal and Spain have 
implemented selective prevention interventions for pupils 
in vocational schools, a group of young people identified 
as at increased risk of developing drug problems. Ireland 
has taken a broader approach with at-risk youth, by working 
to improve literacy and numeracy among disadvantaged 
students.
Selective prevention responses for vulnerable groups are 
implemented in European countries through interventions 
that address both individual behaviours and social contexts. 
At the local level, such approaches can involve multiple 
services and stakeholders (e.g. social, family, youth and 
police) and are common in the Nordic countries and Ireland, 
as well as parts of Italy and Spain.
The approaches with the highest availability are reported 
to be those targeting families with substance misuse 
problems, the provision of interventions for pupils with 
social and academic problems and interventions for 
young offenders (Figures 3.4 and 3.5). Little is known 
about the actual contents of these prevention strategies 
and evaluation is limited. Expert opinion data, however, 
FIGURE 3.4
Availability of selective prevention interventions for different groups of vulnerable young people in Europe, 2015/16
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Pupils with 
social/
academic 
problems
Youth in 
socially 
disadvantaged 
neighbourhoods
Young 
offenders
Youth in care 
institutions
Youth outside 
of school
Homeless youth
Full: exists in nearly all relevant locations 
Extensive: exists in a majority of relevant locations (but not in nearly all of them)
Limited: exists in more than a few relevant locations (but not in a majority of them)
Rare: exists in just a few relevant locations
No availability: doesn't exist
No information
NB: The information provided here is based on the opinion of an expert (or panel of experts) in each country.
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FIGURE 3.5
Availability of family-based selective prevention interventions for vulnerable young people in Europe, 2015/16
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Extensive: exists in a majority of relevant locations (but not in nearly all of them)
Limited: exists in more than a few relevant locations (but not in a majority of them)
Rare: exists in just a few relevant locations
No availability: doesn't exist
No information
Families with 
substance use 
problems
Family conlfict 
and neglect
Socially 
disadvantaged 
parents
NB: The information provided here is based on the opinion of an expert (or panel of experts) in each country.
indicates that the most commonly used selective prevention 
techniques are based on information provision. One 
programme of note targeting young offenders is FreD, 
a set of manual-based interventions, which has been 
implemented in 15 EU Member States. Evaluations of this 
programme have shown a fall in repeat-offending rates.
Although prevention interventions for vulnerable families 
exist in the majority of countries, expert ratings from 2013 
indicate that their coverage is often limited. Family-based 
interventions for families where there are substance 
misuse problems in the family are available in most 
European countries, but interventions specifically targeting 
marginalised ethnic minority families, or those with mental 
health problems or criminal justice problems in the family 
are less common.
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 Responding to the needs of vulnerable young people: implications for policy 
and practice
Basics
  The main vulnerable groups of young people in Europe are young offenders, youth out of school or at risk for dropping 
out, youth with academic and social problems, homeless youth, youth in care institutions, youth from marginalised 
ethnic groups and vulnerable families.
  Evidence-based selective and indicated prevention approaches targeting substance use among vulnerable young people 
should be provided rather than only awareness-raising and informational approaches. Go-approaches (approaching the 
target group at home or on the street) are more appropriate than come-approaches (where people are expected to show 
up to services).
  Treatment and harm reduction services need to be provided for the small group of young people with severe problems.
Opportunities
  Indicated programmes that target behavioural and temperamental vulnerabilities of neurobiological origin are rare in 
Europe but have high effect sizes in studies in North America. Expanding provision in Europe has the potential to make 
a significant impact.
Gaps
  There is a need to expand the evidence base on the effectiveness of treatment and harm reduction services for  
under-18s with severe drug problems and to identify and share models of good practice.
  An improved understanding of the availability and levels of provision of drug treatment services for young people with 
drug problems is needed to identify where increased provision is required.
Further resources
EMCDDA
  Preventing later substance use disorders in at-risk children and adolescents: a review of the theory and evidence base 
of indicated prevention, Thematic paper, 2010.
  Multidimensional family therapy for adolescent drug users: a systematic review, EMCDDA Paper, 2014.
  Prevention of addictive behaviours, Insights, 2015.
  Treatment of cannabis-related disorders in Europe. Insights, 2015.
  Drugs and vulnerable groups of young people, Selected issues, 2008.
  Examples of evaluated practices: EDDRA.
  E-health and m-health: using new technologies to respond to drug problems, Background paper, Matthijs Blankers and 
Ajla Mujcic.
Other sources
  INCB. International standards on drug use prevention.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
There are different ways in which families of people 
who use drugs may be affected and may affect the 
drug use of their family member. Some are positive 
and some are negative. This section focuses on the 
problems experienced by adult family members 
of people who have drug problems and the 
potential role of families in supporting treatment 
engagement.
Families of people who use drugs can experience 
a wide range of harms: worry and psychological 
distress leading to physical and mental ill-health; 
harm from domestic violence; exposure to threats 
and violence associated with the drug debts and 
the involvement of the drug-using family member 
in the illicit market; the financial burden of directly 
and indirectly supporting a drug user; impact on 
employment from stress or caring responsibilities; 
strain on family relationships; and loss of social life 
and isolation.
Family members can make a positive contribution 
by supporting the family member who uses drugs 
and encouraging them to engage with treatment.
Response options
  Dedicated family support services providing help and support to 
family members in their own right.
  Support for kinship carers (family members who take on parental 
responsibilities for the children of a drug-using relative).
  Provision of appropriate health care by medical practitioners in 
primary care, including evidence-based interventions, such as the 
five-step programme.
  Proper assessment of family relationships at the point when 
a drug user enters a treatment programme and the provision of 
support to family members in order to enhance their contribution 
to successful outcomes.
  Where appropriate, more intensive and specialist interventions, 
such as intensive family-based therapy, behavioural couples 
therapy, multidimensional family therapy and social network 
approaches.
  Bereavement support.
European picture
  There is no comparable information on the availability of 
programmes to support adult family members of people with drug 
problems in Europe or on the provision of family-based therapies.
  Peer-led family support and advocacy organisations are reported 
in a number of countries.
  3.5  Adult family members 
of people with drug 
problems
 keywords: families,  
 carers 
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|  Main health and social issues for adult family members of people who use drugs in Europe
There are a number of ways in which families of people 
who use drugs may be affected, or may affect the drug use 
of their family member. Very close friends may be similarly 
affected and provide support and in such cases will need 
the same responses as family members. Some of these are 
positive some are negative. The main ones are:
  Adult family members of someone who uses drugs 
problematically may suffer a range of health, economic 
and social harms.
  Family circumstances, such as socioeconomic 
circumstances, parental, siblings’ or a partner’s substance 
use may increase the risk of a family member developing 
drug problems or exacerbate problems when they occur.
  Family support may encourage and maintain a person’s 
engagement with treatment.
  Children of people who have drug problems are vulnerable 
to a range of harms.
In this section, the focus is on the first of these and the 
potential role of families in providing support to treatment 
engagement. This is for practical reasons and not to suggest 
that the other aspects are less important. The impact of 
family circumstances on young people’s vulnerability to 
drug problems has been considered in section 3.4, on 
vulnerable young people. The issues in providing services 
for parenting women with drug problems in section 3.2 also 
touched on the very complex and difficult area of reducing 
harm to children of people with drug problems.
The harms that adult family members of someone with drug 
problems may experience include:
  worry and psychological distress leading to physical and 
mental ill-health;
  harm from domestic violence;
  exposure to threats and violence associated with the 
drug debts and the involvement of the drug-using family 
member in the illicit market;
  the financial burden of providing direct and indirect financial 
support to a drug user, which may include providing kinship 
care to the children of an affected family member;
  the potential impact on employment arising from stress or 
additional caring responsibilities;
  the strain on family relationships and the loss of social life 
and increased isolation they experience as a result of the 
stigma associated with having a family member who is a 
drug user.
The precise impact that a family member’s drug use has 
will vary between individuals and is dependent on their own 
circumstances and their relationship to the person using 
drugs. For example, parents of problem drug users may 
be required to bring up their grandchildren on a temporary 
or permanent basis. Siblings of problem drug users will 
be affected by their chaotic behaviour. They may also feel 
neglected by their parents, whose attention is focused on 
their drug-using sibling. The spouses of people with drug 
problems may have to take sole responsibility for all aspects 
of family life and, in addition to worrying about their drug-
using spouse, may feel guilt and concern about the impact 
on their children. Sometimes, families may feel it necessary 
to disengage with the drug user, which can also pose 
problems and have a big psychological impact. Whether or 
not families remain engaged, the damage to relationships is 
likely to be profound.
In addition to support with day-to-day living, families can 
also be an important source of motivation and financial 
help to get a relative into a drug treatment programme. 
Research shows that there may also be benefits in involving 
families in that treatment. In some cases families provide 
the support and encouragement that enable people to 
undertake detoxification and recovery outside of the formal 
treatment sector.
| Responses available
The types of services and interventions needed to support 
families include the following:
  Dedicated family support services providing help and 
support to family members in their own right; for example, 
peer support groups, specialist support groups and services. 
These can be very valuable in reducing social isolation.
  Support for kinship carers, such as grandparents looking 
after the children of their drug-using child.
  Medical practitioners working in primary care need to 
recognise and address the health needs of individuals 
affected by a family member’s drug use. There are some 
programmes for addressing the support needs of adult 
family members and helping in the development of 
coping strategies in various settings, such as the five-step 
programme, for which an evidence base is emerging.
  Proper assessment of family relationships at the point 
when a drug user enters a treatment programme and 
then, as appropriate, providing support and recognising 
the contribution of family members within treatment 
programmes for drug users. This could typically include the 
provision of information and education about drug misuse, 
the identification of sources of stress, handling relapses 
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and the promotion of coping skills. Treatment services 
need to respect patient confidentiality, but protocols can 
be developed that allow family support where appropriate.
  For some people there will be a need for more 
intensive and specialised support, provided through 
such interventions as intensive family-based therapy, 
behavioural couples therapy, multidimensional family 
therapy, community reinforcement and family training 
(CRAFT) and social network approaches.
  Bereavement support.
|  What is being done in Europe to support families affected by drug problems
There is no comparable information on the availability of 
programmes to support adult family members of people 
with drug problems in Europe.
In Ireland, the National Family Support Network, a peer-led 
organisation, provides support to peer support networks 
across the country and advocates for policy and practice 
improvements. The problem of drug debt and intimidation 
is recognised in the Irish National Drug Strategy and a Drug 
Related Intimidation Programme established by the police 
in collaboration with the National Family Support Network.
Similar peer-led national family support and advocacy 
organisations are available in some other European 
countries, such as Adfam and Scottish Families Affected 
by Alcohol and Drugs, in the United Kingdom. Bereavement 
support is often an important component of the work 
of these organisations, and they may also be involved 
in campaigning for or promoting naloxone distribution 
programmes.
Families of people with drug problems: implications for policy and practice
Basics
  Adult family members of people who use drugs may experience a wide range of harms and need support services to 
help them address these. These include primary health care to address the anxiety and stress they experience, peer 
support, bereavement care and support for kin carers.
  The needs and potential contribution of family members to the effectiveness of drug treatment should be recognised 
within drug policy and practice guidelines.
Opportunities
  Involvement of adult family members of people with drug problems in policy and practice development as well as 
in the provision of peer support has the potential to improve provision of service generally, as well as specifically for 
family members.
Gaps
  Information on the extent and nature of provision of interventions for this group is currently limited, and research and 
monitoring in this area needs to be improved.
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Further resources
EMCDDA 
  Pregnancy, childcare and the family: key issues for Europe’s response to drugs, Selected issue, 2012.
Other sources
  UK Drug Policy Commission. The forgotten carers: support for adult family members affected by a relative’s drug 
problems, 2012.
  UK Drug Policy Commission. Adult family members and carers of dependent drug users: prevalence, social cost, 
resource savings and treatment responses, 2009.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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4
Another important factor that can influence drug use 
and the problems that may be associated with use is the 
setting in which use occurs. The setting will also affect 
the responses that are most appropriate and it is this 
perspective that is taken in this chapter.
The settings considered are:
  prisons and the criminal justice system;
  nightlife, festival and other recreational settings;
  workplaces;
  schools and colleges; and
  local communities.
Each of these very different settings has unique 
characteristics that make them important for responses to 
drug problems. The amount of information available about 
these settings is variable as, in most of these areas, the 
EMCDDA has no established data collections.
In many cases, there is limited information on the 
effectiveness of preventive, treatment and harm reduction 
interventions in these specific settings. The advice provided 
in these cases is often based on a consensus of expert 
opinion about current best practice and, at times, on the 
assumption that evidence-based interventions that work in 
other settings may also be effective when transferred to the 
settings considered here. However, such assumptions need 
to be tested, and the importance of improving evaluation 
and monitoring to augment the evidence base in support of 
activities in these settings is a recurring theme.
 CHAPTER 4
Responding in 
particular settings
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SUMMARY
Issues
People who commit criminal offences and 
enter the criminal justice system have higher 
rates of drug use and injecting than the general 
population. People with drug problems in 
the criminal justice system are often repeat 
offenders, and make up a significant proportion 
of prisoners. Adherence to the international drug 
conventions does not necessitate incarceration 
as a response to the use of controlled 
substances. Nevertheless, a significant number 
of offenders with drug problems are incarcerated 
for use or possession offences. Many others are 
imprisoned for other drug law offences or crimes, 
such as theft committed to obtain money for 
drugs. The complex health care needs of these 
individuals need to be assessed on prison entry.
As the average duration of a prison sentence 
for this group is a few months, they are a 
dynamic population with regular contacts 
with the community; this has implications for 
public health. Drug use occurs in prisons and 
also presents a public health and safety risk to 
prisoners and prison officers. The use of synthetic 
cannabinoids is an emerging issue of concern in 
some countries.
Response options
Alternatives to punishment: Encouraging drug-dependent offenders to 
engage with treatment can be an appropriate alternative to imprisonment. 
There is reasonable evidence for the effectiveness of some, but not all, of 
these approaches in reducing drug use and recidivism. More and better 
evaluations of the different models of interventions are needed.
Responses in prisons: Two important principles for health interventions 
in prison are equivalence of care to that provided in the community and 
continuity of care between the community and prison on admission and 
after release. This implies that all appropriate prevention, harm reduction 
and treatment services need to be provided within prisons and also 
particular attention paid to service provision around admission and release.
European picture
  Opioid substitution treatment in prisons is reported by 28 of the 30 countries 
monitored by the EMCDDA (28 EU Member States, Norway and Turkey).
  Detoxification, individual and group counselling, and therapeutic 
communities or special inpatient wards are available in prisons in most 
countries.
  Infectious diseases testing is available in prisons in most countries, but 
hepatitis C treatment is rare. Hepatitis B vaccination is reported in 16 
countries.
  Needle and syringe programmes in prisons are reported in four countries.
  Many European countries have partnerships between prison health 
services and providers in the community to ensure continuity of care on 
prison entry and release.
  Preparation for prison release, including social reintegration, is done in 
most countries. Programmes to prevent drug overdose among opioid 
injectors are reported in five countries which provide training and naloxone 
on release from prison.
 keywords: prison,  
 alternatives to  
 punishment, treatment,  
 harm reduction 
  4.1  Prisons and the 
criminal justice system
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|  Drug use and its consequences in prisons and the criminal justice system
People who commit criminal offences and enter the criminal 
justice system and prisons report higher lifetime rates 
of drug use and more harmful patterns of use (including 
injecting) than the general population. This makes prisons 
and the criminal justice system an important setting for 
drug-related interventions.
Drug use can be linked to offending in a number of ways: 
use or possession are offences against the drug laws; 
crimes, including drug supply, may be committed in order 
to obtain drugs or fund their purchase; offences may be 
committed under the influence of drugs; and there are also 
crimes that are linked to the drug trade, such as violence 
between different groups of dealers. People who use drugs 
most often commit offences in the first three of these 
groups. The majority of recorded drug law offences in most 
EU countries are for cannabis use or possession, while 
people who have problematic patterns of use tend to enter 
the criminal justice system for acquisitive crimes, such as 
robbery, theft and burglary, committed to fund their drug 
use. This latter group are often repeat offenders and can 
make up a significant proportion of the prison population.
The international drug conventions recognise that people 
with drug dependence problems need health and social 
support and allow for alternatives to punishment to help 
them address their drug use problems. Nevertheless, many 
problem drug users are incarcerated. Drug-using prisoners 
can have complex health care needs that have implications 
for responses at intake, during incarceration and on release. 
As the average duration of a prison sentence for this 
group is a few months, they are a dynamic population with 
regular contacts with the community; this has public health 
implications. Drug use that occurs in prisons presents a 
public health and safety risk to prisoners and prison officers. 
Therefore the assessment of drug use and drug-related 
problems should be an important part of health screening 
at prison entry.
The economic cost to governments of incarcerating 
offenders whose crimes are drug-related is high. Estimating 
these costs is difficult because many are hidden within 
overall prison expenditure. It has been roughly estimated 
that between 2006 and 2010, in the 22 countries for which 
data were available, expenditure on drug law offenders in 
prisons varied between 0.06 % and 0.9 % of total public 
expenditure. This will be an underestimate of the overall 
cost of incarceration for all drug-related offending because 
drug law offences are only one type of drug crime, and it 
does not include the costs of crimes committed under the 
influence of drugs, crimes committed to obtain drugs or pay 
for drugs, and violent crimes committed in the course of 
drug supply, distribution and use.
A particular issue of concern in some countries is the 
increasing use of synthetic cannabinoids in prisons. This 
may be due to the fact that these substances are not 
generally detectable by random drug tests that are used in 
prisons in some jurisdictions, or that they are cheaper than 
other drugs and easier to smuggle into prison (see Spotlight 
on synthetic cannabinoids, page 81).
|  Responses to drug problems in prisons and the criminal justice system
Alternatives to punishment
There are many different types of alternatives to punishment, 
which may be applied at different stages of the criminal 
justice process from arrest to sentencing. A recent European 
Commission-funded study conducted by RAND Europe 
found 13 different types of alternatives to punishment (or, 
as they describe them, alternatives to coercive sanctions) 
available in all 28 EU Member States. These ranged from a 
simple caution, warning or no action to a range of options 
that generally involved some element of drug treatment.
These were:
  caution/warning/no action;
  diversionary measure;
  drug addiction dissuasion committees;
  suspension of investigation/prosecution with a treatment 
element;
  suspension of court proceedings with a treatment element;
  suspension of sentence with a treatment element;
  drug court;
  drug treatment;
  probation with a treatment element;
  community work with a treatment element;
  restriction of liberty with a treatment element;
  intermittent custody/release with a treatment element;
  parole/early release with a treatment element.
Alternatives to punishment are recognised as having the 
potential to reduce drug-related harms by diverting offenders 
with drug problems into programmes that may help them 
tackle the drug problems that often underpin their offending. 
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It also enables them to avoid the very damaging effects of 
a criminal conviction and, possibly, imprisonment and the 
associated costs to the state. The evidence base for these 
programmes is limited, however, as few have been evaluated. 
Where there have been evaluations, these have mostly been 
undertaken outside Europe with generally weak designs.
To develop an understanding of which of the various types 
of alternatives to punishment implemented in Europe 
are most effective and for which groups of offenders, 
information is needed on the primary objectives of these 
programmes, the extent of their use and the outcomes 
achieved. Only with these data, will it be possible to 
compare the potential costs and benefits of alternatives to 
prison relative to other sanctions.
Responses in prisons
In general, where evidence is available, it is supportive 
of the use in prisons of interventions that are effective in 
tackling drug problems in the community. Indeed they may 
be particularly important because prisons are a high-risk 
environment.
Two important principles for health interventions in prison 
are equivalence of provision to that in the community and 
continuity of care before and after prison release. Human 
rights principles should also be respected: there should 
be humane treatment, access to care, patient consent and 
confidentiality, and humanitarian assistance for the most 
vulnerable individuals.
The principle of equivalence of care obliges prison health 
services to provide prisoners with care of a quality 
equivalent to that provided for the general public in the 
same country, including harm reduction interventions, such 
as needle and syringe programmes and drug treatment. 
Barriers, whether legal or structural, should be overcome to 
guarantee high quality treatment and care for prisoners.
Continuity of care between services in the community 
and prison applies both on entry to prison and on release. 
It should also apply to drug treatment, including opioid 
substitution treatment and all types of health care. Many 
European countries have partnerships between prison 
health services and providers in the community to facilitate 
health education and treatment interventions in prison and 
ensure continuity of care on prison entry and release.
To meet these basic requirements, prison reception routines 
need to include systems to identify individuals with high 
Overview of the evidence for … interventions in prisons and the criminal justice 
system
Opioid substitution treatment is protective against death in prison for opioid-dependent prisoners.
Substitution treatment is also important in prison in reducing injecting risk behaviours.
To prevent overdose death in the period directly following prison release, it is important that there is 
continuity of treatment in the community.
Drug court programmes (in the United States, where the vast majority of studies have been conducted) 
can help people achieve financial independence and find employment or enrol in education and reduce 
recidivism.
There is some evidence that quasi-coercive treatment involving programmes diverting people with drug 
problems from the criminal justice system can be as effective as voluntary treatment. 
Psychosocial treatments reduce the re-incarceration rates in female drug-using offenders.
For opioid-dependent offenders the use of naltrexone seems to help to reduce their re-incarceration rates.
Education and training interventions with take-home naloxone provision help to decrease overdose-related 
deaths after release from prison.
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treatment needs immediately on arrival. In addition, proper 
needs assessments and review must be undertaken to 
ensure that treatments are matched to individual needs. 
Where detoxification is appropriate this should be properly 
managed. Acute detoxification management may include 
symptomatic treatment of withdrawal symptoms, and it may 
benefit from the use of clinical tools to monitor symptoms.
Providing universal voluntary testing programmes for 
a range of infections (blood-borne viruses, sexually 
transmitted infections and tuberculosis) on entry to prison, 
and rapid treatment where necessary, can reduce the 
spread of infectious diseases within the prison setting and, 
in the longer term, to the wider community (see section 2.4). 
Training prison health care staff about communicable 
diseases and the promotion of testing may increase active 
case finding and the implementation of these programmes.
|  What is being done in Europe to respond to drug problems in prisons and criminal justice system
Alternatives to punishment are available in every EU 
Member State, and all include at least one drug treatment 
option. Most of these are available at the point of 
sentencing, rather than at an early stage of the criminal 
justice process. The extent to which they are used is very 
variable. Often, eligibility restrictions exclude many of those 
who might benefit. This suggests the need to review and, 
where necessary, adjust rules that are overly restrictive. 
Another barrier to the use of alternatives to punishment 
is the perception of their ineffectiveness or low public 
acceptability among the judiciary. Here investing in studies 
that may make the evidence base stronger would appear 
merited.
Interagency partnerships between prison health services 
and providers in the community exist in many countries 
in order to ensure delivery of health education and 
treatment in prison and continuity of care upon prison 
entry and release. Some opioid substitution treatment is 
provided in prisons in 28 of the 30 countries monitored 
by the EMCDDA, although coverage is not complete. 
Detoxification, individual and group counselling, and 
therapeutic communities or special inpatient wards are also 
available in most countries (Figure 4.1).
Infectious diseases testing (HIV, HBV, HCV and 
tuberculosis) is available in prisons in most countries, but 
this may be limited to, for example, HIV and tuberculosis 
testing on entry, with testing for hepatitis limited to 
symptomatic individuals. Treatment for HCV infection is 
available in only 11 countries, and the new more effective 
treatments may not be being used. Hepatitis B vaccination 
programmes are reported in 16 countries. The provision of 
clean injecting equipment is less common, with only four 
countries reporting syringe programmes in this setting, 
and only three countries report figures on actual syringe 
distribution. Approaches, target group, and modalities of 
harm reduction measures in prison vary by country.
Preparation for prison release, including social reintegration, 
is carried out in most countries. Programmes to reduce the 
high risk of drug overdose death among opioid injectors 
in the period after leaving prison are reported in several 
countries. These include training and information on 
overdose risk reduction and, in some cases, the provision of 
naloxone upon prison release.
In response to the problem of infections in prisons, the 
EMCDDA is collaborating with ECDC to produce evidence-
based public health guidance for prevention and control of 
communicable diseases in prison settings. As part of this 
work, systematic reviews of the evidence base regarding 
tuberculosis and active case finding have been published 
or are in press. Other topics to be included in the future are 
vaccination and the prevention of blood-borne infections.
FIGURE 4.1
Availability of harm reduction interventions in prisons in 
Europe, 2015/16
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Responses in prisons and the criminal justice system: implications for policy 
and practice
Basics
  The principles of equivalence of care and continuity of care require the provision of the same range of evidence-based 
interventions for people with drug problems in prison as in the community, provided by staff properly qualified for 
treating addiction (whether prison staff or outside professionals), and mechanisms to ensure continuity of treatment; 
this is especially important for those incarcerated for short periods.
  Preparation for release should include activities to support social reintegration and training on overdose prevention — 
the provision of take-home naloxone should be considered.
  Alternatives to punishment are recognised in the international conventions as a potentially valuable option for offenders 
with drug problems.
Opportunities
  Prison settings may provide an opportunity to have a significant impact on morbidity, mortality and public health. Firstly, 
by engaging people with opioid problems in treatment, their illicit opioid use and risk behaviours in prison and overdose 
risks on release may be reduced. Secondly, by offering testing for infectious diseases to everybody on entry to prison 
and following up with treatment as needed.
  Increasing the use of alternatives to punishment through review of the regulations that govern their application and 
addressing public and professional attitudes to their use may have the potential for improving long-term outcomes and 
reducing criminal justice expenditure.
Gaps
  UN/WHO guidance recommends the provision of harm reduction measures (needle and syringe programmes, condom 
distribution, safe tattoos) in prison, but this is currently rare — scaling up these programmes could make an important 
contribution to health improvement.
  Studies are needed to improve the evidence base around alternatives to punishment, with particular attention being 
paid to the groups that can most benefit from these, and the stages in the criminal justice process at which they are 
best applied.
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Further resources
EMCDDA
  Best practice portal.
  European drug report: trends and developments 2017.
  Prisons and drugs: prevalence, responses and alternatives to imprisonment, Thematic page.
  Prisons and drugs in Europe: the problem and responses, Selected issue, 2012.
  Estimating public expenditure on drug law offenders in prison in Europe, EMCDDA paper, 2014.
  Alternatives to punishment for drug-using offenders, EMCDDA Papers, 2015.
  Health and social responses to drug problems in prisons, Ciara Guiney, Background paper.
Other sources
  World Health Organization. Prisons and Health, 2014.
  ECDC. Systematic review on the diagnosis, treatment, care and prevention of tuberculosis in prison settings, 2017.
  European Commission. Study on alternatives to coercive sanctions as response to drug law offences and drug-related 
crimes, 2016.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
Drug and alcohol use in nightlife 
settings, such as bars, nightclubs 
and other recreational venues, 
is linked to health and social 
problems, including acute health 
harms, aggressive behaviour and 
violence, and driving under the 
influence of alcohol and drugs. 
There are also longer-term health 
effects and addiction. Adverse 
social consequences may include 
drug dealing and public nuisance. 
Because many of these harms 
are associated with excessive use 
on a particular occasion, many 
responses aim to reduce the 
amounts of alcohol and drugs that 
are used.
Response options
Most of the evidence on responses in recreational settings relates to alcohol. Few interventions 
targeting drug use in recreational settings have been robustly evaluated.
Prevention or harm reduction information material can be provided to young people in 
recreational settings. Peer educators disseminating this type of information may be seen as 
more credible. These activities can be supported by websites and apps providing more detailed 
information on drugs, alcohol and related harms, and tips on avoiding them. However, the 
evidence for behavioural change effects from these interventions is scarce.
Environmental strategies have a better evidence base. This approach includes measures that 
target factors that promote excessive consumption (e.g. discounted drinks, loud music and poor 
serving practices) or that create safer spaces and venues (e.g. by reducing crowding, providing 
chill-out rooms and free water, serving food, enforcing rules on behaviour and access).
Drug-checking services (sometimes called pill testing) enable individual drug users to have 
their synthetic drugs chemically analysed, providing information on the content of the samples 
as well as advice, and, in some cases, counselling or brief interventions. The effectiveness of 
this approach in changing behaviour is not clear, but it may provide a valuable opportunity for 
engaging drug users and for drug monitoring purposes.
European picture
Various environmental and regulatory approaches are used across Europe to address 
substance-related problems in nightlife and other recreational settings. These include zero 
tolerance rules, regulatory measures against venues that have visible problems, the training of 
door and security staff, health and safety measures, and training in recognising and responding 
to drug- and alcohol-related emergencies. Structured evidence-based environmental prevention 
approaches are now being used in more countries, as are local regulatory coalitions between 
the police, the nightlife industry and services (prevention and harm reduction). Two European 
projects, the Nightlife empowerment and well-being implementation project (NEWIP) and the 
Club Health Project, are developing good practice standards for people working in this area.
The number of drug-checking services available across Europe is growing. These use a variety 
of different models, including off-site testing centres and on-site testing at festivals and in 
nightclubs. The impacts of different models of drug checking need to be investigated.
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| Drug issues in nightlife settings
Bars, nightclubs and other recreational venues provide 
young Europeans with opportunities to socialise and dance. 
Large music festivals during the summer months attract 
thousands of visitors, among whom the use of drugs is 
much more common than in the general population.
In addition to illicit drug use, excessive alcohol use is also 
common in these recreational settings. A study carried 
out in nine European cities estimated that over three 
quarters of visitors to nightlife venues had been drunk at 
least once in the last four weeks. School surveys show that 
most 15- to 16-year-old students who had used MDMA/ 
ecstasy during the last month had also consumed five or 
more alcoholic drinks at least once, underlining the strong 
association between alcohol and drug use among young 
people.
Drug and alcohol use in nightlife settings are linked to a 
number of health and social problems. These include acute 
health risks and other problems, such as acute intoxication, 
unconsciousness and unintentional injury, aggressive 
behaviour and violence, unsafe and unwanted sex, and 
driving under the influence of alcohol and drugs. Adverse 
consequences of longer-term use of alcohol and drugs can 
include liver and brain damage and addiction. The adverse 
social consequences may include drug dealing and public 
nuisance.
Most of these harms are associated with binge use, that 
is, excessive use on a particular occasion. As a result, 
many responses aim to reduce the amount of drugs 
or alcohol used. There are also concerns that drug use 
in these settings is increasingly viewed as the norm 
in many countries and the risks associated with drug 
use underestimated. Another cause for concern is the 
increasing availability of a wider range of substances, for 
many of which the content and psychoactive effects are 
unknown.
| Responses to drug issues in nightlife settings
Most of the evidence for responses in recreational settings 
relates to alcohol use and harms. The body of evidence on 
the effectiveness of interventions that target drug use in 
these settings is growing. However, few interventions have 
yet been subjected to robust evaluation. Despite these 
limitations, some lessons from the evidence on responses 
to alcohol use and harms are likely to be useful when 
considering drug-related problems.
Good practice in responding to drug problems in nightlife settings
The available research evidence and expert opinion suggest that a balanced approach is needed to tackle the drug- 
and alcohol-related health and social problems associated with recreational nightlife. There is less consensus on 
individual measures, although all of the following items merit consideration as part of a comprehensive response in 
this area:
  co-ordinated multicomponent interventions involving community stakeholders, generic health and emergency services, 
regulatory bodies, and policing and law enforcement;
  environmental strategies, such as providing chill-out rooms or free drinking water;
  training staff in these venues;
  rapid emergency response measures;
  early warning systems and monitoring of substances being consumed, including drug-checking services;
  provision of prevention and harm reduction materials — although on their own they are unlikely to be effective.
Overall, the evidence for the effectiveness of interventions to reduce alcohol-related harm is stronger than that for 
drug-related harm.
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The Healthy Nightlife Toolbox is available at hntinfo.eu. It 
is made up of three databases: evaluated interventions, 
literature on these interventions, and other literature within 
the field of nightlife alcohol and drug prevention. The main 
types of interventions available are described briefly below.
Education/information for nightlife users
Young people who are involved in nightlife activities 
can be provided with prevention or harm reduction 
information material, such as brochures and pamphlets 
on intoxication and related harm. Peer educators may be 
helpful in disseminating credible information on harms 
and harm reduction to young people in these settings. 
These prevention activities can be supported by websites 
and apps that provide more detailed information on 
drugs, alcohol and related harms, and tips on how to 
avoid them. The promotion of harm reduction strategies 
addressing some key harms, such as drink and drugged 
driving (designated driver schemes, for example), may also 
be adopted. However, research evidence suggests that 
information provision alone is not an effective way to reduce 
drug- and alcohol-related problems, and risk communication 
approaches still require further research and development.
There is a consensus that it is important to provide good 
information on different substances, their associated risks 
and ways to minimise harms. However, risk communication 
strategies need to ensure that the information provided 
allows people to make choices that minimise adverse 
consequences, while avoiding using terminology that might 
make dangerous drugs appear more attractive. There is a 
risk that some people may deliberately seek out substances 
that have been identified as high-dose or high-potency. 
Understanding how to communicate risk in a way that has 
the desired impact on behaviour and avoids unintended 
negative consequences is an important research need.
Drug checking
Within the European Union, drug checking is a controversial 
harm reduction intervention for illicit drugs (see Spotlight 
on drug checking, page 139). While checking may provide 
users with some information on the substances they use, 
critics fear that consumers may be falsely reassured that 
tested drugs are safe to use. Commenting on this issue is 
complicated by the different analytical approaches that are 
used for testing and the technical difficulties in providing 
rapid, accurate chemical analysis of the substances 
and mixtures sold on the illicit drug market. A variety 
of drug-checking schemes exist in Europe, among the 
most longstanding of which is the Drug Information and 
Monitoring System (DIMS) in the Netherlands. This service 
provides users with information on the content of the drug 
and delivers a prevention message, which is based on 
scientific information on the chemical contents of the drug 
sample. DIMS also publishes qualitative information on 
changes in the content of drug samples in the Netherlands. 
On-site drug-checking services are emerging in several 
EU countries at festivals and in clubs and may provide 
an opportunity for brief interventions with people who do 
not usually engage with services or see their drug use as 
problematic.
It is not yet clear to what extent consumers change their 
drug use when informed about the contents of their pills. 
Nevertheless, drug checking does provide an opportunity 
for reaching people who do not usually engage with 
services or see their drug use as problematic. It also 
provides useful information for drug monitoring purposes. 
Alerts are sometimes issued, for example, when a very 
high potency ‘brand’ of MDMA pill is detected, although 
more work needs to be done to understand the behavioural 
impact of this approach. Given the developments in the 
European drug market and growing interest in these 
approaches, evaluation of the impact of different models of 
drug checking should be regarded as a priority.
Environmental strategies
Alcohol- and drug-related problems may also be 
exacerbated by the physical and social environment 
of entertainment venues. A permissive environment, 
characterised by, for example, tolerance of intoxicated 
behaviour, discounted drinks, poor cleanliness, crowding, 
loud music and poor serving practices, may promote higher 
levels of alcohol intoxication, and this may also apply to 
drug use. Environmental strategies for which there is some 
evidence of positive impact include creating safer spaces 
and venues by reducing crowding; providing cool-down or 
chill-out rooms; serving food; enforcing clear house rules 
on behaviour; and preventing access to minors. Ensuring 
that drinking water is available free of charge at venues 
where drugs such as MDMA are used is one way to prevent 
dehydration.
Training of staff and availability of first aid services
Training for bar servers, door supervisors and other staff 
in recreational venues combines information and skills 
building. The areas covered can include alcohol legislation, 
the psychoactive effects of alcohol and drug use, the links 
between alcohol and violence, first aid, how to refuse 
service to intoxicated customers, manage conflict and 
respond to drug dealing on the premises. Evidence for the 
effectiveness of staff training in preventing alcohol- and 
drug-related harm is inconclusive, in part because of the 
high rates of staff turnover in these venues.
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Spotlight on … Drug checking
What is drug checking or pill testing?
Drug-checking services enable individual drug users to have their synthetic drugs chemically analysed, providing 
information on the content of the samples as well as advice, and, in some cases, counselling or brief interventions. 
Service aims vary, ranging from information collection to harm reduction by informing and warning users about the drugs 
on the market. The analytical techniques used also vary: from sophisticated technology that is able to provide information 
on strength and content of substances to self-testing kits that simply show the presence or absence of a particular 
drug (see figure). The sites at which testing occurs include fixed laboratories, to which individuals and organisations can 
submit drugs for testing (with results days later), and mobile laboratories at festivals or in clubs, which provide almost 
immediate results.
An important aspect of drug-checking services is how the results are communicated to individuals and whether this is 
accompanied by harm reduction advice or brief interventions.
What is known about the effectiveness of drug checking?
Drug-checking services are controversial. They have certainly provided a valuable contribution to early warning systems 
in the European Union. However, evidence of their impact on drug use or risk behaviours remains limited. Advocates 
argue that there are case examples in which information from drug-checking services has had a positive public health 
impact and that drug checking can potentially reduce harm by engaging with young recreational drug users not seen 
by existing services; identifying drugs that contain unwanted or unknown chemicals allowing an early public health 
response; and helping avoid overdose by providing information on potency. On the other hand, critics suggest that 
drug checking may give a false feeling of safety because the reliability of some of the testing approaches used is 
questionable; may give the impression that drug taking is normal and acceptable behaviour, potentially undermining 
prevention efforts; and that drug users will go ahead and use their drugs regardless of results.
Continued on next page.
An illustration of the range of models of drug checking available and their relative strengths
Counselling and communication
Warnings/alerts on-site
Mass media warnings/national alerts
Input in national monitoring
High-perfomance 
liquid chromatography Multiple methods
Fourier transform 
infrared spectroscopy
At home On-site/at festival On-site/at festivalOn-site/at festival Stationary at drug
checking facility
Reagent test kit
Thin-layer 
chromatography
Accuracy and reliability of test results
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Medical first aid services can result in prompter 
identification of and response to drug emergencies, 
potentially saving lives and decreasing transfer time to 
hospital emergency departments. European guidelines exist 
for responding to acute emergencies in nightlife settings.
Co-ordinated multi-component approaches
Partnerships between stakeholders can facilitate the 
implementation of effective nightlife interventions. Such 
partnerships, between local municipalities, venue owners 
or managers, the police and health authorities, aim to 
mobilise communities by raising awareness of harms and 
creating support among stakeholders and the public for 
preventive measures. The number of evaluated community 
interventions is slowly growing. Multi-component 
interventions can have an impact on levels of violence, 
problem drinking and street accidents. Where this is the 
case, leadership, continuity of interventions and funding are 
critical for success.
Legislative measures
Problems such as underage drinking, violence within or 
outside nightlife venues and drink driving are best addressed 
by multicomponent community interventions that include 
prevention services, regulators, the nightlife industry, as 
well as policing and enforcement of appropriate regulatory 
measures. This can include police visits to high-risk nightlife 
venues, age verification checks on entry to venues, and the 
use of sanctions (e.g. revocation of operating licences) to 
enforce licensing legislation. These measures have been 
shown to be effective in reducing alcohol-related problems, 
but their positive effects rapidly diminish if they are not 
carried out regularly and linked to real deterrents, such as 
loss of licence for failure to comply. They may also result in 
the displacement of activities to other locations or settings.
Spotlight ... On drug checking (continued)
Any assessment of these arguments is hampered by the lack of robust studies and the difficulties in generalising 
given the very different approaches and models used. Nevertheless, given the growing importance of synthetic drugs 
in the European market, including high potency synthetic opioids, any response that may reduce risks merits careful 
consideration and evaluation.
Drug checking in Europe: challenges for the future
The impact of different models of drug-checking services should be evaluated in order to identify the best models for 
different purposes (e.g. early warning versus harm reduction). The behavioural impact of drug checking is particularly 
in need of research. This research needs to pay particular attention to risk communication, and a behavioural insights 
approach may be useful.
Legal questions around the handling of controlled substances must be addressed, as many countries do not accept drug 
checking as a reason for a legal exemption to drug control laws, whatever the purpose. This issue also extends to users 
of drug-checking services, staff and proprietors of recreational settings where there is on-site testing. Close collaboration 
with the police is always recommended.
Changes in drug use and markets pose challenges for drug checking and associated responses:
  Accurate drug checking requires advanced and sophisticated laboratory equipment, although simpler and cheaper 
techniques are being developed. In addition, testing new psychoactive substances requires knowledge of their chemistry 
and spectral databases. Co-ordination between drug checking, academic and forensic services could maximise the 
value obtained from investment in these services.
  Even when substances can be identified, the risks of using them may still be unknown. Polydrug use further complicates 
the provision of advice linked to drug checking because interactions between drugs are much less predictable than the 
risks of using one drug alone.
See the Background paper, Drug-checking as a harm reduction tool for recreational drug users: opportunities and challenges and NEWIP guidelines.
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|  What is being done in Europe to respond to drug issues in nightlife settings
Some European projects have developed guidelines and 
standards for prevention and harm reduction activities for 
interventions in nightlife settings. These voluntary standards 
and guidelines include:
  Good practice standards on Safer Nightlife labels and 
charters, drug checking and peer education from the 
Nightlife empowerment and well-being implementation 
project (NEWIP).
  A ‘Set of standards to improve the health and safety of 
recreational nightlife venues’ that have been published 
by the Club Health project. This project, involving 20 
associated and 15 collaborating partners from 15 EU 
Member States and Norway, had the aim of reducing 
diseases (especially addictions and sexually transmitted 
infections), accidents, injuries and violence among youth 
in nightlife settings.
More structured, evidence-based environmental prevention 
approaches, such as the STAD-project (Stockholm Prevents 
Alcohol and Drug Problems), are now being rolled out to 
more countries. Some local regulatory coalitions between 
the police, the nightlife industry and services (prevention 
and harm reduction) have been found to have an impact 
on violence, sexual assaults and hospital admissions in the 
United Kingdom and the Netherlands.
Although there is some evidence to support the use of 
a number of regulatory measures, they appear to be 
less frequently applied. These include no ‘flat fee’ or 
happy hours, minimum drink prices, refusal of service to 
intoxicated persons, mandatory staff training, no access for 
minors, limiting the density of nightlife venues and opening 
hours, and an ‘apple juice law’ — whereby in all drinking 
establishments the cheapest drink has to be non-alcoholic.
The multidisciplinary Euro-DEN network, in collaboration 
with the EMCDDA, has adapted existing UK guidelines 
to the wider European context. The guidelines cover the 
identification of individuals with acute drug toxicity who 
require clinical assessment in emergency departments and 
for whom the emergency services should be called. This 
enables early assessment and management by emergency 
Responding in nightlife, festival and other recreational settings: implications for 
policy and practice
Basics
  Provision of environmental prevention and harm reduction interventions, supported by the guidelines and standards 
drawn up in the NEWIP and Club Health projects, should be implemented as appropriate.
  There should be provision of emergency health care to deal with adverse events in recreational settings and linked to 
emergency departments. The European guidelines may be useful here and need to be built on.
  Community-based initiatives that deliver a range of co-ordinated interventions through a multi-agency partnership are 
more effective than single interventions. They often combine community mobilisation, staff training and enforcement 
and appear to be effective in reducing violence, problem drinking and street accidents.
Opportunities
  Increase the sharing of good practice and guidelines for prevention and harm reduction interventions in these settings 
and promote evaluation of their effectiveness.
  Drug-checking services have the potential to be useful both for reducing harmful use of drugs and for monitoring 
what drugs are on the market. However, research is needed into the effectiveness of different models of provision and 
their appropriateness in different scenarios.
Gaps
  The evidence on the effects of information provision for clubbers/peer education (often harm reduction) is limited. 
It has the potential to be counterproductive so more research is needed on the most effective ways to present 
information on risks, safe dosing etc.
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services and, if necessary, the emergency department, of 
those at highest risk of significant morbidity or death from 
acute drug toxicity.
At the time of publication 16 drug-checking services, using 
a range of different models, have been established in 
11 European countries. Some provide national coverage 
but others, particularly those operating on-site in festivals 
and clubs, are restricted to a particular area or venue. There 
appears to be growing interest in this sort of provision.
Further resources
EMCDDA
  Responding to drug use and related problems in recreational settings, Thematic paper, 2012.
  Best practice portal.
  Healthy Nightlife Toolbox.
Other sources
  Nightlife Empowerment & Well-Being Implementation Project (NEWIP) standards available at  
http://newip.safernightlife.org/standards
  Peer education interventions in nightlife settings.
  Drug checking services.
  Safer nightlife labels and charters.
  Serious games in nightlife settings.
  IREFREA Manual: Set of standards to improve the health and safety of recreational nightlife venues. 
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide. 
SUMMARY
Issues
A significant proportion of workers in Europe are likely to 
have problems associated with alcohol or drug use; for 
example, it is estimated that between 5 % and 20 % of 
the working population in Europe have serious problems 
related to their use of alcohol. In addition to the general 
public health and social implications, substance use 
problems are highly relevant in industries where safety 
issues exist or where individual performance failings can 
have a significant impact. This includes, but is not limited 
to, the construction, farming, transport, power, ICT and 
financial services sectors.
Alcohol use and drug use are important issues in 
workplaces because:
  they can increase accidents and injuries, absenteeism, 
and, inappropriate behaviour;
  they can impose an economic burden on employers, 
governments and society;
  employers have a duty under health and safety laws 
to protect, as far as reasonable, the health, safety and 
welfare of employees and others affected by their 
activities;
  workplaces also provide an opportunity for health 
education about alcohol and drugs and opportunities to 
identify individuals who have problems with alcohol and 
drug use or have family members with drug or alcohol 
problems.
The workplace also has a potential role in supporting the 
social reintegration of people with a history of serious 
drug problems.
Response options
  Workplace policies on the consumption of alcohol and drugs 
in the workplace.
  Prevention through information, education and training 
programmes addressing alcohol and drugs issues, 
preferably as part of wider health promotion programmes.
  Workplace screening and testing to identify substance use 
problems, which may arise informally through discussions 
around performance issues or as a result of formal 
assessments, which may include testing in safety-critical 
industries.
  Interventions to address problems that have been 
identified, including assistance, treatment and rehabilitation 
programmes.
  Providing employment opportunities for people with a 
history of serious drug problems.
European picture
Most European countries have some kind of general 
legislation or agreements to prohibit or regulate the 
consumption of alcohol and drugs in the workplace. However, 
the type of legislation in force and nature of occupational 
safety and health legislation varies considerably depending 
on the national culture and the awareness of and priority 
given to the issue.
There is no up-to-date, comprehensive information on the 
extent and nature of different types of interventions in 
workplaces in Europe. There is also very little European 
evidence regarding effectiveness of different interventions.
Looking to the future, the use of performance-enhancing 
drugs, such as modafinil for cognitive enhancement, may 
become a growing issue in the workplace.
 keywords: prevention,  
 workplace 
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| Substance misuse issues in the workplace
Alcohol and drugs represent a serious problem for a 
substantial share of the working population. National 
estimates in Europe indicate that between 5 % and 20 % of 
workers are either addicted or at risk of becoming addicted 
to alcohol. The problem of alcohol or drug consumption 
by workers (inside and outside workplaces) is especially 
relevant in some economic sectors, such as construction, 
farming and transport.
The reasons for the use of alcohol or drugs at work can be 
differentiated into work-related and social or personal. Work-
related reasons include tough physical or uncomfortable 
working conditions (for example, a cold environment), low 
satisfaction at work, irregular working hours, self-perception of 
low social support from work colleagues and superiors, little 
decision latitude and other factors related to stress at work. 
This might make certain types of jobs more likely to be linked 
to substance use. For example, long-distance truck drivers, 
who need to maintain concentration for long monotonous 
periods of driving, may be tempted to use stimulant drugs. 
Doctors and other health professionals may be vulnerable 
to addiction problems due to easy access to medicines 
combined with stress at work. Other groups of workers in 
high pressure, competitive or bullying work cultures, including 
city traders, academics and lawyers, may use a range of 
performance-enhancing drugs for a variety of reasons, such 
as to improve productivity or to overcome jetlag.
Non-job-related reasons include social factors, such as a 
‘high’ social tolerance to alcohol and drug consumption, 
cultural patterns that make workers more ‘prone’ to this 
consumption, ‘easy’ accessibility to these substances (in 
the alcohol and entertainment industries, for example) and 
personal factors (such as specific personality types or a 
family background of alcohol misuse).
Alcohol use and drug use can increase problems in the 
workplace, such as accidents and injuries, absenteeism 
and inappropriate behaviour. Intoxication by alcohol or illicit 
drugs can affect work performance by impairing decision-
making and reaction times, reducing productivity, leading 
to production of inferior goods and services, and errors and 
work-place accidents.
There are a number of ethical and often legal obligations 
relevant to responding to workplace substance misuse 
problems. Medical professionals brought in to a workplace 
to help employees or advise management have to clarify 
their role and respect patient confidentiality. It is generally 
accepted that managers and supervisors should be trained to 
recognise the signs of problems with alcohol and illicit drug 
use. They also need to know how to respond if they suspect 
an employee has a problem or if they are approached by an 
employee who declares a problem.
In supporting people with a past or current alcohol or drug 
problem back into work, health professionals must avoid the 
application of arbitrary abstinence periods, except where they 
are legally mandated, such as for driving. Health professionals 
can be very influential in addressing employers’ concerns 
about risks and challenging stigma and negative stereotypes.
| Responses to drug problems in the workplace
Workplaces provide opportunities for health education 
about alcohol and drugs. They also provide opportunities 
to identify individuals who have problems with alcohol 
and illicit drug use. Medical professionals who support 
workplaces are well placed to offer health advice to workers. 
They can also train managers and supervisors to recognise 
and deal with alcohol and illicit drug use in the workplace.
The International Labour Organization has produced a 
code of practice on the management of alcohol- and 
drug-related issues in the workplace. In Europe, Eurofound 
(the European Foundation for the Improvement of Living 
and Working Conditions) and the European Agency for 
Safety and Health and Work are EU agencies involved in 
this area. The Pompidou group of the Council of Europe 
has an activity stream on prevention of drug use in the 
workplace. A common theme is the importance of having a 
preventive approach that views drug problems from a health 
perspective rather than as a disciplinary issue.
At the national level, approaches to drug-related problems 
in the workplace will be influenced by the administrative, 
legislative and cultural context in each country. Regulations, 
legislation and policies in the domains of employment law, 
health and safety, may all be relevant to drug issues in the 
workplace. To support their policies, countries may produce 
their own guidance for employers, for example, Drug misuse 
at work: a guide for employers published by the UK Health 
and Safety Executive.
The following responses may be used to address drug use 
and problems in the workplace:
  Workplace policies: these may place restrictions on the 
consumption of alcohol and legal and illegal drugs in 
the workplace, and thereby establish norms and restrict 
availability.
  Prevention through information, education and training 
programmes, such as ‘Top on job’. This programme is 
targeted to young workers before addiction problems 
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occur and uses a peer-education approach. Having 
alcohol and drugs issues incorporated into wider health 
promotion programmes may make them more attractive to 
employees.
  Formal screening for drug problems will generally occur 
in three situations: (1) pre-employment testing of job 
applicants; (2) incident-driven or for-cause testing of 
employees (e.g. post-accident, fitness for duty); and (3) in-
employment testing without specific cause, often selected 
at random from a pool of targeted sensitive positions. 
In Europe, formal screening is generally conducted only 
where necessary to promote workplace safety.
  Identification of problems — workplace screening and 
testing. In the workplace, identifications of drug problems 
will generally arise either through self-assessment by the 
individual concerned or as a result of identification by the 
employer, either informally through discussions around 
performance issues or as a result of formal assessments, 
which may include testing in safety-critical industries. 
These approaches often comprise screening, assessment, 
counselling and referrals to more specialist care and aim 
to provide opportunities for managers to forestall discipline 
or dismissal of employees with substance use problems, 
contingent upon their ability to constructively address 
these issues that negatively affect job performance.
  Interventions to address problems, including assistance, 
treatment and rehabilitation programmes. The type and 
level of support provided will depend on a range of factors, 
including the size of the organisation. Actions that should 
be considered as a minimum are as follows: identifying 
specialist services in the area and providing information 
on these or referral if appropriate; identifying community 
support agencies, such as Narcotics Anonymous, that 
may be helpful to the individual concerned; suggesting 
the individual seeks support from his or her personal 
physician.
The workplace also has a potential role in supporting the 
social reintegration of people with a history of serious drug 
problems. The stigma associated with problematic drug 
use can pose a major barrier to employment, which is a 
cornerstone of reintegration. However, some employers 
have worked with drug services to develop programmes, 
such as supported employment schemes, that facilitate the 
employment of people with a history of problematic drug 
use and find these produce benefits for their organisation 
as well as the individual concerned.
|  What is being done in Europe to respond to drug problems in the workplace
A report produced by Eurofound (European Foundation 
for the Improvement of Living and Working Conditions) 
indicated that most European countries have some kind 
of general legislation or agreements intended to prohibit 
or regulate the consumption of alcohol and drugs in the 
workplace. However, the type of legislation in force and 
nature of the limitations established under occupational 
safety and health legislation varies considerably depending 
on the national culture and the awareness of and priority 
given to the issue. For example, in some countries there 
may be a specific regulation on alcohol, whereas in others it 
is at the employer’s discretion.
There is no up-to-date, comprehensive mapping of 
the practices and interventions relating to substance-
related issues in the workplace in Europe. The evidence 
of effectiveness of the different programmes and 
interventions that are in use is also limited, and what there 
is mainly comes from the United States. A comprehensive 
assessment of most current provision is therefore not 
possible.
However, there may be data sources available that 
can provide some information. For example, EU-OSHA 
conducts the European Survey of Enterprises on New and 
Emerging Risks (ESENER), which focuses on a number of 
issues: general safety and health risks in the workplace; 
psychosocial risks, such as stress, bullying and harassment; 
drivers of and barriers to occupational safety and health 
management; and worker participation in safety and health 
practices. The survey was carried out in 2009 and 2014, 
and the data from these surveys is available online. It 
included a question on whether their establishment takes 
any ‘…measures for health promotion among employees? … 
Raising awareness on the prevention of addiction, e.g. 
to smoking, alcohol or drugs’. In 2014, about a third of 
respondents across Europe said that their enterprise 
did so, ranging from 19 % to 59 % in different countries 
(Figure 4.2).
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Key principles for the management of drug-related issues in the workplace 
identified by the UN International Labour Organization
  Drug policies and programmes should promote the prevention, reduction and management of alcohol- and drug-related 
problems in the workplace.
  Drug-related problems should be considered as health problems, and dealt with like any other health problem at work 
and covered by the health care systems (public or private) as appropriate.
  Employers and workers and their representatives should jointly assess the effects of alcohol and drug use in the 
workplace, and cooperate in developing a written policy for the enterprise.
  Employers should cooperate with workers and their representatives to do what is reasonably practicable to identify job 
situations that contribute to drug-related problems, and take appropriate preventive or remedial action.
  The same restrictions or prohibitions with respect to alcohol should apply to both management personnel and workers 
to ensure a clear and unambiguous policy.
  Information, education and training programmes about alcohol and drugs should be undertaken in order to promote 
safety and health in the workplace as part of broad-based health programmes.
  Employers should establish a system to ensure the confidentiality of all information communicated to them concerning 
alcohol- and drug-related problems.
  Testing of bodily samples for alcohol and drugs in the context of employment involves moral, ethical and legal issues of 
fundamental importance that require a determination of what is fair and appropriate testing.
  Holding a job is an important factor in facilitating recovery from alcohol- and drug-related problems. Therefore the 
workplace has a special role to play in assisting individuals with these problems.
  Workers who seek treatment and rehabilitation for alcohol- or drug-related problems should not be discriminated 
against by the employer and should enjoy normal job security and the same opportunities for transfer and advancement 
as their colleagues.
  The employer has authority to discipline workers for employment-related misconduct associated with alcohol and drugs, 
but counselling, treatment and rehabilitation should be preferred to disciplinary action. Should a worker fail to cooperate 
fully with the treatment programme, the employer may take disciplinary action as appropriate.
  The employer should adopt the principle of non-discrimination in employment based on previous or current use of 
alcohol or drugs, in accordance with national law and regulations.
Adapted from: Management of alcohol- and drug-related issues in the workplace. An ILO code of practice. Geneva, International Labour Office, 1996.
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Providing a comprehensive overview is difficult, given 
the wide range of different programmes involved and the 
need to avoid over-burdening employers. Focusing on the 
interface between drug treatment services and employees 
and describing and evaluating access to treatment for 
employees who have substance-related issues or are 
on programmes to support people in treatment for drug 
problems into employment might have the biggest impact.
Looking to the future, the use of drugs for performance 
enhancement may become a growing issue in the 
workplace. This includes the use of prescription stimulants, 
such as modafinil, as an aid to concentration or because 
they are believed to provide cognitive enhancement. It 
appears that the use of performance-enhancing drugs 
is becoming more widespread and, as mentioned above, 
some groups of employees have a greater likelihood of 
using them for work-related reasons. Therefore it might be 
expected that, in an increasingly competitive society, use 
in the workplace could grow. It will be important to monitor 
the use of performance-enhancing drugs in the future, and 
more work is needed on the effects of use of these drugs in 
the workplace.
FIGURE 4.2
Provision of health promotion interventions for 
employees: share (%) of workplaces reporting measures 
to raise awareness on the prevention of addiction 
50.0–59.940.0–49.930.0–39.920.0–29.9< 20.0
Provision (%)
Source: EU-OSHA: European survey of enterprises on new and emerging 
risks, 2014.
Responses in workplaces: implications for policy and practice
Basics
  It recommended that employers have an alcohol and drug use policy as a component of their health and welfare 
policies rather than as a disciplinary matter.
  The key principles for the management of drug-related issues in the workplace identified by the UN International 
Labour Organization, and highlighted above, should also be promoted.
Opportunities
  Gaining employment is an important component of reintegration, therefore it is important that people with a past 
or current alcohol or drug problem are supported back into work. Working with employers to overcome barriers to 
employing people with a history of drug problems offers benefits to employers, to those trying to overcome their drug 
problems and to society as a whole.
Gaps
  There is a need for an overview or mapping of existing data sources, current responses and interventions addressing 
drugs in the workplace as well as evaluation of existing interventions in Europe.
  Research is needed into the extent and nature of the use of performance-enhancing drugs in the workplace and on 
the effects of their use in that setting.
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Further resources
EMCDDA
  Social reintegration and employment: evidence and interventions for drug users in treatment EMCDDA Insights, 2013.
Other sources
  OSHA. A review on the future of work: performance-enhancing drugs, Discussion paper, 2015.
  OSHA. European survey of enterprises on new and emerging risks, 2014.
  Eurofound. Use of alcohol and drugs at the workplace, 2012.
  Management of alcohol- and drug-related issues in the workplace. An ILO code of practice. Geneva, International 
Labour Office, 1996.
  Shahandeh, B. and Caborn, J. (2003), Ethical issues in workplace drug testing in Europe Geneva: ILO.
  Pompidou Group. Prevention of drug use in the workplace.
  UK Health and Safety Executive. Drug misuse at work: A guide for employers.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
SUMMARY
Issues
Adolescence and young adulthood are 
periods of risk-taking and experimentation 
that often includes substance use. 
Schools and colleges are important 
settings in which to reach young people, 
although some vulnerable groups may not 
be well-represented within them.
In schools the focus is mainly on 
preventing or delaying the initiation of 
substance use and on the development of 
skills to support healthy decision-making.
Poor school attenders, frequent truants or 
young people with behavioural problems, 
such as poor impulse control, are at 
increased risk of developing problematic 
forms of substance use. This makes 
schools an important setting for early 
identification of at-risk individuals.
The greater independence of young people 
attending colleges and the tendency to 
increased alcohol and drug use in this age 
group make colleges an important setting 
for harm reduction and for referral of those 
developing problems to specialist services.
Response options
Drug use among school populations is generally low and can be part of a wider 
pattern of behavioural problems and risk-taking. Interventions therefore need to 
address the wider determinants of risky and impulsive behaviour rather than the 
drug use in isolation.
Most prevention interventions in schools aim at having an impact on the whole 
student body and staff. Those that are supported by current evidence include:
  evidence-based universal prevention programmes that focus on developing 
social competences and refusal skills, healthy decision-making skills, and 
correcting normative misperceptions about drug use;
  school policies around substance use; and
  interventions aimed at developing a protective and nurturing educational 
environment that is conducive to learning and establishes clear rules about 
substance use.
Other approaches that may be beneficial include events or interventions 
involving parents and the use of peer-to-peer approaches.
European picture
Of the interventions for which there is good evidence of effectiveness, smoking 
bans in schools are reported in all countries providing information, while 
21 countries reported that school policies around substance use are in place in 
the majority of schools. Programmes aimed at developing personal and social 
skills are less widely implemented, with only 11 countries reporting them in the 
majority of schools. This is lower than the level of provision of information only 
programmes, which have not been found to be effective, but are reported in the 
majority of schools in 16 countries.
Some evidence exists in support of other types of programmes. Among these, 
peer-to-peer programmes seem to be relatively uncommon, but creative 
extracurricular activities and events for parents are more widely available. Drug 
testing of pupils is not recommended and is rarely used; it was only reported as 
being conducted in a few schools in 10 countries.
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| Drug use issues for schools and colleges
Adolescence and young adulthood are periods in life 
associated with risk-taking and experimentation with new 
experiences, including substance use. Schools and colleges 
are important settings for reaching the general population 
of young people. They may also provide opportunities for 
identifying and intervening with at-risk individuals, such as 
young people with vulnerable personality traits (such as 
poor impulse control), poor school attenders and frequent 
truants, who are at increased risk of developing problematic 
forms of substance use. Interventions for vulnerable young 
people are discussed in section 3.4.
In schools the main focus will be on preventing or delaying 
the initiation of substance use and on the development of 
personal and social skills to support healthy socialisation 
and decision-making more generally. In colleges harm 
reduction will also be an important component as young 
people transition to greater independence and may engage 
in frequent partying and believe increased alcohol use to be 
the norm.
| Response options
Drug use in school populations is generally low and can 
be part of a wider pattern of behavioural problems and 
risk-taking. Action to reduce it therefore needs to address 
the determinants of these general behaviours rather than 
the drug use in isolation. Similarly, education systems are 
more likely to support prevention programmes, policies and 
interventions if, in addition to reducing substance use, they 
reduce violence and bullying, improve learning, academic 
achievements and create a better school climate.
Substance use prevention is often carried out in schools 
because schools provide unique access to young 
people during a critical development phase. Prevention 
interventions typically aim at having an impact on the whole 
student body and staff. They may include evidence-based 
universal prevention programmes that focus on developing 
social competences and refusal skill, healthy decision-
making skills and correcting normative misperceptions 
about drug use. Examples are Unplugged, a programme 
that focuses on the development of life skills and the 
correction of normative beliefs, which has been positively 
evaluated in several European countries, and Rebound, 
which was developed in Germany and has also been 
tested in the United Kingdom. Having in place school 
policies around substance use is important to support such 
programmes. Interventions aimed at developing a positive 
school climate that is conducive to learning and establishes 
clear rules about substance use can have a positive impact. 
Evidence-based programmes are available that do not 
explicitly address substance use, but focus on general 
behaviour, and have been shown to have positive effects 
on impulse control and the learning and classroom climate, 
with potential longer-term impacts on substance use and 
mental health. These may be particularly appropriate in 
primary schools. Examples are the Good Behaviour Game 
and Nina e Nino.
Other approaches, for which the evidence is more mixed, 
include events or activities involving parents, providing 
creative extracurricular activities for pupils and the use of 
peer to peer approaches in school-based programmes.
In colleges, where heavy alcohol use and drug use 
may be viewed as normal or an important part of the 
student experience, the prevention focus tends to 
be on challenging these norms. These approaches 
are used quite extensively in the United States, and 
evaluations have shown some impact on harmful drinking 
behaviours although these tend to be small. Social 
norms interventions are based on the premise that 
incorrect perceptions of high rates of peer substance use 
are linked to increased personal use. A cross-national 
research project (SNIPE, Social norms intervention for 
the prevention of polydrug use) investigated if this was 
the case in seven European countries. It found that such 
misperceptions of use existed in regard to use of a range 
of drugs (cannabis, cocaine, ecstasy, amphetamines, 
hallucinogens, synthetic cannabinoids and inhalants) 
as well as nonmedical prescription stimulants use (i.e. 
Ritalin used because it is perceived to enhance academic 
performance). Norms-based programmes are now being 
developed and trialled in Europe.
Although rare, drug testing in schools is practiced in some 
European countries. The assumption that drug testing 
acts as a deterrent to substance use is not supported by 
the evidence. Testing can be either random or targeted. 
Random testing can be viewed as a universal intervention, 
since it aims to create a climate of deterrence on the whole 
student body. Targeted drug testing involves testing only 
individuals whose behaviour raises reasonable suspicion 
for drug use. The evidence that random drug testing 
changes behaviour is weak, even in the United States, 
where it is more extensively used. There is some evidence 
that it may increase illicit drug use or risks associated with 
substance use. Hence it is not currently recommended. 
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The invasiveness of the procedure and limitations to the 
information derived from drug testing all affect its utility.
If drug testing is to be used, further studies should be 
undertaken to guide best practices with adolescents. In 
particular it will be important to identify which procedures 
used to follow up on the results of testing are most 
effective in helping students who test positive. The research 
literature indicates that such infractions are better handled 
by further assessments and providing or referring the 
students to counselling, treatment or other health care and 
psychosocial services rather than punishing or expelling the 
students.
|  What is being done in Europe to respond to drug use in schools and colleges
The range of school-based interventions to prevent 
substance use that are implemented in European 
countries varies both in terms of the supporting evidence 
and in level of provision (Figure 4.3). Expert assessments 
of level of provision in each country of 13 types of 
intervention indicate that, of the measures with good 
evidence of effectiveness, smoking bans in schools are 
fully implemented in all 29 countries providing an answer. 
School policies around substance use are implemented at 
full or extensive level in 21 countries. Programmes aimed 
at developing personal and social skills are less widely 
available — only 11 countries reported full or extensive 
provision. In contrast, a considerable number of countries 
report full or extensive provision of interventions for which 
the evidence is unclear. Sixteen countries report this 
level of provision for information-only programmes and 
9 report it for visits of law enforcement officers. It should 
be noted that the exact nature of what is provided within 
each category of intervention can vary widely between 
countries.
With respect to other types of programmes for which there 
is some evidence, peer to peer programmes seem to be 
relatively uncommon. Creative extracurricular activities 
and events for parents are more common, with 18 and 12 
countries respectively reporting full or extensive provision 
and 8 in each case reporting limited provision.
Drug testing of pupils, which is not recommended, is 
reported as rare by 10 countries, 16 said there was no 
provision, while the remaining four countries did not provide 
information.
Early-detection and intervention approaches are used in 
some schools, often based on the provision of counselling 
to young substance users. A Canadian programme 
(Preventure) that targets young sensation-seeking drinkers 
has been positively evaluated and adapted for use in the 
Czech Republic, the Netherlands and the United Kingdom. 
Interventions for specific vulnerable groups are discussed in 
more detail in section 3.4.
Norm-based approaches are being developed for use in 
colleges in Europe, including a web-based intervention 
being trialled in Germany (INSIST). However, there is no 
information on the extent of provision of drug-related 
interventions in colleges currently.
Overview of the evidence on … interventions in schools and colleges
Effective school-based prevention programmes can delay initiation of use. These are manual-based and 
develop social competences and refusal skills, healthy decision-making and coping, and correct normative 
misperceptions about drug use. Ideally they should be provided within the context of a school drug policy.
Substance use-related problems may be reduced by providing a protective and nurturing educational 
environment that is conducive to learning and establishes clear rules about substance use.
There are evidence-based programmes for primary schools, which — without explicitly addressing 
substances — have effects on impulse-control and, therefore, potentially on later substance use and 
mental health problems. They have immediate effects on learning and classroom climate.
Interventions that only provide information about the risks of drug use have not been found to be effective 
in preventing drug use.
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FIGURE 4.3
School-based interventions to prevent substance use in Europe: provision and evidence of effectiveness
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NB: countries are the 28 EU Member States, Norway and Turkey. Availability: Full, provided in nearly all schools; extensive, provided in the majority but not 
nearly all schools; limited, provided in more than a few but not the majority of schools; rare, provided in only in a few schools.
Responses in schools and colleges: implications for policy and practice
Basics
  Schools are important access points to the adolescent population and their parents. They also have a role in identifying 
at-risk individuals for targeted interventions.
  Education systems should ensure schools provide evidence-based prevention programmes and have appropriate drug 
policies in place. These should aim not only to reduce substance use, but also to reduce violence, improve learning, 
produce better academic achievements and create a better school climate, outcomes that are of intrinsic interest to the 
education sector.
  Ineffective prevention programmes are often popular, but there is a growing number of programmes that have been 
shown to work and these should be used instead.
Opportunities
  Establishing systems that encourage or require schools and colleges to use programmes supported by evidence instead 
of ineffective programmes and providing the necessary support for this would be a more efficient use of resources.
Gaps
  The evidence for effective programmes in colleges is very limited, but this is a period of high risk of drug use and 
appropriate programmes are needed for this setting.
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Further resources
EMCDDA
  Best practice portal.
  Xchange registry.
  Prevention of addictive behaviours. Insights, 2015
  Prevention profiles.
Other sources
  UNESCO, UNODC and WHO (2017), Education sector responses to the use of alcohol, tobacco and drugs. Paris: 
United Nations Educational, Scientific and Cultural Organization.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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SUMMARY
Issues
In this section community is used 
to mean a group of individuals 
sharing a common geographical 
and administrative setting.
Local communities are important 
to drug responses in providing 
a way of promoting bottom-up 
civic engagement and action. In 
Europe, municipalities and local 
governments are often the main 
drivers of strategy development and 
delivery.
Communities may be involved in 
drug responses in different ways:
  as a setting for interventions (as 
opposed to in schools or services, 
for example);
  responses may specifically 
target drug-related harms that 
communities experience; and
  through community involvement 
in interventions addressing drug 
problems.
Response options
  The development of community plans to co-ordinate activities according to local needs;
  community-based outreach provides services for individuals and groups who are not 
effectively reached by fixed-site services or traditional health promotion channels;
  diversionary activities for young people in the community seek to reduce vulnerable young 
people’s involvement in drug use and gangs by providing positive activities that build self-
esteem and life skills;
  programmes to address drug-related harms experienced by the community, for example, 
clean-up schemes picking up needles and other drug paraphernalia and drug consumption 
rooms; and
  community intervention approaches, such as community coalitions and Communities that 
Care programmes.
The way in which communities are defined varies between countries in Europe, as do approaches 
to community engagement.
European picture
Prevention approaches that target high-risk neighbourhoods have been implemented in some 
countries, utilising new methods, including the redesigning of urban spaces. Provision for these 
types of interventions is reported to be highest in the north and west of Europe. Approaches that 
have good evidence of effectiveness (normative and environmental) are implemented in just over 
a quarter of countries.
The Communities that Care (CTC) programme is being used in Germany, the Netherlands, Croatia 
and the United Kingdom. In addition Belgium is conducting a study on the use of CTC for crime 
prevention.
Systematic collection of information on community interventions is limited. The variety of different 
types of interventions, their implementation at a local level, and the fact that they often overlap 
with broader public health and crime prevention activities makes monitoring these interventions 
difficult.
Sharing of best practice may occur through networks, which may also have a broader focus, or be 
specific to a type of intervention. Mapping these networks and obtaining a clearer understanding 
of the different approaches being taken within Europe to the different types on intervention within 
communities can be a useful starting point for developing best practice sharing and monitoring of 
provision.
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| Drug use issues for communities
The meaning of ‘community’ varies between European 
countries. In some cases communities may be defined by 
geographical boundaries, either informally as in the case 
of neighbourhoods or more formally by municipal or local 
government boundaries. In other cases they might be 
defined by ethnic, linguistic or cultural commonalities.
However defined, communities experience a range of 
harms associated with drug use, for example, problems 
associated with open drug scenes in their neighbourhood. 
They can also be important in addressing drug problems 
by promoting bottom-up civic engagement and action. 
Municipalities and local governments are often the main 
drivers and stakeholders of strategy development and 
delivery of interventions.
In this section community is understood to mean a 
group of individuals sharing a common geographical and 
administrative setting. Interventions within a community do 
not necessarily address all of the community concerned, 
but may involve several key actors (for example, family 
groups or associations, health services, schools and sport 
facilities).
Involvement of communities in drug responses can be 
manifest in different ways:
  communities as a setting for interventions, for example, 
through outreach services;
  responses to the drug-related harms that communities 
experience, such as drug-related disorder and crime; and
  community involvement in support of responses to drug 
problems — these may address community-level harms 
but can also address harms to individuals.
| Response options
Communities as a setting for interventions
Community-based outreach services can be a flexible and 
effective component of local harm reduction and prevention 
strategies. In general these aim to improve health by 
reducing risks and harms for individuals and groups 
who are not effectively reached by fixed-site services or 
through traditional health education channels. Outreach 
workers generally make contact and establish rapport with 
target populations and gain acceptance as trusted and 
knowledgeable sources of information and advice. These 
services vary greatly and may be led by social workers or 
trained peers. The target groups can range from young 
people, in street or party settings to high-risk drug users 
and sex workers. Peer-driven interventions need to be 
particularly well-supported by good management practices. 
Issues of confidentiality, defining and respecting boundaries 
and protecting the health and safety of staff members are 
important considerations for services working in this area. 
This is helped by establishing clear guidelines covering 
objectives, services offered, responsibilities and the need 
to recognise and respect personal, professional and legal 
boundaries.
Positive youth development interventions or diversionary 
activities for young people in the community, such as 
those provided by Positive Futures organisations in the 
United Kingdom or the annual ‘adventure weeks’ provided 
in Luxembourg, provide a range of activities (such as 
rock climbing, sports, music or creative activities and 
volunteering) that build skills, new friendships and self-
esteem. They aim to enhance protective factors and reduce 
risk factors and provide alternatives to substance use, crime 
and gang involvement for vulnerable young people.
Responses to harms experienced by communities
The Drug Related Intimidation Reporting Programme in 
Ireland is an example of initiatives to address community 
harms. The programme is a collaboration between the 
police service and the National Family Support Network, 
and it supports people in the community suffering 
intimidation due to drug debts. In other countries telephone 
lines with associated media campaigns may allow 
anonymous reporting of drug dealing in neighbourhoods.
Drug consumption rooms, sometimes known as supervised 
injecting facilities, can also have benefits for communities 
as well as for people who inject drugs (see also Spotlight on 
drug consumption rooms, page 156). There is evidence that 
they are effective at reducing harms to the local community, 
for example, from drug litter and public nuisance, as well 
as reducing the risks of overdose and infection among 
individuals who inject drugs. However, there is often 
community resistance to the establishment of these 
services so community engagement is important if they are 
to be successful.
Other harm reduction services can also provide direct 
benefits to communities in addition to their primary goals, 
for example, needle exchanges may reduce drug litter. 
Some may also engage in proactive programmes, such as 
organising action days to clean up parks or areas where 
drug litter is posing a problem in local neighbourhoods.
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Spotlight on … Drug consumption rooms
What are drug consumption rooms?
Drug consumption rooms, sometimes known as supervised injecting facilities, are places in which drug users can use 
illicit drugs under the supervision of medically trained staff. They exist in several European countries and are usually 
located in areas where there is an open drug scene and injecting in public places is common. Their primary goal is to 
reduce morbidity and mortality by providing a safer environment for drug use and training clients in safer forms of drug 
use.
What problems do they address?
Drug consumption rooms were originally developed as a public health response to the rapid spread of HIV/AIDS among 
injecting drug users in the 1980s. Their aims were to reduce the risks of unhygienic injecting, prevent fatal overdoses and 
link drug users with treatment, health and social services. Their establishment was often opposed because of community 
fears that they would encourage drug use, delay treatment and aggravate open drug scenes. However, there is increasing 
awareness of their potential to reduce harms to communities associated with public drug injecting, such as drug litter.
What is known about their effectiveness?
There is growing moderate quality evidence that drug consumption rooms are able to attract hard-to-reach drug users, 
especially marginalised ones who inject drugs on the streets, under risky and unhygienic conditions. There is also 
moderate quality evidence that drug consumption rooms increase safer injecting and may reduce the transmission of 
blood-borne infections and the occurrence of overdoses near services. There is similar evidence that they reduce the 
public visibility of illicit drug use and drug litter, thereby improving public amenity around urban drug markets.
Drug consumption rooms in Europe
There have been drug consumption rooms operating in Europe since 1986, when the first one was established in Berne, 
Switzerland. As of 2016, 90 of these facilities were operating in six EU countries, Norway and Switzerland. In 2016, two 
opened in France, new facilities were established in Denmark and Norway, and other countries are in the process of 
passing legislation to permit drug consumption rooms to operate.
Looking to the future
Drug consumption rooms were originally established to reduce the harms associated with public injecting of opioids, 
but in some cases they are also used by people injecting other substances. As rates of injecting in some countries 
decrease, consideration has been given to using drug consumption rooms to reduce harms associated with other routes 
of administration (e.g. smoking) or other substances (e.g. cocaine and methamphetamine). This implies some changes 
in the aims of this response, and research and evaluation will be necessary to assess the effectiveness of this approach 
with non-injecting populations. More generally as the number of drug consumption rooms expands, it is important 
that they are evaluated to improve the evidence on the extent to which they reduce individual harms and harms to the 
community.
See Drug consumption rooms: an overview of provision and evidence.
Community engagement
Community coalitions co-ordinate activities and resources 
to prevent adolescent substance use and delinquent 
behaviour. They can bring together diverse community 
stakeholders to address a common goal and mobilise 
communities to participate in prevention and health 
promotion initiatives.
The Communities That Care (CTC) approach is based on 
the premise that the prevalence of adolescent health and 
behaviour problems in a community can be reduced by 
identifying strong risk factors and weak protective factors 
among young people within that community. This then 
allows the selection of tested and effective prevention and 
early intervention programmes to address these specific 
risk and protective factors.
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Although studies on the effectiveness of this approach have 
been conducted mainly in the United States, experience 
of implementation in Europe is now emerging. Preliminary 
evaluations point to a need to adapt the organisation of the 
programme. For example, professional coalitions seem to 
be more appropriate than volunteer-dominated coalitions 
in Europe, as school systems are more usually organised 
at the national or state level, with less local community 
involvement compared with the United States. Evaluation 
research needs to consider the adaptation process and 
programme fidelity. The impact of different implementation 
contexts needs to be assessed systematically across 
multiple sites and countries in order to improve the quality 
of future implementations.
Community drug plans are an important mechanism for 
translating national strategies into appropriate responses 
to meet local needs. The level at which these are developed 
will vary between countries, depending on administrative 
structures and responsibilities. Involving people who use 
drugs and local communities in consultation processes 
ensures that plans are better informed by the local 
situation. It also can help reduce stigma towards drug users 
and promote understanding between different community 
members.
|  What is being done in Europe to respond to drug problems in communities
Prevention approaches that target high-risk neighbourhoods 
have been implemented in some countries, utilising new 
methods, including the redesigning of urban spaces. 
Provision for these types of interventions is reported to be 
highest in the north and west of Europe (see Figure 4.4). 
Approaches that have good evidence of effectiveness 
(normative and environmental) are implemented in just over 
a quarter of countries.
The Communities that Care programme is one example of 
a neighbourhood-focused prevention approach. Currently 
examples of use of this model exist in Croatia, Germany, 
the Netherlands and the United Kingdom. In addition, 
Belgium is conducting a study on the use of this approach 
for crime prevention.
However, systematic collection of information on community 
interventions is limited. The variety of different types of 
interventions described above and the fact that they are, by 
their nature, often driven and implemented at a local level 
makes monitoring these interventions difficult. In addition, 
many of the community activities may take place or overlap 
FIGURE 4.4
Interventions in high-risk neighbourhoods: evidence of effectiveness and provision in European countries, 2015
Intervention Number of countries
approach 
Provision
11
4
11
8
8
8
Good evidence
Normative
Environmental
Some evidence
Incentivisation
Training
Education
No evidence
Information
No data
Not available
Limited/rare
Full/extensive
NB: Level of provision information provided here is based on the opinion of an expert (or panel of experts) in each country. Availability: Full/extensive, 
provided in nearly all or a majority of relevant locations; Limited/rare, provided in a few or more but less than a majority of relevant locations; Not available, 
no provision in the country.
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with broader public health and crime prevention activities. 
Sharing of best practice may occur through networks, which 
may also have a broader focus, or be specific to a type of 
intervention, or cover different geographical areas. Some 
examples are Communities that Care EU, the International 
Network of Drug Consumption Rooms, and Club 
Health. Mapping these networks and obtaining a clearer 
understanding of the different approaches being taken 
within Europe to the different types of intervention within 
communities can be a useful starting point for developing 
best practice sharing and monitoring of provision.
Responding within communities: implications for policy and practice
Basics
Drug interventions in the community include:
  Drug policies and interventions addressing nuisance and harms experienced by communities.
  Community engagement in service provision, such as multi-component drug prevention programmes.
  Outreach services for people not engaged with services.
Opportunities
  Community engagement can reduce stigma towards drug users and hence facilitate the provision of services.
  In some areas the provision of drug consumption rooms or other measures might be considered to reduce nuisance 
from open drug scenes.
Gaps
  Information on the extent and nature of services to tackle the harms experienced by communities and their impact is 
limited.
  There is very little evidence for effectiveness of community interventions, therefore research in this area will be 
important.
Further resources
EMCDDA
  Communities That Care (CTC): a comprehensive prevention approach for communities, EMCDDA paper, 2017.
  Drug consumption rooms: an overview of provision and evidence, Perspectives on drugs, 2017
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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Implementation
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 CHAPTER 5
Supporting successful 
implementation
SUMMARY
Regardless of the evidence that exists to support the 
use of any response option, it is unlikely to be effective 
if it is implemented poorly. This chapter highlights a 
number of activities that may help to support successful 
implementation in three broad domains.
Evidence into practice
These activities focus on ensuring the quality of the services 
delivered and the use of evidence-based interventions, 
including:
  the transfer of programmes to different cultural contexts;
  the use of quality standards and guidelines; and
  sharing best practice.
Systems and partnerships
Activities in this domain promote effective delivery by 
considering the people and organisations involved. This 
includes:
  training and staff development;
  service-user and community involvement;
  promoting links between services and multiagency 
working; and
  taking a systems approach to programme delivery.
Monitoring and evaluation
Monitoring and evaluation are necessary to underpin 
effective implementation. These activities promote learning 
from experience, as well as supporting system-level planning 
and knowledge transfer. The topics covered include:
  the different roles of monitoring and evaluation;
  monitoring of health and social responses in Europe;
  current practice in Europe and priorities for development; 
and
  evaluation to understand the full impact of drug-related 
responses.
This chapter focuses on the implementation of responses, 
as this is a key, but often neglected area. Regardless of the 
evidence that exists to support the use of any response 
option, it is unlikely to be effective if it is implemented 
poorly. The successful implementation of any intervention 
can be complex and will be dependent on interactions 
between a wide array of factors. As it is not possible in this 
guide to review in detail all issues relevant to delivering 
responses to drug problems, the approach adopted is to 
provide an overview of three key activity areas that need to 
be considered to support the delivery of evidence-based 
interventions. These are:
Evidence into practice: Activities here aim to ensure quality 
while configuring programmes to local needs. This includes 
activities that focus on what is delivered, and which support 
the use of evidence-based interventions; translation of 
programmes to different cultural contexts; the use of quality 
standards and guidelines; and sharing best practice.
Developing effective systems and partnerships: Activities 
in this domain promote effective delivery by considering the 
people and organisations involved. This includes training 
and staff development, user and community involvement; 
promoting links between services and multiagency working; 
and taking a systems approach to programme delivery.
Monitoring and evaluation: These activities are a necessary 
underpinning to effective implementation of responses to 
drug problems. They promote learning from experience as 
well as supporting system level planning and knowledge 
transfer.
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5.1 Evidence into practice
To support the implementation process, systems are 
needed to assist the integration of scientific evidence 
with relevant policy and practice. Increasingly in recent 
years, a consensus has emerged that this is best achieved 
through proactive and ongoing dialogue and partnerships 
(‘knowledge exchange’) between researchers, policymakers 
and practitioners.
As in other fields, research findings can be poorly translated 
into drug policy and practice. This can mean that there 
is a gap between the evidence on what are effective 
interventions and the programmes that are actually 
delivered. There are many possible reasons for this. For 
example, it could simply be because the selection of 
programmes has not been based on an evidence review. 
However, new evidence also may emerge that challenges 
historical delivery models, or new problems may develop 
that require new approaches. This means that ongoing 
needs assessment and research and monitoring are needed 
if services are to remain fit for purpose (see section 5.3). It 
is also important to remember that programmes that have 
been shown to be effective in one setting or country will not 
necessarily be directly transferable into a different context 
or culture. Often, to ensure successful implementation, 
a process of translation and testing is necessary that will 
require both time and resources.
A number of tools are being developed to support 
implementation as well as the use of evidence in decision-
making in a range of contexts. The Consolidated Framework 
for Implementation Research, for example, provides a 
comprehensive conceptual framework for thinking about and 
studying the implementation process. It is based around five 
major domains: intervention characteristics, outer setting, 
inner setting, characteristics of the individuals involved, 
and the process of implementation. Within these domains, 
constructs are identified that reflect the evidence on factors 
most likely to influence implementation of interventions. 
The importance of these depends on the stage of 
implementation, from initial adoption and implementation to 
sustaining an established programme or intervention.
Another example, DECIDE (Developing and Evaluating 
Communication strategies to support Informed Decisions 
and practice based on Evidence), was a project funded by the 
European Union, which categorised the dimensions that are 
important for decision-making in health-related interventions. 
It developed tools to help people make decisions about 
health care provision, such as clinical guidelines, decisions 
on intervention coverage, and public health decisions, 
through consideration of the evidence available and the local 
context. The issues to be considered include, for example, 
the setting where the intervention is to be delivered and the 
target population, the potential for undesirable effects, local 
values and implementation considerations, and the strength 
of the available evidence. Ideally a panel of experts and 
representatives from carers, patients and families weighs all 
these factors together through a structured and transparent 
process in order to make a decision on which programmes 
are appropriate for the local context and to specify how they 
should be implemented (see Figure 5.1).
The development of research-based guidelines and quality 
standards (see below) is an essential part of the process of 
getting evidence into practice. Another important element 
is developing a culture that supports and encourages the 
sharing of best practice. The EMCDDA is involved in a 
number of such activities which can be accessed through 
the Best practice portal.
| Transfer of programmes and interventions
Considerable research now exists on implementation 
science and technology transfer in the health and social 
care fields. This provides valuable insights into how 
interventions can be adapted to work in other contexts, 
along with practical hints on how to make them appropriate 
to new target populations.
Central to successful programme transfer from one culture 
to another is establishing how many adaptive changes can 
be made to the programme’s core idea without it losing its 
effectiveness. This is important because the complexity of an 
intervention can hinder its successful transfer. For example, 
some programmes developed in North America require 
the use of elaborate manuals, training systems, technical 
support, supervision and the cooperation of community 
and other stakeholders in ways that may specifically reflect 
the prevailing organisation and delivery of health and social 
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care in the North American context. Such interventions will 
often need to be adapted by adjusting wording, images 
and examples to reflect norms, values and practices 
within European settings. Adaptation to context requires 
knowledge of organisational, and sometimes also political 
and service delivery infrastructures. It is best achieved 
by actively involving key stakeholders in the planning and 
adaptation process. Focus groups and other qualitative 
research methods involving the target populations and other 
stakeholders have been found to be useful tools for adapting 
programmes to local needs and context. Examples of some 
evidence-based prevention programmes that have been 
transferred into different European settings and the lessons 
learned in the process can be found in the Xchange registry 
on the EMCDDA website.
| Quality standards and guidelines
Once an intervention has been implemented successfully, 
the focus should move to maintaining quality. The use of 
quality standards and guidelines can play an important role 
in this area and can provide a benchmark against which to 
monitor services or assist in the setting of these.
Quality standards are principles and rules set by 
recognised national or international bodies about what to do 
and what to aim for. Typically the standards proposed in the 
health field provide clear and aspirational, yet measurable, 
statements related to content, processes, or structural 
aspects of quality assurance, such as environment and 
staffing composition.
Guidelines are used to encourage the use of evidence-
based interventions by providing practice recommendations 
that are based on appraisal, synthesis and grading of 
the available evidence. Evidence-based guidelines are 
generally produced by multidisciplinary groups of experts 
who systematically assess the quality of the evidence and 
agree on practical recommendations and timely updates. 
Tools such as the Appraisal of Guidelines, Research and 
Evaluation (AGREE) have also been developed to assess 
the methodological quality of guideline development. 
Guidelines typically outline a plan of expected activity 
(which may be mandatory in some countries). They provide 
a guide to recommended practice, and may operate 
alongside quality standards, providing a benchmark against 
which to evaluate the quality of the services being delivered. 
It is important that those developing and using guidelines 
consider their relevance to potentially diverse target 
audiences and populations.
A number of standards and guidelines have been 
highlighted in the relevant sections of this guide. In 2015, 
the ministers of the Member States in the Council of the 
European Union endorsed council conclusions that set out 
16 minimum quality standards in drug demand reduction in 
the European Union (see Spotlight on European minimum 
quality standards for demand reduction, page 164), 
and countries have been encouraged to integrate them 
into their drug policies and programmes. The European 
quality standards are a set of aspirational statements 
for prevention, treatment, harm reduction and social 
reintegration. These standards link intervention quality 
to concrete measures that include appropriate staff 
FIGURE 5.1
Using the DECIDE framework for evidence-based decision-making
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More information on the DECIDE project is available at http://www.decide-collaboration.eu.
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training and provision of evidence-based interventions. 
They highlight the need for the participation of all the 
stakeholders, including civil society, in the implementation 
and evaluation of interventions. In addition they include 
key principles for demand reduction interventions, such as 
adhering to ethical principles and respecting human rights, 
which have been highlighted in Chapter 1 of this guide. The 
importance of adapting evidence-based standards to local 
conditions and systems is also stressed.
Quality standards exist in most European countries and can 
be used in different ways. In some countries, the standards 
are linked to service delivery and used to evaluate its 
provision. They are also being used as a requirement for 
participation in competitions for service contracts and as 
instruments for service-level self-assessment. The EMCDDA 
Best practice portal hosts an inventory of European and 
international standards and guidelines. In addition, the 
European Drug Prevention Quality Standards (EDPQS) 
project has produced a toolkit containing materials for 
people who need to provide training on the use and 
implementation of quality standards in drug prevention.
Online e-health support tools may also have a role in 
ensuring adherence to good practice, for example, by 
supporting prescribing according to protocols, enhancing 
case management, or promoting access to evidence and 
best practice (see Spotlight on e-health, page 119).
| Sharing best practice
The sharing of best practice may occur through a wide 
range of channels and mechanisms. For example, 
programme evaluations may be published in scientific 
journals and practice-related articles in the national 
trade press. Increasingly, online portals and tools are 
being developed to provide widely accessible overviews 
and syntheses of best practice. Also available online 
are clinical decision support tools that provide access 
to relevant evidence in clinical situations. While many 
approaches require the user to search and find what is of 
interest on their own initiative, some interventions, such 
as Drug and Alcohol Findings in the United Kingdom, also 
take a proactive or push approach and send out regular 
emails with evidence summaries and policy and practice 
implications. Training initiatives, both online and face to 
face, also offer a fruitful way of sharing expertise and 
experience.
The Best practice portal on the EMCDDA website provides 
an example of the online tools for accessing information 
on evidence-based approaches to tackling drug problems. 
In addition to providing synopses of current evidence 
with links to the supporting studies and the inventory of 
standards and guidelines mentioned above, it now includes 
two wider European initiatives in the prevention field: 
the Healthy Nightlife Toolkit and the Xchange registry of 
evidence-based prevention programmes that have been 
used in Europe.
Sharing best practices requires the existence of a learning 
culture in which processes and outcomes are monitored 
and compared with expected outcomes. Lessons learnt 
are then shared and discussed and changes made where 
appropriate. Ongoing training is also likely to be important to 
this process.
Spotlight on … European minimum quality standards for demand reduction
The EU minimum quality standards in drug demand reduction, cover prevention, risk and harm reduction, treatment and 
rehabilitation and aim to support a focus on quality in drug demand reduction interventions in the European Union.
I. Prevention
a. Prevention (environmental, universal, selective and indicated) interventions are targeted at the general population, at 
populations at risk of developing a substance use problem or at populations/individuals with an identified problem. They 
can be aimed at preventing, delaying or reducing drug use, its escalation and/or its negative consequences in the general 
population and/or subpopulations; and are based on an assessment of and tailored to the needs of the target population;
b. Those developing prevention interventions have competencies and expertise on prevention principles, theories and 
practice, and are trained and/or specialised professionals who have the support of public institutions (education, health 
and social services) or work for accredited or recognised institutions or NGOs;
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c. Those implementing prevention interventions have access to and rely on available evidence-based programmes and/
or quality criteria available at local, national and international levels;
d. Prevention interventions form part of a coherent long-term prevention plan, are appropriately monitored on an 
ongoing basis allowing for necessary adjustments, are evaluated and the results disseminated so as to learn from new 
experiences.
II. Risk and harm reduction
a. Risk and harm reduction measures, including but not limited to measures relating to infectious diseases and drug-
related deaths, are realistic in their goals, are widely accessible, and are tailored to the needs of the target populations;
b. Appropriate interventions, information and referral are offered according to the characteristics and needs of the 
service users, irrespective of their treatment status;
c. Interventions are available to all in need, including in higher risk situations and settings;
d. Interventions are based on available scientific evidence and experience and provided by qualified and/or trained 
staff (including volunteers), who engage in continuing professional development.
III. Treatment, social integration and rehabilitation
a. Appropriate evidence-based treatment is tailored to the characteristics and needs of service users and is respectful 
of the individual’s dignity, responsibility and preparedness to change;
b. Access to treatment is available to all in need upon request, and not restricted by personal or social characteristics 
and circumstances or the lack of financial resources of service users. Treatment is provided in a reasonable time and in 
the context of continuity of care;
c. In treatment and social integration interventions, goals are set on a step-by-step basis and periodically reviewed, and 
possible relapses are appropriately managed;
d. Treatment and social integration interventions and services are based on informed consent, are patient-oriented, and 
support patients’ empowerment;
e. Treatment is provided by qualified specialists and trained staff who engage in continuing professional development;
f. Treatment interventions and services are integrated within a continuum of care to include, where appropriate, social 
support services (education, housing, vocational training, welfare) aimed at the social integration of the person;
g. Treatment services provide voluntary testing for blood-borne infectious diseases, counselling against risky 
behaviours and assistance to manage illness;
h. Treatment services are monitored and activities and outcomes are subject to regular internal and/or external 
evaluation.
Source: Council of the European Union (2015), Council conclusions on the implementation of the EU Action Plan on Drugs 2013–2016 regarding 
minimum quality standards in drug demand reduction in the European Union.
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5.2  Developing effective 
systems and partnerships
| Training and staff development
Staff skills and competencies are essential for the delivery 
of interventions and are a key part of effective systems. 
Both initial and ongoing staff training will be central to 
developing and maintaining these. Training needs to 
encompass basic skills and knowledge, as well as training 
in specific interventions. Training aimed at developing 
competencies in interpreting evidence will help people to 
keep up to date with emerging evidence and programmes. 
The Universal Prevention Curriculum in Europe project 
(UPC-ADAPT), the aim of which is to adapt the Universal 
Prevention Curriculum to the European context, is one 
example (see box).
Training for intervention providers is available in many 
European countries. It ranges from specialist university 
programmes that exist in Germany and in the Czech 
Republic for example, to specific courses offered as part 
of health or social welfare university curricula in many 
countries. Often some type of vocational training is offered 
for those working in prevention and harm reduction 
services.
| Service user involvement/community engagement
The involvement of both those with drug problems, the target 
for the intervention, and the communities affected by the 
problem or hosting the intervention, is essential for the effective 
and efficient operation of services. In addition, involving service 
users can be a pragmatic and ethical way to ensure the quality 
and acceptability of services. Some support may be necessary 
to empower drug users to contribute in order to ensure that 
their involvement is both meaningful and successful.
Active involvement of drug users in shaping drug services 
in Europe has a long history with, for example, some early 
pioneering work early occurring in the Netherlands in the 
1970s. More recently, an increasing number of initiatives 
have been undertaken to facilitate the involvement of 
drug user organisations at national and European level. 
User involvement varies in form and can pursue a range 
of different aims. Activities may include service user 
surveys on accessibility and quality of services, seeking 
users’ advice on staff recruitment, conducting focus 
groups to develop new service areas and the inclusion of 
user organisations in health advocacy and policymaking 
(see Spotlight on user-led interventions, page 167).
The Universal Prevention Curriculum
The importance of staff competencies and training in delivering evidence-based prevention is highlighted in the 2015 
Council Conclusions that set out minimum quality standards in drug demand reduction. The Universal Prevention 
Curriculum (UPC) was designed to meet the demand for an evidence-based curriculum for substance use prevention 
professionals worldwide. The training aims to enhance the knowledge and skills of prevention professionals and 
enable them to develop and implement evidence-based substance use prevention interventions and policies. Use of 
a standardised curriculum will help to ensure that regionally- and nationally-based prevention professionals obtain 
consistent science-based information and skills training.
The Universal Prevention Curriculum in Europe project (UPC-ADAPT), which is financed by the European Commission, is 
being pilot-implemented in nine EU Member States (Belgium, Croatia, Czech Republic, Estonia, Germany, Italy, Poland, 
Slovenia and Spain) and will distil the original UPC curriculum into a shorter intense and interactive training module, and 
an extended academic module, and will also include online training. The aim is to create a standardised EU Prevention 
Curriculum, based on quality standards for staff training developed in the nine countries. The curriculum is built upon the 
International Standards on Drug Use Prevention, which was developed by the United Nations Office on Drugs and Crime, 
and the European Drug Prevention Quality Standards. Primary emphasis is on evidence-based interventions and policies 
and on implementation quality and sustainability.
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Spotlight on … User-led interventions
What are they?
User-led organisations carry out activities that are predominantly designed and delivered by, in this context, current 
or former drug users. The focus here is on one end of a spectrum of organisations with different levels of involvement 
of people with a history of drug problems. However, it can sometimes be difficult to distinguish between user-led 
organisations and other organisations that were founded by service users but which now have mainly paid staff, albeit 
with former drug users as a substantial proportion of the workforce.
What’s happening in Europe
Many European countries have seen a growth in the number and impact of user-led organisations. Most user-led 
activities can be divided into five broad, sometimes overlapping, categories:
1. Mutual aid (typically fellowships where current and ex-users support each other). For example, Narcotics 
Anonymous, SMART recovery and L’Isola di Arran.
2. Recovery enterprises. Recovery-focused networks may provide supportive accommodation, recovery cafes and 
social activities, social enterprises and employment schemes, and peer support.
3. Harm reduction (current or former users provide information and advice on how to use drugs safely). The work they 
do normally takes place in one of four ways: through providing training sessions; attending clubs or festivals to 
provide information and support; providing information and advice online; and drug checking to inform consumers 
of the content of the drugs they have obtained.
4. Advocacy (arguing for the rights or fair treatment of drug users), such as INPUD (the International Network of 
People who Use Drugs) and EuroNPUD, the European network, and more local groups such as Act Up Paris and the 
Swedish Drug User Union. Similar unions exist in Denmark, France and Portugal.
5. Research (conducting peer research projects). The use of peer researchers is recognised as being valuable for 
a number of reasons, including giving better access to hard-to-reach groups, improving research design and 
analysis by incorporating drug user perspectives, and helping people with drug problems develop skills and gain 
employment.
Key challenges for further development
  Stigmatising attitudes towards drug use and drug users is a major barrier to effective user-led organisations. Including 
these groups in official forums, working parties and so on can help to overcome this.
  Long-term engagement between statutory bodies, other agencies and user-led organisations is necessary to ensure 
that treatment and harm reduction services meet the needs of drug users.
  User-led groups need to be properly resourced if they are to develop and represent a large number of drug users with 
different views while remaining independent enough to critique service provision.
See the Background paper, User-led interventions: an expanding resource? and Drug policy advocacy organisations in Europe.
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Historically, drug user organisations have probably been 
most visible in the areas of peer support, delivering 
education on infectious disease prevention and other harm 
reduction activities, and awareness-raising and advocacy on 
behalf of drug users. More recently, in some countries, user-
led organisations have been involved in developing social 
enterprise initiatives. These generally provide employment 
and training to people who use drugs, during or after 
treatment, in order to assist their recovery and reintegration 
into society, and also provide ongoing support for those who 
have completed treatment.
The involvement of local communities is often important 
for successful service implementation. If communities are 
not engaged they may act as a barrier to service provision, 
for example, by campaigning against the establishment of 
treatment services in their area. On the other hand, their 
support can open up opportunities for social reintegration 
of people with a history of drug problems. Some aspects of 
community engagement are discussed in section 4.5.
Another area of community engagement is civil society 
involvement in drug policy. A study of information available 
online conducted for the EMCDDA in 2013 identified 
218 drug policy advocacy organisations in Europe. About 
70 % of these organisations were active in some way at a 
national level, with the rest split almost equally between 
the local or regional level, and European or international 
level. Their primary objectives were predominantly practice 
development, with 26 % advocating use reduction and 
39 % harm reduction. The organisations aimed to influence 
the attitudes and opinions of the public and policymakers 
on drug service provision, drug controls, or both and 
thereby improve the well-being of the individuals, groups or 
societies affected by drug use.
| Linking services: multiagency working
Many drug users present to services with a complex mix 
of drug, mental, physical and sexual health problems. 
Services, however, often specialise in dealing with one 
type of issue. As a result, individuals can find themselves 
having to engage with multiple agencies, none of whom 
have a holistic view of their problems, and the care provided 
may lack co-ordination and cohesion. Alternatively, those 
with multiple problems may be passed between services, 
with no agency taking responsibility for their care, as they 
consider that the individual’s primary problem is outside 
their area of responsibility. For example, vulnerable young 
people with drug problems may find themselves referred 
between childcare and social services, youth offending 
and youth mental health agencies. Similarly those with 
coexisting mental health and drug problems may sometimes 
not be regarded as meeting the admission criteria for 
either specialist drug treatment or specialist mental health 
care. Effective cooperation between services is therefore 
essential to meeting the complex health and social needs of 
many of those with drug problems. This can be facilitated by 
using joint assessment tools, establishing referral protocols 
and running joint training sessions. Effective mechanisms 
for linkage with drug services are needed in a wide range of 
service settings, in particular, housing providers and social 
services, childcare services, prisons, mental health, primary 
care and sexual health services.
As an example, there is growing awareness of the 
importance of sexual health services for those using drugs, 
as interactions may exist in risk behaviours and related 
problems. However, current treatment services for drug 
and sexual health problems operate separately, making 
it challenging to provide ‘joined up’ care for people who 
experience both types of problems (see Spotlight on 
addressing sexual health issues associated with drug use, 
page 72). 
Another area with similar issues is drug use and mental 
health services (see Spotlight on comorbid substance use 
and mental disorders, page 31). Rates of mental health 
problems are very high among people with drug problems, 
but it is well-established that they often find it hard to 
access the services that they need.
It may be appropriate to establish special multidisciplinary 
services in situations where there are groups of individuals 
with particular needs, a high prevalence of problems and 
who may be reluctant to engage with general services. 
Examples of this might be services for men who have sex 
with men involved in drug use and ‘chemsex’, or services 
for women involved in prostitution, or for homeless people 
living on the streets.
| Taking a systems approach
Rather than focusing solely on the delivery of individual 
interventions, taking a whole-system perspective can 
support cooperative approaches and multiagency 
working, and provide a number of benefits for researchers, 
practitioners, and policymakers. It can help ensure that 
synergies are maximised, resources are used efficiently and 
programmes delivered effectively. It also draws attention 
to the many different components in an effective response, 
prompts reflection on how they interact, and encourages 
planning and resource management for the system as a 
whole. Shifting the focus from individual programmes or 
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Spotlight on … Applying behavioural insights to drug policy and practice
Behavioural biases, such as short-sightedness or overconfidence (for example, thinking that ‘I will be able to stop 
when I want to’) are known to affect a person’s choices. This may lead them to act in ways that they might have been 
expected to avoid. Policymakers need to take account of these factors in the design of policies or interventions.
What are behavioural insights?
Behavioural insights use the information that comes from research into how people actually behave, rather than how 
they might be expected to behave if they always acted completely rationally, to design more effective interventions.
Contributions from various disciplines, such as behavioural economics, social and cognitive psychology, neuroscience 
and sociology, are integrated to provide a better understanding of actual human behaviour and, consequently, socio-
economic phenomena. The insights gained are then used to help develop more effective policies and interventions, 
which are based on sound experimental methods.
Behavioural insights can contribute to improving drug policy by offering new tools to influence behaviour, by improving 
predictions about the effects of existing policies, and by generating new policy perspectives.
How can they be applied?
Behavioural biases vary between individuals and groups and between different behaviours. One of the key lessons 
from behavioural sciences is that one-size-fits-all solutions do not work. In other words, behavioural interventions 
should be as targeted and as tailored as possible: they should be designed specifically for the target group and for the 
particular behaviour that is to be encouraged or discouraged.
Behavioural insights have been used in a variety of successful interventions. Examples include the use of tailored, 
individual and real-time feedback on the use, motives and harms of cannabis consumption in an online screening 
programme. This led to reduced cannabis use in the short term. The use of commitment devices, such as encouraging 
individuals to make a plan, has been found to help with quitting smoking. Contingency management (a technique that 
systematically uses the setting of clear consequences that act to discourage drug use and strengthen abstinence) is 
effective in reducing cocaine use and in keeping opioid-dependent patients in treatment.
Whatever the focus, there are three key stages in the process of using a behavioural insights approach in the design of 
interventions in the field of drug addiction and other related areas:
a) Identification of the target groups, behavioural elements (i.e. pre-existing motives and a set of barriers to 
overcome), and target behaviours for the intervention.
b) Consideration of the behavioural biases (e.g. present bias, overconfidence, framing effects) that may be present 
and the specific behavioural levers (e.g. use of defaults, feedback mechanisms and reminders) that could be used 
to design contexts more favourable to healthier choices.
c) Planning the evaluation of the impact of any intervention chosen.
See the Background paper, Applying behavioural insights to drug policy and practice: opportunities and challenges.
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interventions and the evidence to support them, to the 
wider system prompts a broader review of supporting 
factors and actors. It may also encourage consideration of 
a wider range of policy options and stakeholders.
The following components are important considerations in 
both drug prevention and treatment systems:
  the target populations: their characteristics and needs 
have an impact on what is appropriate and what can be 
delivered;
  interventions: the programmes, services and policies that 
are adopted;
  moderators: those aspects of social, political and cultural 
life that influence the functioning, implementation and 
effects of the activities, such as social inequalities, social 
norms; legislative frameworks;
  organisation: where decision-making happens, how 
cooperation between policy sectors occurs, and how 
activities are funded;
  workforce: the professional background and training of 
those delivering the programmes; and
  research and quality control: the development of new 
interventions and ensuring the quality of existing activities.
Monitoring and evaluation
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| The role of monitoring and evaluation
Information, research, monitoring and evaluation is one 
of the cross-cutting themes of the EU drug strategy. This 
is clearly a broad and complex area, and it is not possible 
for this guide to elaborate these topics in any detail. Here 
the intention is to provide a general overview of why these 
topics are important in the context of drug responses, point 
the reader to EU-level resources that exist in this area, and 
highlight some specific system-level issues in respect to 
monitoring response activities in the drugs field.
It is important to note that, although the activities may often 
overlap or be linked, and the terms monitoring, evaluation 
and research are sometimes used interchangeably, 
important differences exist between these areas at a 
conceptual level. In very basic terms, research implies a 
set of activities structured in such a way that evidence is 
collected and evaluated using scientific methods to address 
a specific question. Monitoring refers to the collection 
of information over time and reviewing it regularly, for 
example, to describe the situation at any moment or identify 
important changes. Evaluation may rely on information 
obtained from monitoring, or it may be conducted as formal 
research. However, the objective of evaluation is to make a 
judgement as to how a policy, programme or intervention 
has performed against predetermined criteria for success.
|  Monitoring health and social responses to drug problems in Europe: an overview
Monitoring and evaluation are key tasks in the programme 
implementation stage. Understanding a programme’s 
activities, monitoring progress and client characteristics, 
and ensuring that services are meeting performance targets 
can all be regarded as core aspects of good governance. 
How these monitoring and review activities are conducted, 
however, will be specific to individual services and settings. 
When designing data collection systems, it is important to 
use established tools and measures, wherever possible, as 
this allows programme monitoring to better contribute to 
a more general understanding of activities at the systems 
level.
At the national and European levels, data collection on 
health and social responses in the drugs area is needed 
for a number of reasons. These include building a more 
accurate and holistic picture of the drugs situation; 
identifying emerging trends at an early stage; identifying 
and sharing objective information on best practices in order 
to inform the planning and delivery of interventions; and 
providing decision-makers with the evidence needed for the 
design of national and regional drugs strategies and their 
evaluation. In the EU context, the EMCDDA’s Reitox national 
focal points play a critical role as information providers. 
They also contribute to epidemiological monitoring and 
threat assessment exercises, such as the EU Early Warning 
System on new psychoactive substances. Information on 
the Reitox network of national drug focal points can be 
found on the EMCDDA website.
Epidemiological information is important as it informs 
policy discussions on what responses are needed, ensures 
these responses remain commensurate to needs, and 
facilitates the evaluation of different policy options in this 
area. Monitoring efforts need to reflect the major goals 
of European and national responses to drugs, such as 
reducing the prevalence, incidence or severity of the health 
and social consequences of problem drug use in the 
population. Core areas for epidemiological activities include, 
but are not limited to, monitoring drug use prevalence; the 
transmission of blood-borne viruses, overdose deaths and 
morbidity related to drug use; and the number of people 
entering specialised treatment for drug problems.
In addition to epidemiological data, the European drug 
monitoring system also collects information on the type, 
nature and availability of responses that EU Member States 
implement to address drug problems. While this information 
is clearly important for methodological, practical and cost 
reasons, it can be challenging to collect. For example, 
interventions like drug prevention may be integrated into 
the work of a range of different agencies and form part 
of a broader set of measures targeting other problematic 
behaviours. The costs and practical difficulties of accurately 
auditing these separately, and over time, mean that robust 
numerical data that can be used in an aggregate form is 
often absent. Moreover, delivering drug services increasingly 
forms part of the work of agencies with larger social and 
5.3  Monitoring 
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health care remits, and monitoring and reporting may take 
place within this context. This means that it can be difficult 
or prohibitively costly to collect or access information 
on interventions in the drugs field. The organisation and 
delivery of health and social care also varies considerably 
across Europe, and this presents another challenge to 
introducing standardised monitoring initiatives. Overall, 
these difficulties mean that outside some very narrow areas 
in which numerical data sets exist and can be routinely 
collected, qualitative and expert opinion data together with 
ad-hoc in-depth reviews, provide the basis for comparative 
analysis of drug responses at the European level.
The data presented in this guide does demonstrate that 
responses to drug problems can be described in general 
terms. In addition, areas in which responses appear to be 
lacking or differ can be identified and changes over time can 
be tracked. It is also evident, however, that in some areas 
important data is absent and it is often difficult to identify 
robust measures of the quality or availability of services. 
More positively, information technology developments are 
providing new opportunities for monitoring that are likely to 
impact on what it is possible to collect in the future. Taken 
together this highlights the fact that both identifying the key 
information needs for development of current, and future, 
drug responses, and developing associated indicators 
suitable for routine monitoring, should be regarded as a 
priority. This requires a pragmatic, two-pronged approach 
that identifies and focuses on those areas that are 
currently both most useful and most achievable, alongside 
an ongoing search for and development of new sources 
of information to fill critical gaps or to inform service 
development in emerging problem areas.
At a systems level, monitoring should identify and quantify 
what services exist, what they do, and how much of this 
is delivered to whom. Regardless of the response area or 
level of implementation, the steps necessary to enable 
monitoring to achieve these objectives are similar.
A necessary starting point is the development of a 
framework for monitoring a specific area, informed by both 
a theoretical perspective of what the core components of 
intervention should be and knowledge of what services 
exist. The purpose of this framework is to identify a distinct 
set of activities that can be grouped together to constitute 
a response category for monitoring purposes. From this, a 
minimum set of measures, or questions, is identified. Once 
this has been done and information is routinely collected, 
this can be used to address important questions such 
as: ‘is the level of provision sufficient?’, ‘are there gaps in 
provision?’, and ‘is what is being delivered in line with what 
is known about effective practice in the area in question?’
|  State of play and monitoring priorities for some important response areas
The EMCDDA collects a range of epidemiological indicators 
for all EU countries, Norway and Turkey as well as some 
information relating to important response areas (see 
Table 5.1). The European Drug Report provides an annual 
overview of these data, and country-level data are available 
in 30 Country Drug Reports and the Statistical Bulletin, 
which is updated annually. When supplemented by other 
types of information, for example, costs of interventions, 
these data can support different types of evaluation, 
including impact assessment or a consideration of cost-
effectiveness. More detail on the current state of play with 
respect to data collections in core response areas and 
priorities for development are discussed in this section.
TABLE 5.1
Information relevant to health and social responses to 
drug problems collected by the EMCDDA
Prevalence 
of drug use 
in the general 
population
Adults
Schoolchildren
Prevalence 
of problem 
drug use
Opioids
Injecting
Other drugs
Treatment 
demand
Treatment setting
First or subsequent treatment
Main and secondary drugs
Route of administration and frequency 
of use
Socio-demographic characteristics of 
clients
Drug use among 
prisoners
Before prison
Inside prison
Overdose 
deaths
Toxicology (type of drugs involved)
Sociodemographic characteristics
Infectious 
diseases
Notifications for HIV, AIDS, HCV and 
HBV
Prevalence of for HIV, HCV and HBV
Health 
and social 
responses
Opioid substitution treatment:
  client numbers
  programme information
Needle and syringe programmes:
  numbers of syringes provided, 
clients, contacts
  sites and geographic coverage
Prevention: expert opinion of coverage 
of different types of interventions 
NB: data can be accessed in the Statistical Bulletin and analyses are 
published in the European Drug Report and Country Drug Reports.
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Prevention
Prevention is usually theoretically grouped into activities 
falling into three main domains: universal, selective and 
indicated prevention. This classification reflects the target 
population for the intervention and level of risk that group 
is assessed as having rather than the overall objective 
or content of the intervention delivered. More recently, 
increasing attention has been given to environmental 
prevention approaches. As drug prevention is often 
delivered as part of a broader strategy addressing 
substance misuse, and sometimes other problematic 
behaviours, monitoring provision can be particularly difficult. 
Currently, at EU level, only descriptive information is 
available on the extent and nature of service provision, and 
a need exists to improve reporting to allow a more robust 
comparative analysis. In some countries the situation is 
somewhat better, but overall the ability to monitor activities 
at the system level remains poor. This is an area in which 
evidence for effectiveness is growing, but this information is 
not always evident in the delivery of responses. Monitoring 
efforts are increasingly focusing on developing measures 
that can identify the use of evidence-based approaches or 
aspects of programme quality, such as the use of manuals 
or guidelines. This reflects the fact that identifying and 
encouraging the adoption of good practice can be viewed 
as a priority in this area.
Reduction of drug-related harm
Measures to reduce drug-related deaths and other harms, 
and actions to mitigate public nuisance are an integral part 
of many national drug strategies and a clear policy priority 
in a majority of European countries. Data collection in this 
area at the European level aims to improve information 
on the level of implementation of evidence-based harm 
reduction measures by monitoring national strategies and 
responses, analysing available information and documenting 
evidence-based projects in order to support the transfer of 
expertise across Europe. Current approaches are informed 
by epidemiological data on problem drug use, injecting 
drug use and prevalence and trends for infectious disease 
transmission. In addition to the monitoring of chronic harms, 
data is increasingly becoming available, both at the national 
level and through European initiatives (e.g. the Euro-DEN 
project), that sheds light on acute drug-related harms as 
identified through admissions to emergency departments 
for drug-related problems. Currently, at EU level, the main 
quantitative data sets available to monitor interventions 
for reducing drug-related harms are for needle and syringe 
provision through specialised programmes (from a limited 
number of countries) and opioid substitution provision. 
Increasingly, data are also now becoming available on 
provision of drug consumption facilities and naloxone 
programmes. As with prevention monitoring, at EU level 
some expert opinion and descriptive information is available 
on the extent and nature of harm reduction-related service 
provision, but this needs improvement to allow comparative 
analysis.
Drug treatment
Ensuring the availability of, and access to, targeted and 
diversified treatment and improving the quality of treatment 
are core to reducing drug demand. The EMCDDA collects 
information through several treatment monitoring tools 
which aim to:
  collect data about the policies and organisational 
framework of drug treatment, as well as availability, 
accessibility and diversification of treatment;
  collect data that documents the quality assurance 
measures that countries have taken to achieve and 
maintain a high quality of treatment service provision;
  collect quantitative data on the number of people 
reached by drug treatment in EU Member States, 
including the characteristics of those entering specialised 
drug treatment (e.g. drug type, sociodemographic 
characteristics) and the number of clients receiving opioid 
substitution treatment.
Some European countries have registries of drug-related 
treatment that provide data that can be used to assess 
drug strategies and set new objectives. This is the case for 
the United Kingdom, where the National Drug Treatment 
Monitoring System collects data on all the adults entering 
treatment, including reasons for leaving and outcomes 
of treatment. In other European countries, long-term 
observational studies have provided important insights 
into the outcomes of treatment. In Ireland, the ROSIE study 
also looked into substance use during treatment; a German 
study considered various treatment outcomes in specialised 
centres and primary care, while a Danish study considered 
also abstinence from drugs. Some of these have included 
consideration of mortality incidence and causes, and in 
addition there have been a number of cohort studies of 
mortality among specific cohorts at high risk for different 
reasons, for example, injecting drug users and prisoners.
In addition, in some countries there are data collections 
that incorporate systematic assessment of the quality of 
health care against predefined criteria. These systems focus 
on reporting on outcomes that are considered indicators 
of treatment quality. Examples are: in Italy, the national 
programme for the evaluation of health outcomes (Piano 
nazionale Esiti); in France, the health care quality and safety 
indicators of Haute Autorité de Santé; in Germany, the 
Institute for quality and efficiency in health care (IQWIG); 
and in Sweden, Socialstyrelsen. These systems are part of 
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the national monitoring and evaluation mechanisms and 
should contribute towards service improvement and the 
identification of research gaps.
Prisons
As part of a programme to improve the quality and 
comparability of information concerning interventions 
implemented in prisons in European countries, the 
EMCDDA has published a methodological framework 
for monitoring drug use and related responses in these 
settings. This aims to improve information on drugs in 
prison and increase country comparability of information 
in this area. The framework includes two monitoring 
components (epidemiology and interventions). Currently 
the EMCDDA collates data on the prevalence of drug use 
and drug use patterns among prisoners, on prevalence 
of infectious disease in prison settings and qualitative 
information on the situation and developments in the area 
of drugs and prison at the national level. An overview of 
the agency’s work in this area is available on the EMCDDA 
website.
|  Evaluation: understanding the impact of  drug-related responses
Evaluation involves making a judgement on the impact 
of an activity. Monitoring data is usually a fundamental 
component of such assessments, although it may be 
supplemented by specific information-gathering processes.
The data collected for the evaluation of the impact of 
responses to drug problems, in addition to reflecting the 
specific objectives of particular interventions, may usefully 
include indicators of other, broader, policy objectives. For 
example, the evaluation of the impact of needle and syringe 
programmes could incorporate the potential benefits to the 
community of reductions in drug litter. Similarly, economic 
evaluations of some types of drug treatment (e.g. opioid 
substitution treatment) have suggested that one of its major 
economic benefits is linked to the reduction of criminal 
activity among treatment participants and the associated 
reduction in policing and criminal justice system costs. 
Understanding the full impact of interventions can inform 
policy choices and help to ensure that they represent the 
best use of public resources.
It may be challenging to demonstrate that responses 
have a public health impact. This requires data systems 
and analysis that permit the detection of reductions at 
the population level in the magnitude of the adverse 
effects of drug problems. And it requires evidence that 
enables improvements in these problems to be plausibly 
attributed to the interventions. It is therefore essential that 
policymakers include funding for monitoring systems that 
can generate the information that is needed for decision-
making within their drug strategies and action plans.
Evaluation should assess as objectively as possible the 
effects of a policy or programme, the ways in which it 
operates and the extent to which it achieves its objectives. 
In the ideal case, evaluation is carried out using scientifically 
rigorous methods by evaluators who are independent of 
the services under scrutiny, to ensure conclusions can be 
viewed as unbiased.
Evaluation is increasingly recognised, at the systems 
level, as being central to ensuring the public health 
impact of responses to drug problems. The neutrality 
offered by a dispassionate framework for considering the 
relative benefits of different approaches can be helpful 
in an area in which different stakeholders may have very 
different but equally entrenched views. In addition, owing 
to a constant process of diversification and innovation, 
drug demand reduction programmes and services now 
encompass a large variety of approaches and methods. It 
has therefore become more difficult to assess the relative 
value of these various approaches and programmes. 
The choice of, for example, a particular prevention 
intervention often depends more on considerations such 
as ready accessibility, cost, familiarity or the charisma 
of the proposer, than on a systematic assessment 
of the advantages and disadvantages of competing 
programmes.
Furthermore, the increased provision of prevention, 
treatment and harm reduction interventions, in terms of 
both quantity and diversity, has brought with it competition 
between services for clients. The need to justify the 
expenditure of public funds on treatment services calls 
for rational criteria and adequate data on their efficacy 
and cost-effectiveness. Evaluation of services therefore 
is increasingly regarded as an essential element to the 
development of an evidence-based drugs policy.
Lastly, drug problems continue to evolve and new service 
models need to be developed and evaluated to ensure 
that responses remain fit for purpose. These changes are 
occurring against the more general backdrop of ageing 
populations becoming an increasing economic burden on 
health budgets worldwide. This concern has already begun 
to press health and treatment services for cheaper and 
more flexible solutions, and is evident across the health 
care sector as a whole. Potentially the increasing pressure 
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on and limited resources for health services could lead 
to cuts in funding available for evaluation. Conversely, 
to maximise the value of scarce resources, it will be 
increasingly important to know how well treatment works 
and which treatments work best for which clients.
A number of tools are available to assist with the evaluation 
of demand reduction interventions, including EMCDDA 
guidelines on evaluation. These tools should help to shift 
policy and practice towards more widespread and systematic 
evaluation of prevention and treatment services.
Supporting successful implementation: implications for policy and practice
Evidence into practice
  Implementing the European minimum quality standards for demand reduction and the development of national 
quality standards and guidelines can contribute to increasing the quality of health and social responses to drug 
problems in Europe.
  Websites providing easy access to the evidence of what works and registries of best practice, such as the EMCDDA’s 
Best practice portal, can help promote uptake of evidence-based programmes. Online e-health support tools may also 
have a role in ensuring good practice is adhered to, for example, by supporting prescribing according to protocols, 
enhancing case management, or promoting access to evidence and best practice.
Developing effective systems and partnerships
  People who use drugs are key partners in responses to drug problems. User-led social enterprise initiatives that 
provide employment and training in order to assist social reintegration and recovery and provide ongoing support 
for those who have completed treatment may be a valuable addition to treatment and social reintegration service 
provision.
  Many people with drug problems have complex needs and must engage with multiple services. Multiagency working 
and the establishment of strong links, the development of referral pathways and protocols are important for an 
effective and efficient response to their multiple needs.
  Taking a whole-system perspective to service provision in an area, rather than focusing on individual interventions, 
draws attention to the different components required for programme delivery and how they interact. This facilitates 
efficient use of resources and better support to multiagency working, as well as potentially encouraging consideration 
of a wider range of policy options and stakeholders.
Monitoring and evaluation
  Monitoring the drug situation and the responses to the problems identified is central to effective and efficient drug 
policy and practice delivery. The EMCDDA and other bodies collect a broad range of epidemiological data, but the 
information collected on response provision is patchy and should be a priority for improvement. Important tasks in this 
area include the identification of the key information needs for the development of current and future drug responses, 
and the development of indicators for routine monitoring.
  Evaluation of interventions and policies is also important in order to identify what can work, under what circumstances 
and whether there are any unintended consequences. Currently the evidence base for responses to drug problems 
is weak in many areas and continued support is needed both for evaluations and for initiatives that synthesise and 
make available the results. Expanding monitoring systems to include consideration of the outcomes of responses 
(for example, treatment outcomes) would be useful.
176 |
Supporting successful implementationFramework for d veloping h alth and social responses to drug problems 
Further resources
EMCDDA
  Statistical bulletin.
  European drug report: trends and developments 2017.
  Country drug reports.
  Best practice portal — Xchange registry.
  Drug policy advocacy organisations in Europe, EMCDDA papers, 2013.
  Evaluating drug policy: a 7 step guide, Manuals, 2017.
  Evaluation: a key tool for improving drug prevention, Monograph, 2000.
  Evaluating the treatment of drug abuse in the European Union, Monograph, 1998.
  Guidelines for the evaluation of treatment in the field of problem drug use, Insights, 2007.
  Neil Hunt, Eliot Albert and Virginia Montañés Sánchez, User involvement and user organising in harm reduction, Harm 
reduction: evidence, impacts and challenges, Chapter 12, 2010.
  User-led interventions: an expanding resource?, Russell Webster, Background paper.
Other sources
  Universal Prevention Curriculum in Europe project (UPC-ADAPT).
  The European Drug Prevention Quality Standards (EDPQS) training on quality standards toolkit.
  Consolidated Framework for Implementation Research.
  UNDOC Gap toolkit.
Links to further resources can be found at http://www.emcdda.europa.eu/responses-guide.
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The starting point
This European responses guide has been designed to give readers an overview of the 
complex landscape of responses to drug problems across Europe. Both opportunities 
for improving services and gaps requiring particular attention have been identified in this 
guide. Their relative importance, however, will vary according to national contexts, reflecting 
the heterogeneity we see in drug problems across Europe. Nevertheless, there are some 
general conclusions that can be made from a European perspective about the main 
current public health challenges in the drugs area. The guide emphasises the multifaceted 
nature of drug issues and the correspondingly varied response options that are necessary 
to address differing needs and objectives. It allows the reader to consider the logic for 
selecting different approaches and take a conceptual walk through the different stages 
of designing, targeting and implementing responses to drug problems. Throughout, the 
importance of clear problem definition and understanding the implications of working with 
different target groups and in different intervention settings is emphasised. Acknowledging 
that new problems will occur that are likely to require us to adapt and develop new 
responses, this guide has been designed around the central premise of the need to think 
logically and structurally about developing drug policy and services, based on an ongoing 
assessment of what is needed, and informed by an understanding of what is known about 
what works. Moreover, this sort of structural thinking improves the ability to identify and 
respond to new problems.
To a large extent Europe’s responses to drug problems have been defined by the heroin 
injecting epidemic that most countries experienced in 1990s. Successful service models 
were developed and have dramatically impacted on this problem. In many respects we 
have learnt what is required to respond to the needs of those with opioid problems or 
who inject drugs; it is interesting to note that many of the activities now regarded as core 
responses in this area were first considered as controversial or even counter-intuitive. In 
some countries, however, the level of provision still remains less than optimal, and there is 
a risk that health gains in this area could be compromised. A worry here is that, in times of 
financial austerity, it is possible that the fact that we have seen some success in this area 
is interpreted as suggesting that continued investment is no longer required. In fact, failing 
to continue to adequately support responses shown to be both effective and cost-effective, 
such as opioid substitution treatment, would be unwise from a public health perspective.
Harnessing the potential of new technologies
Looking to the future, it is important to recognise the impact that new technologies, 
globalisation and international political, social and demographic developments have 
on Europe’s drug problem. This can be seen in the emergence of new psychoactive 
substances and in the way in which the internet, social networking applications, new 
Moving on: responding 
effectively to drug 
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payment technologies and encryption software are beginning to change the way drugs 
can be bought and sold. These changes affect not only drug markets, with an associated 
impact on consumption patterns, but also have implications for appropriate health and 
social responses in the future. This is an area in which European countries have often 
been prepared to experiment and quick to innovate. To remain relevant, those involved in 
responding to drug problems will need to continue to develop and, for example, harness 
the potential of new technologies to support the better delivery of prevention, treatment 
and harm reduction initiatives. E-health applications have the potential to extend the reach 
of some services, for example, to rural areas or to vulnerable young people who may be 
reluctant to engage with formal services. However, they can also assist the implementation 
of evidence-based interventions by helping practitioners access the evidence, assisting 
the delivery of appropriate interventions, improving case management, and delivering 
training. Equally, it will be important to keep a focus on developments in neuroscience 
and, in particular, in new pharmacotherapies. These may provide new tools in the clinical 
toolkit, but identifying the best way to implement them alongside other established clinical 
approaches will be important if they are to be used effectively.
The importance of using and building the evidence base
The rationale that responses should be based on evidence of effectiveness is a central 
tenet of European drug policies, although some critics might argue that this is not always 
observed in practice. Nevertheless, evidence-based responses appear to be steadily gaining 
ground in Europe, and within the current financial climate there appears to be greater 
interest than ever in ensuring that scarce health resources are well spent. Understanding 
the evidence that exists to support any specific intervention is clearly important, as is 
understanding the ways in which evidence can be used to inform the development of 
responses. Looking forward, as the evidence base grows, and as interventions become ever 
more joined-up, a more sophisticated understanding of the nature and role of evidence is 
likely to be required. Competencies in this area are growing, as illustrated by developments 
in areas such as knowledge transfer and implementation science.
The perspective used here has been to recognise that being evidence-based is not a 
binary, intrinsic characteristic that any set of activities either has or has not. Rather it is an 
assessment of the current state of the knowledge base across a continuum of uncertainty, 
and in the context of defined outcomes. This last point is fundamental, as evidence only 
makes sense in the context of specific outcomes, carefully measured with reference 
to a particular population and setting. Changing any of these parameters will increase 
uncertainty. Similarly just because a response has been shown to work in one setting, or 
with one population, it cannot be assumed that it will work in the same way elsewhere 
or with different groups. This means the interpretation and application of what we know 
about ‘what works’ is never going to be simple. Using evidence is best thought of as an 
ongoing process; a conclusion and a key message emerging from this guide. It also means 
accepting that for many problems, interventions always have to be based on a partial set of 
information, and they will always need to be tailored to match the specific contexts in which 
they will be used.
In all areas, it is therefore essential to continue developing the knowledge base, not only with 
respect to whether different types of responses, both new approaches and those of longer 
standing, can work and under what circumstances, but also on the extent to which they are 
being implemented and how effectively. Co-ordination and cooperation within Europe in 
research, monitoring and sharing of good practice in relation to health and social responses 
to drug problems will be important to increasing effectiveness and efficiency in this area.
Moving on: responding effectively to drug problems in Europe
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The benefits of systems thinking and partnerships
The value of a systems-level perspective has been emphasised in this guide, and it is 
increasingly recognised that different interventions have to be co-ordinated and work in 
joined-up ways. This is not only because individuals may have multiple needs, but also 
because drug problems are complex and often interact or coexist with other health or 
social problems. Many examples of where there are opportunities to make drug responses 
better co-ordinated and integrated with other areas have been highlighted in this guide, 
including: community prevention initiatives; prisons and the criminal justice system; 
sexual and mental health care; and housing and social support services. These are all 
areas where better co-ordinated responses are likely to both deliver significant health 
gains and contribute to a more efficient use of scarce resources. Some population groups 
have particular needs for integrated services, for example, ageing opioid users who are 
particularly vulnerable to health problems. This is likely to require drug services to reach 
out and form new partnerships with a broader group of generic health and social-care 
providers, such as geriatric health services. In some cases, specialist care services will 
need to be developed — a development already seen in some parts of Europe.
Integral to a systems approach, and another overarching conclusion emerging from this 
guide, is the particular importance of partnerships for developing effective responses 
in the drugs area. This is necessary because the multifaceted nature of drug problems 
requires multi-service cooperation and the need to embed services successfully in local 
contexts requires the engagement and support of communities. Moreover, service users, 
family members and the wider community are all affected by drug problems in different 
ways. Their differing perspectives and experience can provide an invaluable input to service 
development and implementation.
The added value from partnerships also applies at the EU and international levels. This 
guide highlights some examples of EU-funded research projects and good practice 
initiatives, such as those developing standards for interventions in nightlife settings or the 
development of e-health applications. Interagency partnerships are also important and 
have contributed to the development of guidelines for health and social responses in a 
number of areas that have been drawn on in this guide.
Maintaining a focus on harms and deaths
The importance of responding to hepatitis infections has been emphasised in the guide, 
as this group of diseases now account for a considerable share of health costs associated 
with drug use in Europe. Moreover, without effective action, the future costs associated with 
a hepatitis C infection, in particular, are likely to grow exponentially. Currently, a window 
of opportunity exists with the emergence of new treatments, and the eradication of this 
disease now appears a realistic possibility. To achieve this ambition, however, will require 
investment and better co-ordination between drug services and specialist liver services. This 
is necessary, not only to ensure adequate treatment coverage, but also to ensure that those 
at risk are identified and measures are put in place to help prevent future reinfection.
Intervening effectively to reduce drug overdoses remains a clear gap in current responses, 
with the numbers of fatal drug overdoses remaining high in many countries and even 
increasing in some. This is despite the fact that many of the risk factors associated with 
fatal overdose are now well known. Some potentially important advances have been 
made recently, for example, the wider use of opioid antagonists like naloxone. Important 
questions in this area include: Are we seeing a new generation of young opioid and 
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polydrug users in some countries? Is Europe’s cohort of opioid users becoming more 
vulnerable to overdose as they age and, if this is so, what implications does it have for 
service provision? How best to respond to the threat posed by the recent appearance of 
highly potent synthetic opioids, like the fentanils, which may play a role in fatal overdoses 
but sometimes go undetected? With the increase in the availability and importance of new 
and novel substances in the drugs market, increased toxicological and forensic capacity is 
now needed as part of the frontline response to drug problems. Currently, however, this is 
lacking in most countries, meaning our capacity to detect and respond to new problems in 
this area is underdeveloped.
There have also been outbreaks of deaths associated with tablets with high MDMA content 
as well as linked to some classes of new psychoactive substances, such as synthetic 
cannabinoids. The emergence of these new substances also serves to remind us that as 
Europe’s drug problem has changed, to some extent our responses have failed to keep 
pace. In these areas our understanding of what constitute effective prevention, treatment 
and harm reduction approaches remains limited. This represents an important challenge 
for future responses, as some of the health issues and, therefore, potential interventions 
associated with these drugs are likely to be different. It appears that, for example, a greater 
focus may need to be given to acute harms, psychiatric comorbidity and sexual health 
issues. Greater engagement is also likely to be needed with new groups, some of whom 
may not recognise that they have problems or necessarily see traditional specialist drug 
services as appropriate to their needs.
Identifying new policy arenas for exploration and action
A future challenge for European drug responses also potentially comes from changing 
public opinions and some new policy perspectives in the cannabis area. There is, for 
example, a growing interest in some countries in reducing barriers to the use of this drug 
for ‘medical purposes’ and, overall, the general direction of travel appears to be towards 
making policies less restrictive or punitive in respect to cannabis. Any developments 
in this area have implications for prevention, treatment and harm reduction responses 
to this drug, some of which may be specific to the European context. For example, in 
contrast to elsewhere, in Europe cannabis is often consumed with tobacco, highlighting 
another potentially important area of articulation between public health policy priorities. 
As such it is an area where policymakers and planners will need to keep up-to-date on new 
developments and evidence as it emerges.
More generally, viewing drug problems in a substance-specific manner has become 
increasingly inappropriate for many of those seeking help, who often experience problems 
associated with their use of multiple substances, including alcohol or misused medicines. 
In around half of EU countries, drug responses are now organised under the broader policy 
heading of responding to addiction and substance misuse. This is consistent with the 
health-systems approach promoted here, and it will be important to identify the benefits 
or costs that come from this development. It also has implications for the evaluation 
of national drug policies and strategy documents, in which there is growing interest. 
Developing logic models that recognise broader inputs and lead to measures of wider 
impacts will be important.
There are also opportunities in terms of new approaches to developing and implementing 
responses. Highlighted in this report are, for example, behavioural insights that have the 
potential to improve responses through their use in identifying opportunities for new 
interventions, improve their design and implementation, and support evaluation. They 
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can be valuable not only with respect to new responses, but also in reviewing why some 
programmes are not working as expected. Demonstrating the usefulness of these new 
approaches could be a fruitful area for further work.
Ensuring flexible and timely responses to drug problems
The emergence of new psychoactive substances, as well as recent events in North America, 
where a problem with the misuse of prescription opioid pain medication appears to have 
evolved into a major opioid health crisis, remind us that modern drug problems can change 
quickly and have the potential to overwhelm existing drug policies and response models. 
These challenges are also evident in the way social and political problems occurring outside 
of the European Union have led to human migration and demographic changes within some 
European countries. Here, social exclusion, psychological trauma, and social displacement 
may potentially increase the vulnerability of individuals to developing substance misuse 
problems, and it will be important to consider the needs of new migrants when designing 
future drug responses. As in other arenas, the lessons learnt from successful engagement 
with other populations are likely to be transferable here, particularly the need to work in 
partnership with community members to build trust, recognise diversity and to develop 
culturally appropriate service models.
Against the contemporary backdrop of sociodemographic and economic change, 
globalisation and digital developments, epidemiological monitoring, early warning and 
threat assessment are essential to ensuring that our responses to drug problems remain 
commensurate with needs. Rapid information assessment and response approaches are 
also likely to increasingly play a central role in appropriate and timely responses to new 
trends and developments. The EMCDDA’s current operational strategy is based on the 
belief that the agency can best contribute to the health and security of European citizens 
by providing an analysis of the problems combined with a critical review of potential 
responses alongside practical tools to support policy decisions and practice. This guide 
is our most ambitious attempt yet to assemble the information available in one easily 
accessible form. By highlighting gaps in knowledge and practice alongside opportunities 
for improvement and development, it can provide the basis for a refreshed programme of 
work in the health and social responses area for the next three years and beyond.
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